var title_f28_44_29376="Eumycetoma foot A";
var content_f28_44_29376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eumycetoma abscesses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beatriz Bustamante, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29376=[""].join("\n");
var outline_f28_44_29376=null;
var title_f28_44_29377="Partially calcified primary TB";
var content_f28_44_29377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Partially calcified primary tuberculous complex in a three-year-old",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 396px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGMAXcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDrj4mUkqJMmtzw9rbTWlwVfOGArwBtXYO2GYDqTmu18DakzafckMTuYAc0AepT6qwXG/n60W2s+XOpL9TjiuLub91QYHUdTzVX+0XV/VR3oAl+IOrvY6ruRyBIM1wd/wCKpSP9aSf96tb4kOdQ02GeI/Mg59c15PLOW+8T7igDpLnxFO24mVvXrWLNqs7sWaQ57c1lvMSOag2SO3AOPegCa61GQHG4/nWZcXkjgjcfzq+9qMEtzkVnzKD8gwMd6AKplZhyxz9auo7rCpVjjvUMYRfvDJqwy71+QjHWgCM3MquGDHj3rY0/UHKj94QR71hSoR26U+2bDZXk0AdraatMZVzIenrWxYapKswAfPPrXH2ByylhjFbFipFwpByCaAPb/DF+0sKfNyMd69L8O3JFwjb8dK8a8KDCKc4bFep+GyTJGM4zQB6gGBXdnjGaxdU1FBGy4+btz0q9MwTTuDj5ccVw+rXJyxwT60AU9X1E7Du6jnNchPrm12Vsle2asazeTc/L+INcNqOrS+aQIwADyc5oA6WbX2ts7UV8jJ3GqX/CTO6eZbRqOcEA1wGv6zOsJjztZuuKoaFqk6nYJG5Pc0Aex6Xqt1Mvm3BCL2rXtNSiEgaWQkema8ue7upUBjLF+p96tRXN5BGpfcGbnFAHc614ngtQwH3/AErzzX/FN3PA6pIUHsaiupLqd3aTDDPp0rFvIlIbcMg96AMe5vJJ3Lu7E+5rOlnctyxz9atzx7AShytUlTfk4IoAR7hhzuJOPWse+lYZyeT79K1Xiw3AH41k6lET8x4waAM5nYk/MfzphkbJxn86c4wSKYBQA9XY9c/nQ0jAdT+dIKRhmgB25v7x/OmkvkfO3B9aKMUAPZmJzkinJIw43H86ao5xS7SDQBbiuZE6E4+tatlesSAHNYfJAq9pikPknj3oA7zw7dzXeq2VurH5pFB/Ova/EWosJooAeI0ANeS/C2y87XFupANkXI+tdtq120t47ZzuJ5oAtR6k/nFg7YHWqPxC1aZNG04B+WY55qkkgEnzZ/xrK+IsudM09uiqSKAMpdWl+XMjbvTNFc2s5BBHJ96KAI3Jy4zzmvQPCAWCwiU8ufmIz1rzuAbpQPU13Og75GVQrHjGQaAOkunPl4Q4z61XUh4eW5781L9lmZFQkE5/Snf2fMsRK8/hQBjatK5tSnY8ivOtUtR5peEHa3b0Nd5rG9YmHAOcYrmrpQq7Qu7HNAHOxWoIDOfwq21szLlE4FWooQ6nIPNdTpllHBZIJEyTzigDhZIGyFPf0qpc2mxWJGPevUz4VttTINi4huMZ8tzwa53W/DOp2JZbm0cL03AZFAHm0qYY+1KCU79a17mxdZyGjwKFsSDyO1AFExmWJuMUiW+zBxWq9qEiAGc9akjtleHkHdQBY02D5AemR1rTjiKSpjoO9RaYuwAOD0rUgj3ODge9AHc+EZSWXLcAYANeoaNcBWQAjdXkvh1mWRdh4zXommybXUbsk9qAPS/tgazVSwPHY1gXiRSF/mGR2z1qi920cO1sg+xrNmvFfPzHPY5oAz9aZUDK6EDuRXB3MOmmU5lKjP3T1rsNVmDAgt9ea5C/toZJC+O/WgDL1y30uJ1Yx+azLnaT0pPD02kNdCOeyRS3AZSeKz9WksXuMPPtZeMVBY39hFcJznBGMUAdwk8EczLa2/3TgE1oWLebITeOij0ArI+126xGRWQZGTzzilXUIfJDL1HQkUAautJYNbkrt9CyjHFee6tLbx/JbnjuWra1K+DlOreuOlc/e2TTvlz5a+vegDIlK4wSCaroqryRWm1khYxscHHBzUP2YoCCOQe1AGfIhO4hePWsHUw25lbJxzXT3EWxOM4PWse6j+Zi1AHMMGyc03HPWrt4gSQkcUllbGVtzD5aAK4UnoKeImI6Crr2wjGTkjtioHzjOCBQBXlhZe2KFhlIyFyKu2sTSNg5x9K1Y7QqntQBhRx7jwCCKmERI+ZDn2rWNmre3vSvYyhD8rEDoaAMRlYPgDitfS4S7cDJPAFQmAkc5ya6nwzClqytMm49v/rUAd/4Rtl0jQ3LjEkgwD7mnkqznrkcHNV4p2niRP4RyBTnTnJJBPJxQBIQ25jHhsCsHxy5k0SMkH924PIrVVxv3KeRxWZ4ilE1nLDJjlcgg9DQB59DcEybQeaKqOBDLuB+Y8GigDSsjunTDfxelel+HYT5QRCDnnIryi3k2ueeQa9G8Ja3CkaCU7Wxj60AehxWLRoFJ4I5NSeUEVyx4PJqn/bSMi7V3HHbvTV1GS4bEcDkd/lPFAGP4hsy8btGvI9v1rhryPa2O7Dk16HrWoBIljC4bGORXGTx+aWLDoaAKVpb4HI/+vXRafJH8okUY6YNUYEATJ/yKsrDuU7lzgZFAHUWNta3BGyTyZOxzXYWXmJbeXdKsydCSM15bFvJO3hugGO9dFp97qOnIC0jFCMlW6GgDoNV8HaFrKszQCOT1TgiuD1z4V38BMukyC4i/uNw1eg6XrNndFSZBDL3VuMmuqs4GuIy0DAkc4BoA+WtW0250+fybu2eKQcYYYzVGKNxKvHB7V9LeJtKstUtXt9WgUsPuyAcj3FeU33gyfT7xnGZbM/dcdcUAcwtmWw6ZKd8dqvWFqzDB4Pr7V0UFipjMSpti7mhrD7MSx4QdzQA7Ro2hY4fBzwa66x86Mg7txzmuAl1i0tZMGYHHcCnN4ntQQEuJR39OaAPVnuZfKO8Bl9e9VYxBcnermM+hPWuM0jxZmQIZRInTB610MOo27yl4hz2wO9ABquno5KFyrnoa5LVNKvFyEbco7g9a63UL+SSP5YlbHGc81gahNII2dWwQPWgDzu70S7a5bcVBJ7mr2keH5BcKtw4Xn0zUk08pm3bNzE53Z6Vq6E873QWVMjtnrQBsWui2yMGmlV419K3U0+2uVHl25WJR9/tWdBDJEf3y5HbjrV9dRuFhWNAqxA0AZOoWiQN5drB5rk8HFZV3pMwUNcyxoOpBNbV9qckJyr84PIHQVyd3dLLJmaUsxySBzQBJHp6PNlZAy+tTtZR7eF6etUob2C2UMw9uTVhdesgoLIxPcqaAKl1pzby3BU9qxdQ0hgjSx5255U13VlcWOqLsgmAc9FIwaq6lYtCuCflHOaAPJL62aSXYgxg81ctIRHFgDDDiutuNBZg1xBEzu/VVHNX9H8BX186vcqLWHrufr+VAHBPbGQMOpFOtfD99esPs9pNJ/uqcV7/AKF4J0bTwHFububHJfkZrpfszQpiKBIgB91VxigDwfRPh7rc6bmt/KB7u2K6JPh/HAu7UtRijwM7Y+teg3MU75M0hRM8HOKyr6TS7bP2iUzNjJVcGgDkZNO0XT8i0tmupgPvyngfhWRdJ55LSrgjooGAK6W/1XTgSYLA5P8AfNYt5qCSxnbbqvHYUAchqFptvNoHB5rThBVE29Rwab5TTXW8/lV6zhKuSy/KaAN7Rz5yrs+6vB966KHT12ZdW57VjeHFS2Ko5+YnIruLJoyFyBu6c0AcvJpUYdmiLDP8JrlPE8Lwhs5IxgkV6dc20RkJC5zzwa4HxrElupAf5SMkZoA8jvZsXJGBjNFVr5la+Yg96KAL9ufmJ966/wANCOBo5SAc8GuOtjnJPIzit7TLvyfkf7mfyoA9e0+WJDH8mc8/SultZBGN2QAR2FcL4VuUvLfYGDMnvziuz08l41BHPSgDJ8QrFNchJBhiMg1zGoQLEQQM7v1rs9Z09VukmlcBQvTpWZPaQ3YOxSNvqaAOcgQFQDwTV+2szLNtJAAHJ7Yq0mnsiE7CQPQ81Zs4RllJOWH5UANsLaNZt+0E5rX8sTBl2/KVOazkibOCCNpzjPWtDzBBbNISM44FAHLzw4nG04Oetamlajd6VMskc8irkblzkYqFYzJJvbjuM1OLd7hwgQ5+lAHewahHq8SYwxPU+lWDaqylCu6Mjpisbw1pk1lH5rHG7+ECuwgeEW+4qA49e9AHHaloC28bz2sYduoj6V5p4lTUbrelwRboP4B2r2e9nYk7nA9s9K5bxFDpd1auL64RH7MvUUAfPOp2lyrld4YKaqwLc797oSBxXUeKLGGNnNjqMU8YPGBg1h2UrgeXKyk5oAs2+WIHKOPwFdj4eu5oFMbgvkZBBzWLaxJKn7wDNamkwzW0weIbh3A5oA62K7JyAmSw9axtfuzBatvXaSevtXU6UyXULFYVjnUZHHWsrxK1vf2ixzpslVsHFAHnq6hEj5YFjW7o+sx5LGJxg4BFUBotqz4Fwck8ArXR6T4dghtCz3IbJ7dqALNtqDXMmVJJPC5HNXJHkhAQR8461d0yytLECSJtzdAT0FX9QbyLZWEYklcZyO1AHCakrGV5J38uMjv1rmr90yyWwYJ3JHJrrr3S5bu6Ml2+yMnHPWs/U9KiRmKXCBFH3jQByH2USRnc7EjtU1rFHCoKxs3r3q/NdafbfKztK59BgVqaZrdvBjy7WMejMM0AWfDtlcXDLLFZscdDjFenaPottewINSjUsB/BXDDxZfbFCtCigdFStXS/Gc8Dfv44yPbigD0S20aztm22kKquMc1HcaQFbdIw2deaTSvFemXtqjbl8w9VU5was3rjUIFa1kDDuoPNAHN6n4ti08m20y3DuudzkcCucv8AxJql2xVZBGeuAK6HUNFSYkMojl7NisG7sGtZGSRe3X1oAxBNeXU4WeaQnsc1oLYwKu0oGYcFjzmo8BJlOzvwT6VflxC3IGCM5oA5i+04iY+SRtz0qjPCyjaygEc9K6WVlMoKjv3rN1CBpJIyoJLnmgDHittq79oyTUyxH7OqDk7ulaE9pKkY+XB7e9Q2sM8dxiReE5AoAl06wu5pEiVtp3fKX4rfFhqsQx9oiVh/COax7J2fV0+bGT69K6OebZhQCWI6mgDMmuNUtwQwWTjqDXm/jjV7qWby5EC+pBzxXouq3H2aB5pGwuO/evK/EUu6F2kJZ3Y4z1+lAHGyMWmBHeikbiYDFFAGhA+CwP8AeNaEEjFwOCB3NZcQJZvc1p2incq55JoA6Xw/dyWupQNESPmAbFe3ablUiKklX54rx7SrUJESoAOOua9c8BZvdLWNziSE9vSgCz4msJJrOKZA3y9fpWVawAALz68967dp18loXAPasWWz2OWQYSgDKkj2AFRn1FRSqcB1AB9BWubXzF2gdaqTRx2i/OMt0AFAGdNPsjV3U5zjAqtiS5kyxG3PAParwV5xkqABxitDTdMMsuVB8sck+lAEFnpz3ICqAAOp9K3LGwWJAiLls9a0be0UKEjXbGvUmsvVdaitXFtZspYnBb0oA2ppreyt1858EdhXl3xE8dXQkW10seVF3fuTXQ31yMM0jk5681wHi+3jubcvChZl5GKAOdPjXVYX/e3LTIeqvUs3iePULQjO2TBytcvdWsszswi2kdc1SS1EfztLgjqBQBPfSF34bj0qmkrIevOegrZtrayuUBUuWA5GajOlxsGZXIIOADQBb0rUNybZBlf5VraNeyW99hXJRj0NZFlp0yRqVXjPWtXT7EyXqHzRG45we9AHdWN1KsoZXw2OcCs/U/MLMsr4DHINaFjBIEXK5OeSO9J4hgP2dG2HI6k0AcvCjGYBWAAPeur0i1Z1TdI205ziuWTDygg4PTBrrdLKx2W/eQwPAoAnMXllkB+UfrSys7lQ7sQo4qWzw8nyLuZ/Wor+KaJ2kdBjpgUAc/q92UuxuJIQdzXLeItUPl4Uk5PANdBf2vmyNJcyFVbn3rn9U08M42uSMdcUAcvLMcjcuT1Jq5a3HlZZwwQjgAVaubaCKJXc5I7msi+nluTtjBCr0AoAsvr04bbbRnHqRTV1C7uH2vK/0qjbx3Bb7rkj2rotDspTcLLPCSgIyCOtAHX+CreWG3QyM3zcgZr0C2uGhty8cm0qM8Guc0iSybC+X5Z7kVryxxrZyeVJ87dM9aAOk0rU4tUtxHcALN2b1qa7sFlUwzrkH7relcJY/aLaQAZbGD8prvdFvlvoVhm4kxwT1oA5LVNNe1mKsMjtWYsvl7op8lh90gV6Jf2P2iIxSAbhnaa4HWrN4ZNhQg5OeaAKMcJeXe7YVeat29ubmfcpzGvQNxVazij4jeQpz1Nb3kCCHCKMEffHegDMvI0XIxyOODWRdFo33DdvHqeta08ZZzjjJ4qtJavNLtUZcnHNADfDgjvNW/eR4KJlmrRu/LWYrvU471r+HtCOm2s88u0ySDt2rH1JVt7a5uZV4QHaCOpoA4Dx1rcS3CWkLFhH1x/erzzUrx7g5kBx2HpWhrgaSaSZjy7FhWBO5HUnNAELMTIvP40VESd4FFAGna/eOf7xrY0xC10nHesa3JGe53Vv6KmZ1JOAOaAOxsUKwgqc89K9E+G04hvmB4V15rzvTN2Md+td54TGx8gHg8UAdqRi4nDcYbIzTLpiQMcCrMYEzrIQM42tWXqdxum8tScLwTjFAEpcKABx65qvdWwuV44YdKZEyscZJ+tXY8ADA59qAKNlYtJII249TXTWtuFjVIhiMdafZWyhAQPmNP1dhaae6g7GcdR1oA5/xLrflI1rZgsejEd64K986SXzSViGc5J5rU1S7WEkRfeYH5jXO3cvyMzndjuTQB00c1q9ujEGVsd/Wsy8DSIyqkaj0FcuPEUdiPLMrMAeAKoaj4lu5ZD5T+WuMe9AFnxLpMaKWinSInlt7YzXD3K2kI+a5aTPZBVzUboynfNIXbuCax59rRnAA9qAL2m6hp8DlgJWbvWnFfabKDsZ1JPVq5EOFJVeMfrUsHyk4ySKAPTYFjezV4ZFYAc4NMSHfOkkTZbuB2ri9Lvpbd8ZIVuCK37VjJLHsyOc59KAPVPDzS/ZkEq9T6Vr6pB5ZCugZGHSs7w/Kz2MOTllHJNXdVaa4ZfnwAKAOfbQoJHJjyhJ4BHFatt4fm8hBldoPUGpIoyvKsSR7da14FdYl+bg9qAKkdrHZRfL8zdN1VtfjdbVI0APmLkt6Vp3agKBk/hWNqMTgId5Iz09KAONurV0cfaHAVT1JrntRv7aFZ3eVTHnAGcUnjS/kF/J8xwpwBmuB1a5afGRkUAaN9riXAKQou1e5qib65ZwUcKPYVnqygAgDaeKs2zq2FGc9OlAGpZ3NyGLiU5rdsdcvoowBKMe4BrCtEkxtEbYPtVmSKWM5ZHUY4oA67TfFMsMv76GGUd+Ntbw8YaXeOsRQwMO5OQDXmNxKwhCjhj1JqOBSpBwMGgD2+ymYfPAyyKw4Yd63bOZRIrMNrjHINeKaPqt3ZTI9vKygHlSeDXoWi+K7W9kWG8VYJuz/wAJNAHrKYu7RZ48EgfNWBrtgLiHzFQF1798VpeGJz5LA/6s9COhramslkQlep7UAeYSWUUak5+YjoadYO6q8XWMe1bt/Y+TK6yr3yOOKy5tsfCcCgBlzAjjJzn09KsWkELxmSJFMgGKzJrleVLHI9Kn0qRijiPBIPPNAGvFeOiRru+++3HrXN/FWVbW3gs4mwzje4rpII4mu4HbIEQ3Eds1w/xNlS6vUcnJ2bRjtQB5hq0Qe2fABKjPFcbLlicCu6viGBRu461w0wxLIBkAE0AVW+8AKKjkIR1JNFAGrbfebb1BrqvDsRYs3OOK5e0wJWOOQa7jw9EY7MscfNQB0GnKqMWJ+YHgV3Hh6YABVXAHzE+9cZYRFgueSemK6qwb7NESxxnigDqbK+2uyBss/b3qC+ZiwkyTng/WudsbopfJJn5d1dFcKXlZc8NhhmgB9sASrc1saZH5twMLwOpqhp9o8x2AkBf4u1dBbIlsMIOf60Aa0KpBhnIrnPErm5AeQ4QHHWruo3qQrukbt0HeuR1nVEvYJbfdsDA9O1AHE+L9RhsWKqQ7Y6LzXn2oavdXWVDbU9BWt4gV47toyWLDocZzWaukNcDe48sd+eaAMZnyATketRpcSyNhckCtCe08iQhVL49TVK8EqHCLsGPSgCOW2kkJLuqqeajaKCNRli1VmmXB8yZQR+tNjuLZRl5icHOAKALMaxtKgWIEHjnvWhPawj5YkI4rJF9bE7gW9hW/p7W8wQeYMkck0ASadopmkXaSSRnFdHaaTOgXy1ZjnHHatXQbRVTKbSzLjOa11geKL92CD3INAGz4dhMNmkbht44ORitG9AAYKcEciquhllQGdi3pmtW5CjaSoKuPSgDNiPQhuRWxGhZVwDnH4VmRWilzscEE5xWkLacDAPy+uaAIbogOFzz9aztWcQwMSMNj0rTMAjLOWywHTrWH4uvBaRIhwXkXjjp70AeO+MkefUXEf3upFczNp0qAFhjvxzXQazM8l87HJz61mXEwCLvIQD3oAopZIqBip681N5iw58lQuOpxVR9RiXKjL89jSR6inI8gYPcmgDaW4lMCyKTn3py3lwzHcSfw4rDk1iYoFjVFC9OKSLV7t22nbz7UAdKs6TOqui4H60+W2gaT5VKgDkg1kW9zICGkRDxWzp2oWjgreW8hB4BU9KAJIbAykC3l3N6VqWOjXnmgSIQCR05rT0eCzu5VXTZELBeVfg5+td5plr9ghzIN8rgAnGaAL3hS7fTrOODJMS8Hdya9A0+8SaEbGB46VwqmPy/ugemKHvZ7UF7Y7iO3SgDqNTiWcur9CMA+lcTrsL2x2txjnI9K63QtWi1WMwzEJcjj61Fq9j9qhlt5VAlA+U+tAHmXnHcfmGT0q1o11ImoKmRtPXI6VFPbmG5McgxtOCKuaVbh5iVXG89T6UAdPeTReUo3BWfnNcN4oi88u+3LAdRV661YNeSRnop2r9Ko6xMfsxZchTw2KAPPdQixIyhTwK4PUVaO4lXHGa9HusNcncG4HU968/8AEKeXqUmQRu5oAxJiDIMiiknxuGKKAN3T1LXIXGSTzXfWalVjjXjIGa5Dw9CHui7LgKa7fTUMkw/u0AdFp1viMkkgCrcs2xcEnH51EzpFb7FPzdcVVQlnGT17GgC9bTESKC30rtrBWv0gKDLAbWPpXC2wzISMEg8V6b4Ut2h0wyMP3kp4zQBuWduETCAbR1Jrl/FHieC0cxWZV5BkM3ZTWx4qvTpWh7EP7yX72OteQ3IaTe8v3M5x3NAGvD4gubucwsd0h53D0q6bYRoXupMBuy9RXISTsMfZvkI/ujmrcGptHbFtSkWOLpuY0AWdRhgmyFQc8BsVzmpWTW6+Z5yADjBNTaj4mEUJi00K6d5D/SuP1G6muGMssrMfc0ALqWphk/cLmRe56GueutRnuJNs7lePurV+Rxt+devNUJ7fzZD5YGTQBmKgLsBnPbPemNkMRV6OyldmBVwB0OOaVrBwSzDAoAoRKSQp711umW3mLCB0PNYdnYma4ULnB4r1XRdB+z2aMgVn2/KD60AR6PFNZvHKoZlJ29eK7OJS1s7oTkcgE5Brn4op4rcebG25Tk+tdBozrNbPHhlcg4z60AdBobLJZ4kjyVPBq1qMhkWNAAoX2qPSIxHAispGepzVt0UljwQO2aAILNRwAOtXQuVwC3vzUVsMYAA9qtoQoJJ6c0AUL0+UhGcMR0Fcvr128qjciuFHGRzXRaq5fBH3TXK6xuUHaQQBQB5H4muHN27424zhQMVxV3ctNMTIW64xngV3niW3YO7nGWPftXCXFsy3JG089DQBHwPu9KlU/KaVbeQEbhxWnb2cbR4l447UAZkC72APU1dt7ctMFz+lammaZEDJKVJQfdz2rStLSzDlzGSemAaAMh3zIEjQtt9OlaVlCNm+RiCOi1ZFrbxzNtVwM8YrRTTojGuxyGY96AHaSjJhuFUc8DBNdVpfiC8sc/OZgTwknIFcz9muIgMzIV+uMVRury4iUiPJx/EKAPUW8W2MirEx8mcjkHpmrdvPMF358wN82VOeK8QFy7sTIAST3Nbnh7xFe6bOxhlDRHrG3INAHrltfKLlHwVcHqOxrv5x9otIbkf60Dk15V4fvLPXWUQP5N2eTCx/lXp+mS7YBbyAhQMUAcf4vs0WVLgZCv1x61mWckcVtcTg8Iu1fqa6zxnbEaW5gGSDnHoK871GYW2kRxI2N7bmoAwJrryrtmJJJOa04Z/tensnVhyBXP3IDTbhyc81Np9x5MpDfdPB+lAGffr5czbgfl61xPi6IiVJQOCMV6Br0Xl+YwBwa43X1+0ae2wfMnNAHDTkGQAUUyQ4lAHHPP5UUAei6REIYMdyc811uijcc8YAxXMW2CwRSABXU2LJDZs2CCRwaALl3NmfaMCnwqxXPfpk1lQSbrhe/wBa14+PlyPpQBpWSqhADKQ2K9c0xMW1uq4+VBXkuk273E8ccS5YnpXsFkFgskJJ3bQPxoAxvHKbtNLqAzxnP0rzOeJ7lGZQGGPXGK9Q1aaKOF3u2UQY5z3rwjxzrF0l48Vj+6sCflxwW+tAE2q63Z6au2BftF0vcfdWuG1a9uNRmMkkjMM/d7CpZFd0+6Tu569aSK2VAN/J9KAKNrdyxny+WAPQ1Y/eTsWXAHo1aU6ILbdCi57kVQYHnIIbsRQAptQ4USsd/otXbSGK1PyIrye/NZ6XEUJ3ST4cfwjqaeNbtoh+7hdmJ+85oA25LdrkBkXa/TaBXP6pDP8AaGQKwPete11e8nCSx7EVRycVz2sXt1LcSSeZuJPOBQBq6Bp0ss0Y2nGeoBr12xtWWCJPm4HBx0+teUeBLq7S9MoLFEHevQYPEmoK+wkFT220AdhplqZBvuSFbPVhyRV6a0tkCkLwDuyODWFY67vVPPj+QdWrXF/A0ZZjw33c0AWbV1eU7chAKuCADLAfe681XsAHjYI4D5/OtRozHbKsjBnPp2oAzYhIsxBXHpz2qy8+FwykVKGKHOACKjeUsucAt64oAoXO+YDghF6nHWsfW7aNbcEDaWHBrbmlfYQSNpqlqaxXFsqSkIy9DQB5tc2sUkrhwsh7BhXG+IrKSNhiPA7YFeg6gbe0vCkbhu7Oen0rjfE2qKx8qKMYB5agDlmhZyQwwQOtX/JSC3STzFJA+6T0rNn80Y3PlT2qC7GyEMuSD70AdXpj2ptf31woJ7danjn05HKrKcgYGBXJ2W77KDjkVcXaEZzjdmgDpYLjT0fmfHHORU8moWzYEFxGcdzwa4OZth+eTO45NWrJoQnmSHI9PWgDrpY7i8zIsiuPRTURglTCsdo/WuZ+2SBj9nkaPP4VZttbvLZhvYTD/bGaAN8x2T5jlTLj+KofsGG/0Vgw9D1pLbUrO+xvU28x45GQa6nTNGmtPLnn2ODym08UAO8MWklgwuZw0Vx1Q9wK9a0HW47lEhunH2jGA/rXJxYlhXzQjE1Wnia2xLBkwp19aAPTNSffCqPgk/kRXnHjewMTJPCuITwRj7prZ8GeJf7TvGs78BQRiNjWrrFmsyy2twPlbgGgDxuYeWCq5x1z61TmYxEPnjGDmtTVrVrS/kt2B/dnAJ7isO/Zs8nvQBsyzLdaaMcuvBrk7uEbmUnhuDW3p0mQUI4IwKz79Ck3HTnFAHnOoW/kXzKy5Ge1FaniS3xcRT9yMGigDp7Bd1xnIxmtu4lKoqADFY+mMACXwatXMpJUDt70AWrMZkDBsYPNdLaj50Xru9O9cxZuCwwcDrXoXgay+3aiHkG5Il3ZI70Adf4a0n7Ja+ay5kYcnH3fatbUdRh0u1LXTbU/hBPJNW9NABlldisES5I7GvH/ABbqF54g1uWVSUs42wuegFAGlrmsS6rMY4ydp5RP8a5ubT4drf2iNwOcKPWr8NxDHDtT5ZF+8396qjeZdSAnB5xk9BQBz17p77CbXDxgZHGCPash7aVFLSIUTHJauxvtTstPhaNG8+cd16A1xmsX02pSMbogL2VeBigCm2oRWz7EDSkdgeKpXl3NMCV+RPQU8gIGGAR2NWba1Z0DTJ8hoAwPLy+7GT3q8lgJ0yHIA9RXWWmgtcKrRW7HjP3eDXQ2HhiXyyq2uGx3FAHnptpoLMCLd0wRmqtvE8ucjGOteoHwbqE42YVAec4qlb+D5E1Jo3UsB14xQAnh6z+y6dGWi+ZxzkdqvxEwzJKI+vX0rpbKyWErFIrFFGDn09qc+mQvIp2gJ79aAM2yLTSMI0PuMVswAR27eYR8nFO062NrI5UqqH86feBJVICjn0oAtaMxuXBP3c5FdZHGzJyM1zegQhOe+OO1dXbkiPBoAoTrtLY7jpVZGG/aeK0LnIUlSKyHJBywOaAElUvknjB61Rv4VMRbJJH41fLbvun6rUd+o8hm6cflQB5Tr6lLqQZwGbIritThlLkH5smvR9espLsFooyWQ8cVyupaQ9vl5flfGdp9aAOZa2LR428gcVSntpxH84O0HpiuttYt7DYuO5yKluLON0Ks43f3ccGgDkIlk8gbEI/Cq88s3l4VCPU11TabKqMv3U7HHFZeqWssQRFAIPUigDmcbj8xJqYyZCqFOB2rai019wJGOM5IpTBukC7AeeCBQBkQo7Y3EY7VZRGkfaq8jvW7BoXnSkspVf51p2+kWoQKS0bL1NAGHa26qQcbn/lXV6Pqt3pbKSwkg/55PyCKqrp6hcwypt9xiql2Joxl0Pl+vagD0rS9VsNTjAt5Fhn6+STx+FNuLhkn8hsgDknOBXkkt63HkbkK/wAanFdd4a8VRyJHaavlx0SYdR9aAOyhtR50dzZ/LKpDEg9cV6LqitcWFvOw+fYN1cHDbGIwNasHicjaynivTJYRcaZGqHbIq4NAHlfxCsUjltrmMECRMH8K8/vQGOARgV6z8QISNEtwwy6OR+leUXced2cfSgCC3cqV56UaoA8e7vUAyCOpxUtwS0TZ64oA5vVUE9vtHJVhxRT5yVlI45NFAGpafdI4GOgpXkBbaOTVSKQE596liw8pXqBQBsabEHdepAPOK9h8BweRok0m355G2qRXl2kRlSDkr/WvafAsG/QoS/CbiaANq6j8nw5OJDgbfm968Z1OcCdwvyx/wgd69t1YCXT3twM7xjFeBeKNSt9Gnmg/1t7nG3sn1oAzdRlit18+9maNOqRr941lXHiyS8j+z7hbwdAB1P1rntQkuL+4Lyu0jn9KSPRXPLyFR1x3oA6O1CSIq7kcetbFn4Vk1BDgbFHcisTRLf7Jt2gk5713Wl6gIJVBm256g0AVbDwNYxOGuJGlbuvauts/CmnQ2zMYVWT+AHmizuoZ2VAnzKcl89a3JpbdVTModsfw8mgCpZ2awW/lkKuBgBR1o06CVdwdSGzz7ip3uV8raEUMRkO3b61gyX90JnEsjtHjCsgxmgDpyd+1UARsY5qGbTpJc4Mav3OetZNjcxzMBKz7hzlmzWnLdx+QCoyRwSO9AFK4iFu+yWeL6E1BcT20gISdA68Hnik1LypYVHkkn1AyRXP3FuYhhgcHpQBvkgRKFO7jrmrNojOMrjjrxXKRSSpKBGrHFddp8paFVIGO5oA2tJTEe50UtnsK3Cv7kPjr2FUNMVQpRunqK15mU2yKgxjrQBjXgY5KLn8azJklY5eM57YFbkvUgY49Khbcq5zn2oAxYopBKpcYUHvV+7jVrde+cmpHjBAJP50jzBY8FAcCgDjtXil835B8ueoFcD4iSY3ThmJ5wSRXo2rX+2Rxt2j+VeVeJ7uS5uXCMQmcE0ATwXlpEAHfDgYOKzr3UYopEeKNs54J6VkLuBxkEetWhaAgO5JX3oA3G8Q+XaZaCIgjPrmsC41+ORCq2SDByWFbWnact3bmNEBJ6ZrK1XRDpx2SDDNyAKAM0XwclpVZc9gc1btdR0xSGl3gjtiufuI7hJCpOOeh9KijhkZjgHHpQB3MetWBZRDKYwexHWpo2S54t5Q7Z6bq4ZT5a4lYbev0qNrshm8hipP8Q4oA7+4YWaZlG5j/AAgVmG5lmGOdn932rmrXW7uDA8zzYxxh629P1a3uTtI8uRuMHpQA2409bpchth7bTgVW8iS2bawyOx61u/MilNvB5yOlTWdubqZYFTcW9ulAHUfCzWXS98m7Zmsh1zztPtXuVuQUDI+6NhkEV4pZaOLQr9jB2jluOteheEdaVJltZCSv+11FAC/Ee2kuNNRoBypLMPavFbptrnIr6D1sBrjaw3QuMKT0xXiXjTTGsNYliHCH5lOO1AHKuxEhOTwM8U5pztIUAk8YpjN+8OORg8VErcsSOMdqAMu/YLOrKMnoaKZfNmT5R35ooAnicBTk81oaeAxzWcFzJt2itWyeOBctyT2FAHX+HrVr27itl4U/ePoK9s8PbIoBZwAAR9PevMfh5bE6fPqEn8TbFBrvY7pNA0K51e64IHyJ60AS+LdaGlwPHGQ10w4xzivn3xPptxqFxJqS7iWOZM9/evT4bmPWZft9wzFJQWCntWTq0QnUiIgRkEFQOKAPJIWFuf3XI6Emp0upElO05b161razoLQI00PEOeT02muTutRS3YrbkyMOC/bNAHUQSbCryyhe+W4qZ9dtQwGDKw4BHSvP7m6nuG3SuSTSQztH91qAPRotXuQVJkZbc9hXbeG9as7S3jnMm5ydpRzzivHLTVJTD5bDcD0PpXXeHLpHRVeDLocZ6596APY5b+1lhSW1CNvHQc1nSTTNBvnt0VF9sZrJ0HzPtaqkiCNeQp4rujatPCrNhQeRigDlUiaYu0fyFRkL6VcTKRDcctjpW5FpIjWQ4+ZjnOKimsyhGxQRjk+lAGfDmSD5QBk9TXP6jFI1yQitn1rqm2pFtP3vSsidfNnH8Iz270AZ9nYsjKSxLN2rpLVFhQIyESHgjOaislRX3Fcip5UJYunJ96ANzSuSMcYrYG0xn1B6Vy+kNKjFnB5PboK6OA71zQBG4yCBjNVwFB5GasyIQ5IIBquQwYg9fQUAMKjPse1I8QZcEUMOOSBz0pzHbHxn2NAHG+K4AkJO05FeVX2ntK0mxjljzmvZ9ai82F1cE5rj73RnWPeAoycnmgDzX+zpY5ACPlzTrjzgu0ocA12Nzp6L8xOT7Cs+S2Rg6gfMTjnoKAIdGvHt4yUQZx0JqjqsF5dTGdwzMOmORirmoW0tpGixhW3DJx2qnJdSxpt3YQDmgDkNXM6zM8hJUe1Zn2yQH5GArrJohdM5Ykr3Brmrm1WOVlVScHgYoArLJub5z+NPITtjFSLZF24OM9RSS2TR9DzQBGqRk/Pwv86kzGoYIfm9fSoJEkxg4NPhtpZGGIzjuQKANLSdVubedIzuljJwVPpXqfhqzt7q3Elm+XIy4z8ymvN7O1SJAcAsfXrW3pV1NYzLLbsY3U5znj8aAPWLOKSGMGRsPngH0rN8SSSW0Pm2R/0p+uD29aj0rxPaakAt2ViulGAx6N9Kzri4le+Mm3JJwB7UAeleF9ROteD43ckXEPDE+ormviPbLPpFveAAyRnYxFdL4FiB0S62ptyTuHrWH4ldY/DephwSsbBh7c0AeNXhMcxAHvVeR8e3r7Vd1Jo5iJIiTmsa63OAEYqQcn39qAKV7JiYehoqG5Q7xv8AWigC1FcOxOTznsK07JTnLEk1k2KZkc85zxW/YqMgHpQB7d4ftRb+G9JgPy+YodgOvNafxHRU8N26PnZuGFPerHhy2E+l6dO2NqRLjHQ8VH8SLdr7SYI4lLbW5x2oA8t0W6l+2GHOyInAB6Z9q2dV1Ow0i3Zrhg9wekKnnNcX4p1yDRYTbWeJL3oX/ufSuFh1OS4kY3UrPMT1bqaAOh8SareaqT5jFIBysangVx7wKzlV5auhgt5JlLs5VfU0PZxdIVBOOWPWgDljDIDgqwHqRSrHt61uzW7MQJBhKqtZo4ISgCvaTeXgBeexrstB1Jg0fAByMj1rkI7EhyWfavrWpo7Ri6KK5cjoRQB7Dpd1FiN0AWRuNoXJr0GxclY0XcOh56V4zo2tyRvHBGib+m9ua7mw1mYSRrK+ecHjFAHo7RBlDEjBqs32dSQ0ygdxiobK6SayDA5wOeetZU4kuZH8xSkeevtQBT1G6sxcNE0pLE8YFVVe3UllLn2xUF3FF57MHGAcc1VkkUM4B6D1oA2IpowuA2M+1Wt4CfX3rn4J2CEPyR0NWLedt4GcnuPSgDptPJA3cHHAFblmjyQk7QMd6wdDZSSR8w6c+tdJHKwGFUBe4oAikt96jL7T7VC1pwPnJPrV5eTnio8fNnnNAFf7EoAbcWx61LJEBbcDJB5xUjEhB0H9KaJWRCOMEUAc1rCsIt3QH0rJOx4QT1PHPOa3NZLPGSx46Yrm7p5DGY4AoI55oAp3gghAOCPauM1rUraRmVYiTnscGum1Npmx5rckcVx+q6azjzIh8x70AZY1K3UsJIpyR0IarsN7pclsZJUkLg8D1rH1KF4oCmMP3x3rDg+0+a0YckdeaAOkv9csFQJHhDjDZFcfeSRy3DMs4OT0qa5tUMqmV1BPXFZt1a+XKQpyvagC8WMWGjkDN9aVrl2GWXJrLCleM1ZhZo23bs+oNAGlb2jTv+8wsePxrXs7Exq3l4/Gsq11Ibt0mNo6DFa9vcRzhcTrG5PAJoAla0iIG45c9SD0qG4SW2jOW3w+tW2dbOB3mIJ6ZHOaypbwXQXBIUdqAKE2oNM6qhZQh4wa77wdrMOoBbG/AWYD93KT19q4wwQTZUjbIehFTaPZTf2rBGu45YYYdhQB9QeEIGtNKSKVcSt1wOGrB+IFssGg6g/Ajdf1zW74f1CPUNOjWIjzYQFOO+KreM7f7b4entDjzZBkZ9qAPm26leHdj16VTMySqxTCuOuTWlqETRSSRsNrAkGuZv4mRuO/WgB106iRdzg/Q0VkythwMCigDfspSHbHXPSul0SJru8igj5eQhQMVzVihLHPc16b8KbDzdUmu3wY7dOM+vagD2/QI0h0a1tox/qlCfiKyPH18bLQLqOBh9plQhfY1o+HJdtpPPMfkByua4jxA8+s3ruTttlPcdaAPnWZZby7kMm4vu+YmnixWHac5Y9xXb+KdMW2maS1TZGx+auWdtpO3BAPOaAFtLsD93NllXp7Vf3gf6k7mHPFYtw8O7dK2M9hVaXUWBP2UbQOM+tAGzczoozdSDd0wtZF3chWAgPHris/f5r75SST1yakCdcnIoAPNZ1O9icnpUts0kTho2IPtUGNvWpIi7vtTOScACgDufDimdUkkzvzXqWg2YnhLEZIHDHtXl3hm3vIXRPKYgn0r2vw5p0sUCNO21SM4FAGjp0MsKbeGT0Jpb1pdr7SQuOlTLLbmYRByWWpZXjELAHj1NAHKeW8m5ipJzzVCa2fzWPl5XuTXVNEGiYx8nrVGWJi58wgL296AKEVoCvMmGPOM1HLG0bDGfYjvV4W7ZYqO+OtSPbyiPJj3A9MdqANLw4xK4YbT6e9dPApPPX61zOkRNGoO3nvXR275QNzQBbJGwcHrTBy3sKVnAGSCFNQ+egJHOaAJBk/eHNLt38Dr6VEZwRxmpIw7oWA9+KAMTWVCowHc1zXlZlZvTjNdHquSCSOM1iyREKxAyM84oAzry0EzLtAJx3rn9StpIwyKvUdK7RI8ncQAPSqd/bLKpbgc+lAHnWoaTJJHu2YYiuR1HTrpVIjTGP4s9a9huIArFHGYyOCK53U9K2Su2Cy55A6UAePXEbO4H8YOGpwikgG7ORnkYrqfEGli1uBMiBkJ5x2pNOsrXUIiTlGXk0Actc26480DPrVQOMcgrXV6hpYiDYcFSeAa5+/gWNsuPyoApsxDdePSo3lIYEHkUjMSaYwGKALEV/PG2C7OvoTmtewuYZzt+5IfXvXO52nIGaesjAhgMMKAOuS3eN/u5GM8V6D4J0tobdprlAzS9BjlRXnfhLVgLuJNTXzLMH5j3r3KwjtZ7WO6snVrYr/AAnO360AO0aebR9UhUn/AEWVsFq6vXJF8+CdTmJuB6Vxuq30VtZlH5abhM9frXVXkOfCVsxOTsBBoA8T+IFmtl4hulAwkh8wDtzXCaiBgevavTfitD82nXeBmSLaR9K8ov5WPJ60AZNyHEgxjriikkDM/PJz3ooA6iwOG5Ar2T4bxCLwldzKQGlm259cV4/p6g5JFe2/DaH7V4VWGLoJ8njtQB1usSNZeDfMB2kY/H2rl47yK8tFKfKmM4712fjCFB4QMaZGDgCvJrK9i0eKb7fJ5cHVSerH0FADtciaQSFh+5Aw27sK8k1y7hiuJIrUhlyfm7V0niTxLJqsrRwMYrYcBQeT9a426QM3A5oApFmY5fkmnr0FDJ/dpVHY0ABNPXJGBTkAJAVc+uauQQFVJZePQ0AV4YFPLc47VtaNZnf5pQKFORUEFvHMWbdsPpV53FvCsYfAoA6TTtZuI7rzBkj6dK9RsNXebT4mI5K9jXhi6gkUShPmcjrXb+Hby5uNE4dVdT0HXFAHomlq+9pVwM8k5yasTTgIwkmQDOQSawbEuliEaZjnk84NUZ4P3uCSVJ7mgDtNNu7aQlRMh/Gm3c0G8oX3HPGB0rl9OC29wFBG7rxV26uYRIpLBST60AbMckJj+V+enNPD5yAc4NYL3UaNjdke1W4b/JHyigDo9P3CL3JxW3p0YMTZ5WsTSpNkQ4BDc4NbaT5QKBs+lAFpoomX5icDpiontFLZUk8etSBjtHoakKkNuByDQBXjtU4JOOelWY0KwSBMgkdqMKq9MnrgU3zSmSAOR0oA5zUQwJUDA71ih/L3K+cdRW9q877XK7cnnpzXMzOyk5+Zs5xQBZ81UXJ3D1FUJ9XhChXgYktgjNMubmUJkYJPXPasSVWeUOQTzzQBsy3dk68pIvfjFF9eaY8XLFTjBBXrVGGMPkcAdc+9Z+u2zCJXHAJoAoX40y6R0EqE+5wa4N2FrfP5b5RG7HqK2NXUJMoUbWx6da4LWpHjvGOSCe44zQB0mrGS6RZISSF7da52eVgSH+93pdN1OaL5SS46c0t/Mkr7zHsOOaAIVjLqTjPtUUsAK56H0pyvnlTilOeO470AUzHtbNOiVpHwB+FadratKRlTg961rbS4g2WXJI4YUAZ1jEEA3c12fhnxLJoUgwxa2/jjY8fUVzFzYyRFniG5RzisS9u5GPlFiPWgD2W/vI9cdNRsTut8Y2f3DXr9hCJ/BFuj/e2ZGexr5o+GWsm01eKym+a3nYJg+tfUwQW+lwQqMKFGAKAPEPi0hGj6Uq/LIN4rx+/44Pf0r3P46QGJtO8tSEKkmvEb9ORx+dAGQVCyqSaKJziQE9OlFAHT6ceWBJr6B+C8BXwxO7jhpTtHtivn2xABOB1NfSvgYLZaXZWYODJED6c0AdDqsccnh+78/wD1cQLn8K+R/G+vS6vqkm0lbaP5UTsPevrDxtdpY6Mbdio+0KUPvmvkDWtLmtdTuo3XYiuTlh1FAFa1naQ7U5c9DWnHbjYTKAX7AVlKPKwYwQT3rWsZo2ZRIfnA7d6AI3thJDkIQR6CqrWTsfl610IijZflBJIzk1TuJ4oY+SWf0oAy441jY7zgr296SS7JyAcUyWYzy5VTzUTxsGoAVp33AoxB+tWI5GZSbhs+1VEXGXYd6R354NAG9bRRtCrjoD+ld94auFhthtUKM9+9ec6PskjYOxwO1dbpJQhUQtjoMHNAHfR3H2iZSv3B121pzowtoyF4PcjkVm6PbTwqo8oBSM5Y1qSsXgIZiSOyjpQBzVxP5MrMXy+eMUzz5btVKpk5was3KRvOW2LkeoqeyiO8MMhQc8CgC1p1u7Kd2B6VdjhMRG4gGlWPzQWVORzgGnujYAdCMnigDo9HmDxgEDcv61uxLk8cHviub0eF413Edec56VvRuQobOBQBfLHAyAR71KDyDnFQJOwwSFKgZ6Uv2liR90enGMUAWSRgE8NUbEt2xntTGuGLjJ4Ht0qeFWkCnnB5oA57V05YAD3rmZwyyfy5rq9XQGdxxgHmude3P2gj+EUAVfs7SRbsDPeq0lmVTESjPvWukRZQueOuBVhbYAgucL2oA560t3jlIkQgdRnpUuqw+ZGuF3qBzxW1Km1Pl5z0p8UaugVlU5oA8j8SW6wT7XBOehrz7xYIcKuPnHOcYr3bxhocLyCYMEJHTrXjHjfR7mJmcjeo/iFAHImQINy9alEpkj+brVZFyO4x2qWPnhaAAEjvU8DZYbjwKjVM8HrUiDyzkjcPQUAdBYXMZCxhhk8VqANbp97IPWuLkl+YMuUNSLq06KFd2ZOlAG1f6i0TSRwj6n2rDe3EzFgfnJzUsdyshJxjP506KMlsqQaANbwLYu/iO3Z1ISJg5P05r6x0m5TVNLjmjJOBivD/AAXp8Vro7NcqDNOOMHkV6p8N/Mt9OvIZDlVJKn60Ac18XYTfaJJMvP2ZwM+grwHUOJOmfU19CawDd+H9bTGTtL81886gHGRkZoAwLofN+NFFyTvxRQB2GlLueMY/iH86+i4cw32nIOioo4+lfPGi/wCuhH/TQfzFfS8Fubi/tHKjykUZI9aAKXxIiE93a+Zny403Ko9a8g8f6a17ZrqCR/PH8rqO4r1bxvceZrrW5bbhAVHrXG3MZJZZUDRsDu54xQB4l5W9sJn8e1RSOIScnDA5rR8UYsb6SO1bMLNww7VzpYscn9aALxv5n3KHIA7g9aEdnBBJJ9TVOMc1ZiOxgfSgC/aR+UcsBz61OFiw5bvziqP2gu445q1CjuQ8gwooApzupJ4qOKB5VzGvTrV26hR5x5IOD+lXoIggOP4eTQBSsoHiUljjd2rtvCYDCIQnDqwzkZrjr1ys2/7ox0q7oerDTZhISxB9DQB7pcTMRGpbIAHIGKgmjkZTHGQVxnriuIHimWaGNolC7vXk1HeapLNGrPO5I7DgCgDqTbDaxeZFKnuwqzaXNrDEytcpj+EDk1ykX72NZCeCO9S24VGBOPrQB3uk3NvIcJKCx4PHNWpDmcK2TjpXJaPKsUwz36GulguQroXZST60AblgojXrwxzxW1ZqGhkyOCfyqhZrBJChcYHXjvWkZAkGEGB3oA0Iog0QYICenFNCIz/PGBUWnSsF5zjHSrqcyZ6j+VAEawh5OV+UdauRIuMEcYwBTei55pGdVXd6daAOY1Rdk7gnoayAdrhj1FbuoTxs7sUBPp61z8km4scqBQBdjuIkYMwXFRy3sDThBkD9KzWlBDcqcdcVVmlBk6ADtigDfbyT/Gu4dDmoYypkUKQTnkA1keYNjPn5cdaq2zCCcTGQkjoM0Aa/iCLzYlAXrxXAeMdPkXS2LAbGODxW3qmr3MdwQHBXr61znizWhJYnIYoRzzwKAPLbe0jSdllXKk4HFSXulLGA0RwDzzUT3Kyz4jYbQc1owXO/5W4Re9AGHdRNEMsPoR0qFZgDg9a0dQlVpWVMEevasmTO4+uaAGXDHdxUNTTZ2c1AcngdaAFEjo27n1Fdp4Fit9U1SKG6dYwMEk/xGuJQFmCkHnvWvZStasvlOQwPXvQB75NYpFHsiIwORj09K6n4c3y3Go6hYLyqR5J968t8JeLY5LX7NqT4mQZjkI+8fSvRvhPayRTanfSjHnDFAE1/AIdO1lMbcQuPrxXzXqeVkctzX1P4mQDwxqtyvDCFhXyhqzEzsDQBiXJPmZB5z+VFRzhfMXqD2ooA7jQ2Pnx5xgSAj86+rrOMJYWjKOWCk/lXyz4Rtjdapaw9mlH86+rtOxLbw9flUDj6UAcB8TojFq1tdxrzs5boBivKvFPixJUa108jy+juD1Neh/tC6k1p4eggtjiaRyrkdVWvnCJzGwHO084oA1LtnuVIPzDrk9RWXLCyNhh16cVc+0bRgNyanitzcRdT7mgDMQAfWp0gdhnHFWpdNMKb1OT1OaRA4ULjGaAEgQb+wxVwOwXapHBqFcKMPgN7VG1yqqQh+cfrQBejC5EjD681FdXqJH+7HfpVSJLqeM7ThfQ1esNHLHfOPl9KAMmaeSZvm49KXy5G2rtPTvXUfYIVUbI/pip10oSTqcHpnFAFXQopm2xsDntiuog0+N/3dwSoPfsap2lpLHcKSu0L0NdjBbi4tFZgckdAKAK8ENskBjUjaPek8kZ+QZWrEFkzodsJJB9KtWenONvmblHXmgCnboxbqAc/TFbMIDbQcEjjNJ9hRflZSTnOQatxKEIIUewoA6PSWaSBU9uK0vnAHXHpWXpwPkBy2Fz9K0l3BSVPFAGlpzZ55APFaiAEgegrAsZJY2bBOK04bp1Od2fwoA0yAOeR6VBcbSh3YBpFmZ1yxP8AhTZV8yEsCcYxzQBzeoMoB9PauX1KfBCr0ro9SUohCtkVx12583G7mgAWfahOCe9QpMz3AY9Oij1qxFGksZWRvpVbyGeXbCd2B2oAl85hhWY7SeRVO9nCNjPzEYFTXEUkY5U57msS7n/elm+gxQBPqFxEtth0/eEdzzXnXi/UQ1u6A4A4Ara1zUJDMWZskDHFcD4km86fYCQMZ5oAzVdg2VPNTJdSpxnr1qkCQcnH50/eR06UAW3l3NlTimE5qsrFRyakR8980ASNz2zS/Z/OXCA7x0xT4UaRiqgZPrW1pka24IxmQ9c0AYgga2wGBzTmYbx9a1bpA7uHFYN2REGC5J7E9qAJJrpvNUIzcH16V9T/AAXvm1DwYhnI+0Biv1FfJ9opkdR3JxX0D8J799P1WytM/uXULj3oA9U8TQqfDl9A6/65SuBXyRroEN3Km3BUlSD2r638XuI5LeLdw7ZxXyr8Qbf7P4pvlIx8+cUAcZcbTOuOvNFNn+W5FFAHrfwng8/xNEcZEas5r6M8J3Qk0+eaXgRZzXgXwbjxqd9MP+WcJr2TRJzb+C9TmY4dtxGaAPJfiRdya02pK+SSSyH2HQV4o4JbueeB6V6xqksrzHA3Fuw71wmuac9heE4z5hyMdBQBn2gCOrTDKeldJZqPK38BMcAViRwFiSxyOtTxTSxMBH9wdQaANV4jK3AyOwPai4iiRVEgwR1xUR1KNY8RDdIewq9puj3N+UmnyEIzigDFNjLdykWynaejEVp2OhmLHmjLH1rrrLSkgA2qSQOMVp2Wlh3Tg5PXIoA5qy0gFDujwB3FXo9LLfwfL2ArtJtLSK3SJFxJnJxzmp9K0Z2P7xCPb0oA4f8As35jhcbe1a+laTJIQAM+oxXew+GY0kWSQZY84rUt9ORTnaqDp6UAcUPDsxA+VQOp45roLLSIoLddgz71uyQqo6fjUEs0cMXUE+goAx5YXRiEGPTAqu0DswLg59cVp3d1uTfDGDjjOaxnuppHKmQ49qALsdmxAwam+xbFVuSR/nmqdrLOj4ViQeea14GaVsdzwTQBetYg8SA9uwFattEfIcY4BHPeo4bKRgihT06itIwGCHB5I9KAIYEfbhOe1WUQjACqaLKMluPXpWgkWACBzmgCKBSz7doz9KmuI9ttIoUA4POalRQrnBwcU513L6ZBFAHn+owyK0nUjGa5SeweaYlMggZxXo2pWjK5AGV9RWBLGIpSyp1HegDjorC8O7cnAOMZ61LHb3sbARxEetdXGHbgYA6mpIplik3SbCPpQBzVvbX8xcOnyk8g1Vm8NPcyusox7iu8W/sFUB/lqrLqNh5hxLHnP97BoA8s1fwgYGY7d4AzzXnWoaI8k7u0BTPAz0r2jxJ4gt1kliAYKOMnvXEz69GI2iW3V1B4LDmgDzSbQ+SCcGqjaQ4l8tG5PQGuu1S/MhJjiVcH86jsbm0uLhftiGM+o6UAcRdWs1vIUkX9KhBPTjA7ivVrjRYLgF7fbID6c1zGr+Gihfy1KsKAOagkIxzge1aEV6NyhudtZk8T28hSQYIFQebnoTQBu6hepLGDGAJeh9qyCMnJGfrUMcpV8NzVpDuI2jdntQBp6BprTzmdE3RxckV33g+7aHXLSRnOFkXHtzWL4ftxZwKnOXGW+taTRGG4S6j4dGBZfb1oA908cS51OwJHylRg186/FyIxeMrgEYJCn9K991uY3lnpNyFyXjU4PavC/jUuPGcme8S8fhQB5fc/8fQ/Gii4YG5HFFAHuPwjIjs9VkwA20LXoviK4ax+G0joNxLAcd+a85+FD4sNTwRyR1r0fWVWf4fT+YcrGc0Aeb2sSxWqzNhp5Fzg/wAIrM1bT4rq1ZQv7wfdyKm0md3Qkndg8Zqxqt0ltEZJSFcjgCgDz+d/sm5WG1hwQaz/ADJ7qcRwr14yK3J9OuddnMqgKB7dRXYeGfDUFuq71wx6kjNAGL4b8NEATPhm6nNei2Vmogjwm0gYwOgq/aaXHFtyuABWjb6YkpyS6r2FAGZa2G8jIGM1t2emBGwoHTggVpQ2ACgIOBWpBAE2kgb6AMxNNywLAEjqa07W1x/CcetWgoXqDmpIm2AsD0oAg8oqTknIqEuoBG3cc5+lPu3aViUwM1DGrDBA/DFAFS4MjvgH5T0AqhcI2CoXGPQ1pyKRk/xd6pyqXU55284oAz3zFHgdDzUHl703IBx19avsGMb8DGelVU+Vzg9aAGwK0bEnoexrVsHOcBVA9faqmzDAkZA6gVesYwzEgcUAdTZPlQM8dKtMwCYwSc4zWVY5DKqccdK1QTjnGfcUAWrOIKMg9atEZwVwCPWqMUsqrztHtVhbksuWFAE64CjkGllY+V8vJ/pVdnLEZx+VS5JiyDQBnXjnbnPOehrktZuo7TJfDMP4a6m/wiM79R0FeZ69c75JmkOcHjFABdaw21jE+AegqjDqEwmy5yT2zWC0/wC84Bx61GLoiUkNx6+lAG9f3zlCXwCfSuM1PUpYZ/MBJz09qu398QpBfIPSuX1G78xvmJIFAFLVdbvPNLM+5W7E1Rj1dZV+f5faqepnd86/drIdugFAG5dXaswIIxTYrj96CR06VgKzKeGJHvU6SsSPmoA7XTtRe2lEkfB7gV0lnqFrqEckdyipI3QjnNedw3eFHOSRWzopd7rfu6dB0oAqeLNOLyHyxhR0I71xkqGFyHPNeypY/wBp28kcagunPI61wfiTRGjZiEwVPOBQByfmA+tX9Kl8q5R3GVXnmqHlskoXGccZq4hGzFAHo1lPDPEHhOWPUZovbj95Cikl2YDjoRXE6XfvaShc/J35rrvDwbVNWs2RhtZ1AH40Ae86jEYrHRwFBxGox6cV4R8Z23+NJO5ES/yr6LltzcW8KkgtEAVr5o+LU3m+M7vcdxUBeO3FAHnMjZuRgYopJeLqigD2z4XEC31FG7gV6zqVof8AhXUsA5dxuA9s1418Mmc6q1uOTN8uB35r6AnRWtvsmPk2bcfhQB8/3wXTYRL02dqyLPzddulLEmEHAxVzxxvl1mSwjI2xsQ+K2vB+mCAplSqZxx2oA6bQdDigUAD7o4OK6i30xNqyKg3e/ep7G2Xy14GK2bW13quRhR2oAzLezZ2AVQPXNasNrt2qxzitOK1VU6D6UgUY2jscZxQBFDAqnCggVI6bcEAY/WnlwgK9vWqzycgDk96AHMRwDnNQyE4IPSpossxFPaNW5I496AIIlG0Y5qUIVHIOD3p6xkcbeT0qYr0XHPp2oAy7i3IBKkZ9M1SlUqcr1FdCbcuOnP0qCWyBOcH3NAHPNAzq3ljrTWtFx86gMK33tVjTIAANQSwjcG4xjkmgDL8rI4GD0q7p8JDhDwTUiKgIAK81q6dCFkyQC3qaAL1jbJFGC33/AFq46IEVscGmbCRwMk1ZK7I1DLggUAVm2gAY69aBt28AYqOQFs/3u1RbiThuAv60AaESq5XA5HpV1YV2HJ4HOBVG3J7jitBf9W4HWgDC1tQ1rIE+9zivG9fkJlZMAtnk16vrszKrc889K801eGOa4EjyhDyPrQBy77I8s5OfSqM3zys0P5VZ1BfLmZd2RnrWf5gjfrg0AUbuZslHGD2rntSfaCp6nniupuZVlQqRuY9CK5vUrR1YkcjpQBzl1IxTGe9UWHNatzb4U9sGqDoQTQBVoUYNSMuKRRk0AWrKTDhTjHSu98IWiTzAOMk/yrz2KNi4Ck7vQV7P8MNBl2re3SYXsGoA7nQ9BhtoPM27WYdK57xH4YF5MxjXa2eT6ivTLWDfGvpnNNmt1VWGAQfWgD5u8VeEBCpECYcc5HevPJIntnKSAhgcV9X6/oKSxs6KM46ntXh3xB8PGHe5QLKOmO9AHnckh24BGR3Nej/BSZbjxEtrNyqjzF49K8v+ZZSjqQ2cc9K7P4f3L6ZqUV+Dt2OAfcd6APrXTecM57Yr5P8AiLJnxdqhznEzdfrX1ck6ppUF4MFJE3L+Ir5Q+IqMvinUdwG5pCT+NAHDbg84NFKAFnwePSigD134auV8V6eeg8zk+1fRMpHlyz87VzXzv8M49/iC3K84DEZr3dp2k8GySLzKW2cfWgDyjWtHVtckv+onYsfY10Oj24ChQuU71rNYJNZGNlHmMOD6GnaLaH/VsP4uTQBuaFb5VQ3EeeM966eOJEUcfhWZaRBAF6KvStMS4VgCM4oAWQ9wKgmfauCCWpGmO0Z6+3FQkliCf1oAadxNCJ3x0604E9Owq1CnHJznk0ARwxkHJ4HbNWFhJ7547Usa7mxgYHar0cJJyeB7UAVoYM5znIqzDbZwxBwe1WFjAAPFSFgqHPQUAQtCFHSqd3tXvjnpVi5nZuFPGME1m3Jyxzn6mgCleXL44UbRVFy0g5yfoa0LiINg8/SoBHtAwAR0oAqxAg8iug0fb5ihwQDWT5Q3CtqxQoi4oA3444wNyZOKinI6j8T2qOCZl429utOllATGMZ9KAKcnDZ7UzaJCCQMVJLIgbmlV4/WgB6cEADCg1ft2j6HPPGKzhIiAnJNSpcKMEZoAzfEFkArHIK/rXj3ieQwSsFbkZIr1jXborC+7gYPFeG+MpnkmZmJAA9eKAOT1S9laRz5pyeeDWXHqU6SZMmf97vVe9mImYVSR9zE0AdHHqySACVNuO4qfMU653Ag+lc+owvr9aSOV4m+UsD9aANW808PCSSCO2OtYF3p7JkgE4rct9R3kLIvzetX5YkkiBPJPNAHAyRNnpUYjbniuxn0pZVbC89qhsdBmuLuO3RCWYgA0AN8EaNLqOrIqR7wMbuOlfRWm2Yt4YYf7i4OBWZ4D8IRaBF5z8zuuDjtXYx24MhYjmgBYFZI/b0prcgngmpXULwM1Smk8kMQ2B3oAZdkeUd3uMGvOPFmmLdrJ5xHPQgdK76aUTEHqO1ZOqWyzxFSPm7UAfNXirQ2t7lzErHnA4pNNDJCI8bTnoa9kuvD6XLsZUyBnbXB+INHXT7kypwufm9qAParW+M/ww0qQH5vlQnPoa8D+KQMfiq8yvO0HHrxXrfhq9+0fDaEJ0husfhXkvxawvim5yDnav8qAPOwS1wC1FMi/1oooA9j+FrKNfjz94xt+HFezC4WHwrFkjHn4P514Z8Mp/K8RWuejMV/OvabqJm8N3sIxuiff9OaANO0hDBSOSea1orKOJQdvOOcCsfwhJ9sgUvkMgxn1rqwCEHFAFYY2Y9KZIw/GmXDeUcgcn17VWjO85IP1oAtpuJO4jFTIMscioo0bBxzV23BA+bGT3oAWOLpn86sRQkkhRx60+2hLHLDjNaUUXHFAFaG2AXk8+tWgm0EE/hUjhR71GzcDFAEUzYG0EZqswkY8nn26VaMZPWlVMdOTQBUaPMfPLVVkiJYArz7VsCIkEAdaZJbksO340AY0lvuPINQtbfNnp7VveQOODQLYknA49KAMDycvgA1sW0TCMBuDjoKk+x4lXI/Kte2tliAJGT70AVobdmjywIpksW1eSDjvitrAK4xwfSs+6UDIxx2oAyHQBs4pmwDpnFTOdzEjt1pn06ZoAiKsWAzwB0qaNCSc56dKAAPvVftUHl7gKAOU8Vx+XYPIvpivDPGEhaYqOAK+hfFODZsCuVPUEV4F44tPJu96jCPmgDzO8XEze/NQwgFuB9a0L2Aglu3aqNooErZzz0oAtqPlwRSGIYyKkEbEn+lTxQ7s7unrQBSWPBzg1YhlkjIG4lfQ1Zjt15yaeLQhgSMg0AaloomgVQQf5133w+0KaW/S4MeEj6EivP8ARbeaW/jSFeM4NfR/heFYNKij2BTtHPegCdLJxggfWnyxhCdo7c1sIAsPIzmqF5Hwcce1AGPMx3YY1mXZ8wEE5FaM4/Duao3QJT5e1AGPI7QOcDjP1p4fzxhG3MafPHzjGD3osYvLkJI4zQArWgWEArnFea/Eu1FtZsyj/WD5eK9aZeOB15rz/wAdWhvrSXcCTEcrQBS8Hx+R8PLaNxlpLnd9ea8o+LMok8VX2w8YVR+Ve220As9G0u22YC4cjNfPvj+6W48QahIp4MhAoA5SH/WCiiH/AFgooA9B8J3BtryGVTykgb9a+hLBllknTIYXMW8H1yK+bdCY+YQeMHrXv3hS4NxpemXAxmM+W1AHR+HYhY2ke7gk4YV00kwWPJbIx0qjLBsuScfKQDVJ7vfcmMMCq96ALc4D4Jzg+1Mj9DyPelBPr1oVAW68+hoAvQgjBrStIf3gLEkdarWkBHXOMZFa8C7VBx+FAE0UYB7Cpz8iEcVASdhYkbuwpuS+Mk0AOBJJqdITgjAY+9NjTbz3NW0AAwpye9AEIi2gBTyfTnFOS3xnceatRpkD+gqcQ7mzQBVWDGQBn1phtiW6fMK1Y4jnnGKeIMsD2oAyBbHeB3HPFWorPPIwM+/etZYkQdAceopjuqk7QCcUAZbWmPmYYPTFS7cICRx61JNLuByABSQShYyGXIPrQBGAN2RVC6/i75rRd0x8o4PYc1m3JweBQBlTHDnGKg8wh8cVal5OSAahIXrgUACMxPH41pWzfJjnGKz1YLyBzVmByCC3SgCrq4EkBU9DxzXlPizRjNbSoeVB3A+lewXkUcyZ3BcVyuq2kM/mxZ3A+1AHz/LoUs0rxpgBeuazBorQy/OuBng4r3Q+HVAyiruPbFZreEJJpCDGDn3oA8hms2iKbU3KfSrMemzvCCYzzXpi+A7pZdyxkpnpmt/TvB08MeZBhf7uO9AHjtro05IAjPXHSuksfDcoZPNtyc9favVbDwikEqySHeV56VsLp0ayqzJ09qAOK8NeF4Le5ScQ4PfIruokIlGF2qKsRxAfKowtEgCY5GaALAcbcMcY9KgmUcse/amNLgdRupqzZYqeTQBTu4N3zAYz29Kypos7gRiujIzk44qjd2+77vTvQBgi2BY7uh9qbLEFXgcdq05F2qQKzryURxZPXHFAFQ3fy+WrfN/Ksy6s1urgIQTGfvE1Se78q/Ejt1PPpXSW0Q2CY854HvQBxeuXAtba4lbkW6EAj9K+addkMk0jnBLuWJr3f4n3X2SzmgQgPMxyB6V4JqvzngdDQBnQ/wCsFFEP+sFFAHV6QxS4x2LV7b8LLlXuDYv0fDr9RXiOmxgTDlutet/DbMev2ZUnOf6UAe46i4GnyyIOUGAK5O3OTuwQScmuo1L5bBMd25rGniRHBUYOM0ATW7EqdwP51q2Man5mHHasuzXfMoJOCM10NooAVe1AF63UKBu7dKslgpznIqFRyKYw/enk9KALAJds549KspGOD0PXiq0Y5q5EcnHpQBYRBgf3T1571ZWMDhRtJFQryv0qzFzjPYYoAkSIbOeAPTvVyBCVwce1QwoMg+lX1AHPegBFQDPencCioJGJJ59qACZiWCjJz6VCY8tlm/AVJ3zUYJJJ9KAIpURk7VXlX5Op46Crco796hKg8GgDNbcG4JGOOtVbhnLHqa2njUA4Has+cDFAGTIzDtg1Xd35zitBhzVZgNxoAqNK4+tOimYHB55qSVARUaRrkHmgAeYs/IIx6mkWFHclgOalkiUjvUiIA+B0AoAjjtgW3DGQMdK1NNtYn+8gz64qCJQB71oWg2jigDThsoiAAAB9KgvVgiG1FBbHWniRlhyCazp3YS5BoAz7uaRG+QAnvxUcdwV++c+tWLkb2bJP4VWEKmTnNAFrdFIhKnFVZsbs5BxViFAMjHFLPAgPAoAzGYEnIAJphyH6DJPWrs0CAZAqnIvz96AJUkyuKf1ye5qmBt6E1YdiNuO9AFK+jxuOBxya5nUZCxx/CK6q+G6Jge9clfKFZwCcUAc5fQG4lSNemeT6V2tjtfTbdQfu8Z9a52CNRHJIM7/WtbTWK6CWH3t5GaAPEfildm51+9XP7uI7VNePakcucHqa9S8dLu1K+JJyXNeYX0QaXknrQBSh/wBYKKnihXzByaKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a partially calcified primary tuberculous complex in a three-year-old girl. There is right-sided hilar adenopathy with some atelectasis along the horizontal fissure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey R Starke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29377=[""].join("\n");
var outline_f28_44_29377=null;
var title_f28_44_29378="Nodules in coccidioidomycosis";
var content_f28_44_29378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular lesions of coccidioido- mycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 257px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prominent raised nodules on the nose and cheek due to disseminated coccidioidomycosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29378=[""].join("\n");
var outline_f28_44_29378=null;
var title_f28_44_29379="Iobenguane: Patient drug information";
var content_f28_44_29379=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Iobenguane: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/23/32117?source=see_link\">",
"     see \"Iobenguane: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6860203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AdreView&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to see if there is a tumor in the adrenal glands or nervous system.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to iobenguane or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12178 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29379=[""].join("\n");
var outline_f28_44_29379=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6860203\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020045\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020047\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020046\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020051\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020052\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020054\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020049\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020050\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020055\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020056\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/23/32117?source=related_link\">",
"      Iobenguane: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_44_29380="Bismuth: Patient drug information";
var content_f28_44_29380=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bismuth: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     see \"Bismuth: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/14/30948?source=see_link\">",
"     see \"Bismuth: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bismatrol Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Bismatrol [OTC];",
"     </li>",
"     <li>",
"      Diotame [OTC];",
"     </li>",
"     <li>",
"      Kao-Tin [OTC];",
"     </li>",
"     <li>",
"      Kaopectate&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Kaopectate&reg; [OTC];",
"     </li>",
"     <li>",
"      Peptic Relief [OTC];",
"     </li>",
"     <li>",
"      Pepto Relief [OTC];",
"     </li>",
"     <li>",
"      Pepto-Bismol&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Pepto-Bismol&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691873",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn and upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701635",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bismuth, salicylates, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705277",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems, chickenpox, or flu signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698374",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in tongue color.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698234",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Metallic taste. This will most often go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11924 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29380=[""].join("\n");
var outline_f28_44_29380=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141521\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023246\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023245\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023250\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023251\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023253\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023248\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023249\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023254\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023255\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=related_link\">",
"      Bismuth: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/14/30948?source=related_link\">",
"      Bismuth: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_44_29381="Surgical treatment of human bite";
var content_f28_44_29381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Surgical treatment of human bite",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Human bite injuries require hospital admission, antibiotics, debridement in the OR and delayed primary wound closure. A wide exposure of the wound is required and the joint should be opened and inspected, even if the joint capsule appears intact. As shown in the photograph, exposure of the metacarpophalangeal joint is required to demonstrate the true extent of the injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29381=[""].join("\n");
var outline_f28_44_29381=null;
var title_f28_44_29382="Spica cast application";
var content_f28_44_29382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Spica cast application",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Application of a 90 degree/90 degree spica cast.",
"    <br>",
"     (A) Generous padding is applied over the foot, and a pad is placed on the popliteal fossa to prevent injury to the peroneal nerve and popliteal vessels.",
"     <br>",
"      (B) A long leg cast is applied with the knee flexed 90 degrees. Longitudinal traction should NOT be applied while extending the long leg cast to the spica component to avoid the risk of an acute compartment syndrome.",
"      <br>",
"       (C) A mold is placed over the apex of the fracture, generally correcting a varus deformity into slight valgus.",
"       <br>",
"        (D) Using a standard spica table, the spica cast is applied with the hip flexed 90 degrees and abducted 30 degrees.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced with permission from: Kasser JR, Beaty JH. Femoral Shaft Fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"        </div>",
"        <div class=\"contractual\">",
"         <br/>",
"         <a href=\"file://www.lww.com\">",
"          file://www.lww.com",
"         </a>",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29382=[""].join("\n");
var outline_f28_44_29382=null;
var title_f28_44_29383="Gestational hypertension";
var content_f28_44_29383=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gestational hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/44/29383/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29383/contributors\">",
"     Lissa Magloire, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29383/contributors\">",
"     Edmund F Funai, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/44/29383/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29383/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/44/29383/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29383/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/44/29383/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational hypertension is one of several causes of hypertension in pregnant women. It occurs in about 6 percent of pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational hypertension is defined as systolic blood pressure &ge;140 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic blood pressure &ge;90 mmHg in a previously normotensive pregnant woman who is &ge;20 weeks of gestation and has no proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The blood pressure readings should be documented on at least two occasions at least six hours apart. It is considered severe when sustained elevations in systolic blood pressure &ge;160 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic blood pressure &ge;110 mmHg are present for at least six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gestational hypertension is a temporary diagnosis for hypertensive pregnant women who do not meet criteria for preeclampsia (both hypertension and proteinuria) or chronic hypertension (hypertension first detected before the 20th week of pregnancy). The diagnosis is changed to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preeclampsia, if proteinuria develops",
"     </li>",
"     <li>",
"      Chronic hypertension, if blood pressure elevation persists &ge;12 weeks postpartum",
"     </li>",
"     <li>",
"      Transient hypertension of pregnancy, if blood pressure returns to normal by 12 weeks postpartum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, reassessment up to 12 weeks postpartum is necessary to establish a final definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK OF PROGRESSION TO PREECLAMPSIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of gestational hypertension is unknown. It is not clear whether gestational hypertension and preeclampsia are different diseases with a similar phenotype (hypertension) or if gestational hypertension is an early or mild stage of preeclampsia.",
"   </p>",
"   <p>",
"    There are some data to suggest preeclampsia and gestational hypertension are different diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primiparity is a strong risk factor for preeclampsia, but not for gestational hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The recurrence risk for gestational hypertension is several-fold higher than that for preeclampsia (20 to 47 percent versus about 5 percent for preeclampsia at term) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Total blood and plasma volumes are significantly lower in women with preeclampsia (mean 2660",
"      <span class=\"nowrap\">",
"       mL/m2",
"      </span>",
"      and 1790",
"      <span class=\"nowrap\">",
"       mL/m2,",
"      </span>",
"      respectively) than in women with gestational hypertension (3139",
"      <span class=\"nowrap\">",
"       mL/m2",
"      </span>",
"      and 2132",
"      <span class=\"nowrap\">",
"       mL/m2,",
"      </span>",
"      respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is also consistent evidence that preeclampsia develops in 15 to 25 percent of women initially diagnosed with gestational hypertension, and that women who progress to preeclampsia have characteristics different from those who continue to have nonproteinuric hypertension:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with early onset of gestational hypertension are more likely to progress to preeclampsia than women with late onset. In one study, women who presented with gestational hypertension who progressed to preeclampsia presented four weeks earlier (33 versus 37 weeks) than those who did not progress [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/11\">",
"       11",
"      </a>",
"      ]. In other studies, 40 to 50 percent of women with gestational hypertension presenting at &le;30 weeks developed preeclampsia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/12,13\">",
"       12,13",
"      </a>",
"      ] compared with about 10 percent of those who developed gestational hypertension at &ge;36 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women who go on to develop preeclampsia have higher total vascular resistance at presentation than women with uncomplicated gestational hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serial measurement of sFlt-1 levels reveals a substantial increase over time in women who go on to develop preeclampsia, but remain normal or only mildly elevated in women who maintain a diagnosis of gestational hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link\">",
"       \"Pathogenesis of preeclampsia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of gestational hypertension is clinical. As defined above: systolic blood pressure &ge;140 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic blood pressure &ge;90 mmHg in a previously normotensive pregnant woman who is &ge;20 weeks of gestation and has no proteinuria (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The main goals in the initial evaluation of pregnant women with newly developed hypertension are to distinguish gestational hypertension from preeclampsia, which has a different course and prognosis, and to determine whether hypertension is mild or severe, which affects management and outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in other patients with newly diagnosed hypertension, white coat hypertension should be excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .) In addition:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Measure protein excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary protein excretion should be determined since the presence or absence of proteinuria is the key clinical criterion that determines whether the patient will be given a diagnosis of gestational hypertension or preeclampsia. A urine dipstick of negative to trace should not be used to definitively exclude significant proteinuria since false negative results occur with low specific gravity (&lt;1.010), high salt concentration, highly acidic urine, or with nonalbumin proteinuria. A positive urine dipstick value, especially if only +1, also requires confirmation since false positives occur. Urine protein can be quantitated using a urine protein-to-creatinine ratio on a random urine sample or with a 24-hour urine collection. We prefer the latter, as it conforms to the most widely accepted diagnostic criteria for preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23544?source=see_link\">",
"     \"Evaluation of proteinuria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even after this evaluation, it can be difficult to exclude preeclampsia conclusively. Studies have shown that 10 percent of women with clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histological manifestations of preeclampsia have no proteinuria and 20 percent of women with eclampsia (a form of severe preeclampsia) do not have significant proteinuria prior to their seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/16\">",
"     16",
"    </a>",
"    ]. Therefore, when mild hypertension is accompanied by any of the signs and symptoms of severe disease (see below), the patient should be managed as a patient with severe preeclampsia, even if proteinuria is not present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Evaluate for signs/symptoms of severe preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be questioned regarding signs and symptoms of severe preeclampsia, such as severe headache, visual changes, epigastric or right upper quadrant pain,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    or decreased urine output. Severe preeclampsia can be present even though hypertension is mild and proteinuria is absent (",
"    <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Perform laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation helps to determine whether there is end organ involvement, which occurs with severe preeclampsia, but not gestational hypertension. Changes consistent with severe preeclampsia include hemoconcentration, thrombocytopenia, and elevation in creatinine concentration, hepatic transaminases,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lactic acid dehydrogenase (",
"    <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Determine the severity of hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is considered severe when systolic blood pressure is &ge;160 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic blood pressure is &ge;110 mmHg, and mild when systolic blood pressure is &ge;140 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic blood pressure is &ge;90 mmHg. There is no established definition for moderate hypertension in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Assess fetal well-being",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all hypertensive pregnancies, fetal well-being should be assessed with a biophysical profile or nonstress test with amniotic fluid estimation. We also obtain a sonographic estimation of fetal weight; umbilical artery Doppler velocimetry is reserved for fetuses with growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PERINATAL OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy outcomes of patients with mild gestational hypertension are generally favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/2,5,6,13,17\">",
"     2,5,6,13,17",
"    </a>",
"    ]. The mean birthweight and rates of fetal growth restriction, preterm birth, abruption, and perinatal death are similar to those in the general obstetrical population.",
"   </p>",
"   <p>",
"    By comparison, pregnancies associated with severe gestational hypertension appear to be at increased risk of maternal and perinatal morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/2,5-7,13,17,18\">",
"     2,5-7,13,17,18",
"    </a>",
"    ]. These pregnancies have rates of preterm delivery, small for gestational age infants, and abruptio placentae significantly higher than the rates in the general obstetrical population, and similar to rates reported for women with severe preeclampsia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study that compared selected outcomes in women who developed severe gestational hypertension (group 1) and women who remained normotensive or developed mild gestational",
"      <span class=\"nowrap\">",
"       hypertension/mild",
"      </span>",
"      preeclampsia (group 2) reported the rate of delivery at &lt;35 weeks for group 1 and group 2 was 25.0 and 8.4 to 9.7 percent, respectively, and the rate of delivery of small-for-gestational-age infants was 20.8 and 6.5 to 4.8 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/6\">",
"       6",
"      </a>",
"      ]. However, there were only 24 patients with severe gestational hypertension (group 1), which limits the interpretation of these results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pregnant women with hypertensive disorders is based on practice patterns established over the years. There are sparse data from well-designed randomized clinical trials on which to base recommendations. Moreover, available data often come from studies with patients with a variety of diagnoses, including mild preeclampsia, mild gestational hypertension, mild pregnancy-induced hypertension, mild chronic hypertension, and nonproteinuric preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mild gestational hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients can be managed safely as outpatients with weekly antepartum visits. Bedrest appears to reduce the risk of worsening hypertension, but neither bedrest nor use of low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    prevent progression to severe preeclampsia, nor do these interventions improve outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Patient education and counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education and counseling are important components of management since these patients are at increased risk of developing preeclampsia, and other pregnancy complications. We instruct patients to report any symptoms suggestive of severe disease (severe headache, visual changes, epigastric or right upper quadrant pain,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    or decreased urine output). We also review signs suggestive of possible",
"    <span class=\"nowrap\">",
"     fetal/placental",
"    </span>",
"    impairment, such as decreased fetal movement and vaginal bleeding, and signs of preterm labor. Patients should be given appropriate numbers to call care providers for questions and emergencies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fetal assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for, type, and frequency of fetal assessment are controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/2\">",
"     2",
"    </a>",
"    ]. There is no evidence from large randomized trials that any routine surveillance method results in a decreased risk of fetal death or neonatal morbidity. Nevertheless, antepartum fetal monitoring of pregnancies deemed to be at increased risk of adverse fetal outcome is a routine obstetrical practice in the United States, based upon circumstantial evidence.",
"   </p>",
"   <p>",
"    In our practice, we ask patients with mild gestational hypertension to monitor fetal movement daily and call if it is decreased or absent. We order either a nonstress test with sonographic estimation of the amniotic fluid index or a biophysical profile weekly. We also perform serial ultrasound examinations to monitor fetal growth every three to four weeks, as hypertension of any etiology may be associated with placental insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=see_link\">",
"     \"Overview of fetal assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     No antihypertensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We refrain from using antihypertensive agents, unless hypertension is severe because data from randomized trials show that medical therapy of mild hypertension does not improve maternal or neonatal outcome. These data are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     No antenatal glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A course of antenatal glucocorticoids is usually not indicated for pregnancies with mild gestational hypertension because the disorder typically develops after 34 weeks of gestation and is not an indication for preterm birth. A review of pregnancy outcomes in women with mild gestational hypertension found that delivery before 34 weeks occurred in only 1 to 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Timing of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/23\">",
"     23",
"    </a>",
"    ] and a retrospective cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/24\">",
"     24",
"    </a>",
"    ] suggest that induction of labor of hypertensive patients by 40 weeks is associated with a lower rate of adverse outcome than expectant management, even when the cervix is unfavorable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/25\">",
"     25",
"    </a>",
"    ]. Given the low risk of neonatal problems with delivery at term and the potential increase in risk of serious complications with expectant management, we deliver patients with gestational hypertension no later than their estimated date of delivery. The optimum time for intervention is more controversial.",
"   </p>",
"   <p>",
"    A consensus opinion from a workshop held by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the Society for Maternal-Fetal Medicine (SMFM) suggested delivery at",
"    <span class=\"nowrap\">",
"     37",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     38",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks for all women with any degree of gestational hypertension because of the risk of progression to preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/26\">",
"     26",
"    </a>",
"    ], a recommendation endorsed by the American College of Obstetricians and Gynecologists (ACOG) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/27\">",
"     27",
"    </a>",
"    ]. Authors of a retrospective cohort study from the Consortium on Safe Labor concluded induction of labor between 38 and 39 weeks of gestation achieved optimal balance of low maternal and low neonatal",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/28\">",
"     28",
"    </a>",
"    ]. We individualize these cases based on the degree of hypertension, presence of comorbidities, and the presence of risk factors for adverse pregnancy outcome. For uncomplicated pregnancies with only occasional blood pressures no higher than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg, we may not intervene until",
"    <span class=\"nowrap\">",
"     40",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    weeks. For pregnancies with more frequent or higher blood pressures in the range for mild hypertension (ie,",
"    <span class=\"nowrap\">",
"     &lt;160/100",
"    </span>",
"    mmHg), we deliver at 37 to 39 weeks depending on patient specific factors: severity of hypertension, presence of other risk factors for adverse pregnancy outcome, past obstetrical history, increasing blood pressure over time. Given low but increased neonatal morbidity of early term birth",
"    <span class=\"nowrap\">",
"     (37",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     38",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks), we attempt to avoid intervention before 39 weeks in women with stable mild gestational hypertension and otherwise uncomplicated pregnancies, but monitor them closely. There is no benefit to late preterm delivery and these infants are at increased risk of morbidity compared to term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/26,29\">",
"     26,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22713?source=see_link\">",
"     \"Late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During labor, we monitor women with gestational hypertension for development of proteinuria, worsening hypertension, and symptoms of severe disease since preeclampsia can manifest intrapartum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/4\">",
"     4",
"    </a>",
"    ]. We do not administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    seizure prophylaxis unless proteinuria is noted or the patient develops severe hypertension or symptoms or laboratory abnormalities associated with severe preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Severe gestational hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with severe gestational hypertension (blood pressure",
"    <span class=\"nowrap\">",
"     &ge;160/100",
"    </span>",
"    mmHg) are delivered preterm. Systolic blood pressure &ge;160 mmHg or diastolic blood pressure &ge;105 mmHg is treated with antihypertensive agents to reduce the risk of a maternal cerebrovascular event (",
"    <a class=\"graphic graphic_table graphicRef55212 \" href=\"UTD.htm?8/42/8875\">",
"     table 2",
"    </a>",
"    ), although there are no data showing that severe gestational hypertension is associated with cerebrovascular regulatory defects (as seen in preeclampsia) or that these women are at increased risk of stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who develop severe gestational hypertension have rates of pregnancy complications comparable to those with severe preeclampsia, and thus are managed similarly (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Perinatal outcome'",
"    </a>",
"    above). Delivery of pregnancies at or beyond 34 weeks of gestation and administration of a course of antenatal glucocorticoids to patients less than 34 weeks is a reasonable approach. If the patient's blood pressure is easily controlled and she remains free of proteinuria or other symptoms of severe preeclampsia, inpatient hospitalization is an option, with delivery if",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    of severe preeclampsia develop. There is no strong evidence to recommend one approach over another. We tend to favor delivery at 34 to 36 weeks in severe cases, especially if fetal lung maturity is documented via amniocentesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link&amp;anchor=H31268927#H31268927\">",
"     \"Preeclampsia: Management and prognosis\", section on 'Severe preeclampsia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We give women with severe gestational hypertension peripartum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    for seizure prophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MATERNAL PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42894607\">",
"    <span class=\"h2\">",
"     Postpartum course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with gestational hypertension become normotensive within the first postpartum week [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/30\">",
"     30",
"    </a>",
"    ]. By definition, all should be normotensive by the 12th postpartum week, otherwise they are given the diagnosis of chronic hypertension, which happens in about 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean time to normalization of blood pressure postpartum after preeclamptic pregnancies is about two weeks. The slower rate of recovery in preeclampsia may reflect the time required for resolution of the endothelial injury, which may not be present in gestational hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42894614\">",
"    <span class=\"h2\">",
"     Recurrence risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational hypertension tends to recur with subsequent pregnancies. In two large studies, the prevalence of gestational hypertension in a second pregnancy ranged from 22 to 47 percent among women with gestational hypertension in their first pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42894621\">",
"    <span class=\"h2\">",
"     Long-term prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational hypertension is associated with development of hypertension later in life, and possibly associated with development of diseases related to hypertension (cardiovascular disease, chronic kidney disease, diabetes mellitus) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. A prospective study of over 15,000 women with a first singleton birth observed that women with gestational hypertension in three consecutive pregnancies had significantly higher blood pressure later in life than women who remained normotensive (systolic pressure 27 mmHg higher, diastolic pressure 12 mmHg higher) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29383/abstract/33\">",
"     33",
"    </a>",
"    ]. They also had more unfavorable lipid and glycemic profiles, but these differences appeared to be due to higher body mass index at follow-up in women with a history of hypertension in pregnancy. Clinical monitoring, risk factor evaluation, and early intervention might benefit women with a history of hypertension of any etiology in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=see_link\">",
"       \"Patient information: High blood pressure and pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gestational hypertension is defined as systolic blood pressure &ge;140 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic blood pressure &ge;90 mmHg after the 20th week of pregnancy without proteinuria in a previously normotensive woman. These criteria distinguish gestational hypertension from preeclampsia (proteinuria must be present) and chronic hypertension (hypertension antedates pregnancy or develops before the 20th week of pregnancy). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preeclampsia develops in 15 to 25 percent of women initially diagnosed with gestational hypertension. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk of progression to preeclampsia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy outcomes of patients with mild gestational hypertension are generally favorable, whereas pregnancies associated with severe gestational hypertension are at increased risk for maternal and perinatal morbidity, similar to the rates reported for women with severe preeclampsia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Perinatal outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main goals in the diagnostic evaluation of women with gestational hypertension are to distinguish this disorder from preeclampsia, which has a different course and prognosis, and determine whether hypertension is mild or severe, which affects management and outcome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We follow pregnancies with mild gestational hypertension with weekly prenatal visits and fetal assessment. For otherwise uncomplicated pregnancies with only an occasional blood pressure no higher than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg, we suggest avoiding intervention before",
"      <span class=\"nowrap\">",
"       39",
"       <sup>",
"        0/7ths",
"       </sup>",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       40",
"       <sup>",
"        0/7ths",
"       </sup>",
"      </span>",
"      weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For pregnancies with frequent elevations of blood pressure to",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg or blood pressures",
"      <span class=\"nowrap\">",
"       &gt;140/90",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       &lt;160/100",
"      </span>",
"      mmHg, we suggest delivery at",
"      <span class=\"nowrap\">",
"       37",
"       <sup>",
"        0/7ths",
"       </sup>",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       39",
"       <sup>",
"        0/7ths",
"       </sup>",
"      </span>",
"      weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The exact timing of delivery within this interval depends on patient specific factors; more severe hypertension warrants earlier delivery. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Timing of delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If gestational hypertension is accompanied by any of the symptoms or laboratory abnormalities associated with severe preeclampsia, we manage the patient as if she has severe preeclampsia, including antihypertensive therapy, prompt delivery, and use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      for seizure prophylaxis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gestational hypertension is likely to recur with subsequent pregnancies and is associated with development of hypertension later in life. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Maternal prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/1\">",
"      Yoder SR, Thornburg LL, Bisognano JD. Hypertension in pregnancy and women of childbearing age. Am J Med 2009; 122:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/2\">",
"      Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003; 102:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/3\">",
"      Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/4\">",
"      ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/5\">",
"      Hauth JC, Ewell MG, Levine RJ, et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 2000; 95:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/6\">",
"      Buchbinder A, Sibai BM, Caritis S, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol 2002; 186:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/7\">",
"      Villar J, Carroli G, Wojdyla D, et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol 2006; 194:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/8\">",
"      Hjartardottir S, Leifsson BG, Geirsson RT, Steinthorsdottir V. Recurrence of hypertensive disorder in second pregnancy. Am J Obstet Gynecol 2006; 194:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/9\">",
"      Brown MA, Mackenzie C, Dunsmuir W, et al. Can we predict recurrence of pre-eclampsia or gestational hypertension? BJOG 2007; 114:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/10\">",
"      Silver HM, Seebeck M, Carlson R. Comparison of total blood volume in normal, preeclamptic, and nonproteinuric gestational hypertensive pregnancy by simultaneous measurement of red blood cell and plasma volumes. Am J Obstet Gynecol 1998; 179:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/11\">",
"      Davis GK, Mackenzie C, Brown MA, et al. Predicting transformation from gestational hypertension to preeclampsia in clinical practice: a possible role for 24 hour ambulatory blood pressure monitoring. Hypertens Pregnancy 2007; 26:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/12\">",
"      Saudan P, Brown MA, Buddle ML, Jones M. Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol 1998; 105:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/13\">",
"      Barton JR, O'brien JM, Bergauer NK, et al. Mild gestational hypertension remote from term: progression and outcome. Am J Obstet Gynecol 2001; 184:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/14\">",
"      Valensise H, Vasapollo B, Novelli GP, et al. Maternal total vascular resistance and concentric geometry: a key to identify uncomplicated gestational hypertension. BJOG 2006; 113:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/15\">",
"      Noori M, Donald AE, Angelakopoulou A, et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/16\">",
"      Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990; 163:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/17\">",
"      Hnat MD, Sibai BM, Caritis S, et al. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol 2002; 186:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/18\">",
"      Knuist M, Bonsel GJ, Zondervan HA, Treffers PE. Intensification of fetal and maternal surveillance in pregnant women with hypertensive disorders. Int J Gynaecol Obstet 1998; 61:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/19\">",
"      Crowther CA, Bouwmeester AM, Ashurst HM. Does admission to hospital for bed rest prevent disease progression or improve fetal outcome in pregnancy complicated by non-proteinuric hypertension? Br J Obstet Gynaecol 1992; 99:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/20\">",
"      Schiff E, Barkai G, Ben-Baruch G, Mashiach S. Low-dose aspirin does not influence the clinical course of women with mild pregnancy-induced hypertension. Obstet Gynecol 1990; 76:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/21\">",
"      Corr&ecirc;a RR, Gilio DB, Cavellani CL, et al. Placental morphometrical and histopathology changes in the different clinical presentations of hypertensive syndromes in pregnancy. Arch Gynecol Obstet 2008; 277:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/22\">",
"      Magee LA, von Dadelszen P, Bohun CM, et al. Serious perinatal complications of non-proteinuric hypertension: an international, multicentre, retrospective cohort study. J Obstet Gynaecol Can 2003; 25:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/23\">",
"      Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009; 374:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/24\">",
"      Nicholson JM, Kellar LC, Kellar GM. The impact of the interaction between increasing gestational age and obstetrical risk on birth outcomes: evidence of a varying optimal time of delivery. J Perinatol 2006; 26:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/25\">",
"      Tajik P, van der Tuuk K, Koopmans CM, et al. Should cervical favourability play a role in the decision for labour induction in gestational hypertension or mild pre-eclampsia at term? An exploratory analysis of the HYPITAT trial. BJOG 2012; 119:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/26\">",
"      Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/27\">",
"      American College of Obstetricians and Gynecologists. Committee Opinion No. 560. Medically indicated late-preterm and early-term deliveries. Obstet Gynecol 2013; 121:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/28\">",
"      Cruz MO, Gao W, Hibbard JU. What is the optimal time for delivery in women with gestational hypertension? Am J Obstet Gynecol 2012; 207:214.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/29\">",
"      Barton JR, Barton LA, Istwan NB, et al. Elective delivery at 34(/) to 36(/) weeks' gestation and its impact on neonatal outcomes in women with stable mild gestational hypertension. Am J Obstet Gynecol 2011; 204:44.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/30\">",
"      Ferrazzani S, De Carolis S, Pomini F, et al. The duration of hypertension in the puerperium of preeclamptic women: relationship with renal impairment and week of delivery. Am J Obstet Gynecol 1994; 171:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/31\">",
"      Reiter L, Brown MA, Whitworth JA. Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension. Am J Kidney Dis 1994; 24:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/32\">",
"      Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003; 326:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/33\">",
"      Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol 2009; 114:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/34\">",
"      Robbins CL, Dietz PM, Bombard J, Valderrama AL. Gestational hypertension: a neglected cardiovascular disease risk marker. Am J Obstet Gynecol 2011; 204:336.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29383/abstract/35\">",
"      M&auml;nnist&ouml; T, Mendola P, V&auml;&auml;r&auml;sm&auml;ki M, et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation 2013; 127:681.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6805 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29383=[""].join("\n");
var outline_f28_44_29383=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK OF PROGRESSION TO PREECLAMPSIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Measure protein excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Evaluate for signs/symptoms of severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Perform laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Determine the severity of hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Assess fetal well-being",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PERINATAL OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mild gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Patient education and counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - No antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - No antenatal glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Timing of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Severe gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MATERNAL PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42894607\">",
"      Postpartum course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42894614\">",
"      Recurrence risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42894621\">",
"      Long-term prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6805\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6805|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/60/43979\" title=\"table 1\">",
"      Criteria for severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/42/8875\" title=\"table 2\">",
"      Drug doses for oral treatment of hypertension in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23544?source=related_link\">",
"      Evaluation of proteinuria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22713?source=related_link\">",
"      Late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=related_link\">",
"      Overview of fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=related_link\">",
"      Patient information: High blood pressure and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_44_29384="Chapter 4B: Countercurrent mechanism";
var content_f28_44_29384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 4B: Countercurrent mechanism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/44/29384/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29384/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29384/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/44/29384/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29384/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/44/29384/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29384/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/44/29384/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2003.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid leaving the proximal tubule is isosmotic to plasma. However, the excretion of an isosmotic urine is usually not adequate to meet the homeostatic requirements of the body. After a water load, for example, water must be excreted in excess of solute. This requires the excretion of urine that is hypoosmotic to plasma. Conversely, water must be retained and a hyperosmotic urine excreted after a period of water restriction. The formation of a dilute (hypoosmotic to plasma) or concentrated (hyperosmotic to plasma) urine is achieved via the countercurrent mechanism, which includes the loops of Henle, the cortical and medullary collecting tubules, and the blood supply to these segments.",
"   </p>",
"   <p>",
"    Before discussing these processes in detail, it is useful to summarize their basic aspects. The excretion of a concentrated urine involves two major steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The medullary interstitium is made hyperosmotic by the reabsorption of NaCl without water in the medullary ascending limb of the loop of Henle. Urea entry into the interstitium from the medullary collecting tubule also contributes to this process.",
"     </li>",
"     <li>",
"      As the urine enters the medullary collecting tubule, it equilibrates osmotically with the interstitium, resulting in the formation of a concentrated urine. Antidiuretic hormone (ADH), released from the posterior pituitary, plays an essential role in this process by increasing collecting tubule permeability to water, which is very low in the basal state. ADH appears to act by inserting aquaporin-2 water channels into the luminal membrane, thereby allowing transcellular water reabsorption to occur down an osmotic gradient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link\">",
"       \"Chapter 6B: Antidiuretic hormone and water balance\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, two modifying factors are important for the maintenance of medullary hyperosmolality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Water equilibrating in the medullary collecting tubule dilutes the interstitium, a change that would decrease maximum concentrating ability. To minimize this effect, the volume of urine presented to this segment is markedly reduced in the cortex by ADH-sensitive water reabsorption in the cortical collecting tubule.",
"     </li>",
"     <li>",
"      Medullary blood flow in the vasa recta is arranged in a hairpin configuration to minimize removal of the excess interstitial solute.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Urinary dilution also has two basic steps, the first of which is the same as in urinary concentration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NaCl reabsorption without water in the ascending limb of the loop of Henle decreases the osmolality of the tubular fluid at the same time as it increases the osmolality of the interstitium.",
"     </li>",
"     <li>",
"      The urine remains dilute if water reabsorption in the collecting tubules is minimized by keeping these segments poorly permeable to water. This requires the relative absence of ADH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COUNTERCURRENT MULTIPLICATION: LOOPS OF HENLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In humans, the maximum urine osmolality that can be attained is 900 to 1400",
"    <span class=\"nowrap\">",
"     mosmol/kg;",
"    </span>",
"    the normal plasma osmolality is much lower at about 285",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    Since the urine becomes concentrated by equilibrating with the medullary interstitium, this means that a similar high osmolality must be achieved in the interstitium. The process by which the interstitial osmolality in the medulla is increased from 285",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (isosmotic to plasma) to 900 to 1400",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    is called countercurrent multiplication. (Countercurrent refers to the opposite directions of flow in the descending and ascending limbs that result from the hairpin configuration of the loop.)",
"   </p>",
"   <p>",
"    The exact mechanism of countercurrent multiplication is incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The following discussion has been simplified by emphasizing the generation of an interstitial osmotic gradient from the corticomedullary junction to the inner medulla. At any level, however, there are also likely to be variations in the interstitial osmolality with increasing distance from the vasa recta capillary bundles [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One essential factor in countercurrent multiplication is the different permeability and transport characteristics of the descending and ascending limbs of the loop of Henle. The descending limb is permeable to water and to a lesser degree NaCl and urea, whereas both the thin and thick segments of the ascending limb are impermeable to water, but are able to transport NaCl into the interstitium (",
"    <a class=\"graphic graphic_figure graphicRef54287 \" href=\"UTD.htm?17/40/18063\">",
"     figure 1",
"    </a>",
"    ). These differences in water permeability are related to the presence (thin descending limb) or absence (ascending limb) of water channels in the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The water channels in the thin descending limb are called aquaporin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]; they are similar to those in the luminal membrane of the proximal tubule but different from the ADH-sensitive water channels (called aquaporin-2) in the collecting tubules (see Chap. 6) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As will be seen, the",
"    <strong>",
"     only active step",
"    </strong>",
"    in countercurrent multiplication is NaCl reabsorption in the thick ascending limb, the mechanism for which is depicted in this figure (",
"    <a class=\"graphic graphic_figure graphicRef75301 \" href=\"UTD.htm?30/62/31725\">",
"     figure 2",
"    </a>",
"    ). In contrast, only passive solute transport appears to occur in the descending and",
"    <strong>",
"     thin",
"    </strong>",
"    ascending limbs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The mechanism by which the thin ascending limb might reabsorb NaCl will be reviewed below; for the sake of simplicity, the following discussion on the generation of the interstitial osmotic gradient will assume that the thin and thick ascending limbs function in a homogeneous manner.",
"   </p>",
"   <p>",
"    The efficiency of countercurrent multiplication varies directly with the",
"    <strong>",
"     length",
"    </strong>",
"    of the thick ascending limb. Thus, this process primarily occurs in the 30 to 40 percent of nephrons that have long loops of Henle that descend into the inner medulla (",
"    <a class=\"graphic graphic_figure graphicRef75301 \" href=\"UTD.htm?30/62/31725\">",
"     figure 2",
"    </a>",
"    ). The glomeruli of these nephrons are located in the juxtamedullary area and the midcortex. In contrast, there is little direct contribution from the outer cortical nephrons, which have short loops that turn around in the outer medulla or even the inner cortex (",
"    <a class=\"graphic graphic_figure graphicRef75301 \" href=\"UTD.htm?30/62/31725\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Generation of medullary interstitial hyperosmolality",
"    </span>",
"    &nbsp;&mdash;&nbsp;If one could start at a hypothetical time zero, the fluid in the descending and ascending limbs and in the interstitium would be isosmotic to plasma, similar to that delivered into the descending limb from the proximal tubule (",
"    <a class=\"graphic graphic_figure graphicRef56829 \" href=\"UTD.htm?19/61/20446\">",
"     figure 3",
"    </a>",
"    ). The first and primary step in countercurrent multiplication is the transport of NaCl from the ascending limb of the loop of Henle into the interstitium; this process is limited by the maximum transtubular gradient that can be achieved, which in this example is 200",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    Since the ascending limb is impermeable to water, this results in an increase in interstitial osmolality from 285 to 385",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    The fluid in the descending limb then equilibrates osmotically with the interstitium, primarily by water movement out of the tubule. As water enters the interstitium, interstitial osmolality is maintained by continued NaCl transport out of the ascending limb. The net effect is the establishment of a 200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    gradient between the fluid in the ascending limb (185",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    and that in the interstitium and descending limb (385",
"    <span class=\"nowrap\">",
"     mosmol/kg).",
"    </span>",
"   </p>",
"   <p>",
"    As",
"    urine flows through the tubules, and NaCl transport in the ascending limb continues, the initial step in this figure (",
"    <a class=\"graphic graphic_figure graphicRef56829 \" href=\"UTD.htm?19/61/20446\">",
"     figure 3",
"    </a>",
"    ) is multiplied, resulting in the generation of a much higher interstitial osmolality. An example of how this might occur is shown in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef53203 \" href=\"UTD.htm?17/43/18103\">",
"     figure 4",
"    </a>",
"    ). For the sake of simplicity, steps 1 to 8 are depicted as discrete instants in time, even though ion transport and urine flow occur simultaneously in the intact kidney. In steps 1 and 2, a 200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    gradient is established between the fluid in the ascending limb and that in the descending limb and interstitium. In step 3, urine moves through the tubules, with the hyperosmotic fluid in the descending limb flowing into the ascending limb. As NaCl is again pumped into the interstitium to a gradient of 200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in step 4, the osmolality of the inner medullary interstitium is now 485",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    as compared with 385",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in step 2.",
"   </p>",
"   <p>",
"    These steps illustrate the basic aspects of countercurrent multiplication: NaCl transport out of the ascending limb makes the interstitium and descending limb hyperosmotic; the hyperosmotic fluid in the descending limb then flows in a countercurrent fashion into the ascending limb; the combination of a higher tubular fluid osmolality in the inner medullary ascending limb (385",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in step 3 versus 285",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in step 1) and reestablishment of the 200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    gradient between the ascending limb and interstitium results in a further elevation in interstitial osmolality.",
"   </p>",
"   <p>",
"    As the sequence in this figure (",
"    <a class=\"graphic graphic_figure graphicRef53203 \" href=\"UTD.htm?17/43/18103\">",
"     figure 4",
"    </a>",
"    ) goes on (steps 5 to 8), the osmolality continues to rise, being highest in the tubule at the hairpin turn and in the interstitium at the papillary tip (the inner medulla). The osmolality at these sites is directly proportional both to the length of the loops and to the gradient achieved between the ascending limb and the interstitium. In humans, the maximum osmolality at the papillary tip can reach 900 to 1400",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef80628 \" href=\"UTD.htm?3/1/3102\">",
"     figure 5",
"    </a>",
"    )&dagger;. This is relatively inefficient in comparison with other mammals. As an example, the desert rat, which infrequently comes in contact with water, has relatively long loops of Henle and can attain interstitial and urine osmolalities in the range of 5000",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;&dagger;Only about one-half of the papillary solute is NaCl, with urea accounting for most of the remainder. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Role of urea'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to increased length of the loop of Henle, more efficient urinary concentration in some species is also due in part to stimulation of NaCl reabsorption in the medullary thick ascending limb by ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. A cyclic adenosine monophosphate (AMP)-mediated rise in activity of the luminal Na+-K+-2Cl- carrier seems to be responsible for this effect [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/9\">",
"     9",
"    </a>",
"    ]. The applicability of these findings to humans is uncertain, since studies in isolated human tubules have not demonstrated an ADH-induced increase in cyclic AMP activity in the thick ascending limb [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Notice also that the osmolality of the tubular fluid leaving the ascending limb is hypoosmotic to plasma (",
"    <a class=\"graphic graphic_figure graphicRef80628 \" href=\"UTD.htm?3/1/3102\">",
"     figure 5",
"    </a>",
"    ). This fluid is further diluted by NaCl reabsorption without water in the cortical aspect of the thick ascending limb. As a result, the osmolality of the urine leaving the loop of Henle is approximately 100",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/12\">",
"     12",
"    </a>",
"    ]. If the collecting tubules are impermeable to water (ADH absent), this dilute urine will be excreted relatively unchanged. In contrast, if the collecting tubules are permeable to water (ADH present), the urine will equilibrate with the interstitium and a concentrated urine will be excreted (",
"    <a class=\"graphic graphic_figure graphicRef80628 \" href=\"UTD.htm?3/1/3102\">",
"     figure 5",
"    </a>",
"    ). Thus, the",
"    <strong>",
"     final osmolality",
"    </strong>",
"    of the urine is mostly determined by the water permeability of the collecting tubules, not by events in the loop of Henle&dagger;.",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;&dagger;Although the interstitial osmolal gradient is primarily created by those nephrons with long loops, urine from all nephrons drains into the collecting tubules (see Fig. 4-1) and equilibrates osmotically with the interstitium in the presence of ADH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COLLECTING TUBULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the loops of Henle, the cortical and medullary collecting tubules possess distinct permeability characteristics, being in the basal state relatively impermeable to the passive movement of NaCl, and, with the exception of the innermost part of the medullary collecting tubule, to urea and water (",
"    <a class=\"graphic graphic_figure graphicRef54287 \" href=\"UTD.htm?17/40/18063\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The impermeability to NaCl is essential, since it permits the high NaCl concentration in the interstitium to act as an effective osmotic gradient between the tubular fluid and interstitium.",
"   </p>",
"   <p>",
"    ADH promotes urinary concentration primarily by increasing the water permeability of the collecting tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/2,13,14\">",
"     2,13,14",
"    </a>",
"    ] via the insertion of unique water channels (called aquaporin-2) into the luminal membrane (see Chap. 6) * [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/7,15\">",
"     7,15",
"    </a>",
"    ] *. In the medullary collecting tubule, this allows the tubular fluid to reach osmotic equilibrium with the hyperosmotic interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. The reabsorbed water then returns to the systemic circulation via the capillaries of the vasa recta.",
"   </p>",
"   <p>",
"    The cortical collecting tubule plays an equally important role in the concentrating process. The maximum urine osmolality attained in the medulla cannot exceed that in the interstitium at the papillary tip. As water leaves the medullary collecting tubule, it decreases the interstitial osmolality by dilution, thereby reducing the maximum urine osmolality that can be achieved. This effect is minimized because the volume of fluid presented to the medullary collecting tubule is",
"    <strong>",
"     markedly reduced",
"    </strong>",
"    by ADH-induced water reabsorption in the cortical collecting tubule&dagger; [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. In the presence of ADH, the hypoosmotic fluid entering the cortical collecting tubule equilibrates with the cortical interstitium, which is isosmotic to plasma (",
"    <a class=\"graphic graphic_figure graphicRef80467 \" href=\"UTD.htm?33/5/33885\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If, for example, the osmolality of the tubular fluid entering cortical collecting tubule is 100",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    then osmotic equilibration will result in the reabsorption of almost two-thirds of the water that has been delivered. Furthermore, additional water will be reabsorbed, down the osmotic gradient established by aldosterone-induced NaCl reabsorption in this segment (see Chap. 8). This marked reduction in tubular fluid volume permits concentration of the urine to proceed in the medulla with minimum dilution of the medullary interstitium. Since cortical blood flow is more than 10 times the maximum rate of urine flow, the water reabsorbed in the cortex is rapidly returned to the systemic circulation without dilution of the cortical interstitium.",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;&dagger;Water reabsorption is probably minimal in the distal tubule and connecting segment, which, like the ascending limb, are relatively impermeable to water both in the basal state and in the presence of ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of ADH, the collecting tubules remain poorly permeable to water. As a result, much less water is reabsorbed and a dilute urine is excreted. Since active NaCl transport continues in these segments, the minimum urine osmolality may be reduced from 100",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in the distal tubule to 50 to 75",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in the final urine.",
"   </p>",
"   <p>",
"    ADH is able to play this central role in the regulation of water excretion because its release varies directly with the plasma osmolality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    .) Thus, a water load sequentially lowers the plasma osmolality, ADH secretion, collecting tubule permeability to water, and the urine osmolality. The net effect is excretion of the excess water. These steps are reversed with water loss, as the increase in plasma osmolality stimulates the release of ADH, resulting in a rise in urine osmolality and a marked reduction in further water loss. Increased water intake due to a concurrent stimulation of thirst then returns water balance to normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ROLE OF UREA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discussion thus far has emphasized the importance of NaCl accumulation in the medullary interstitium in the concentrating process. However, almost one-half of the approximately 1200 mosmol of solute per kilogram present at the papillary tip during antidiuresis is urea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/1\">",
"     1",
"    </a>",
"    ]. The high interstitial concentration of urea is produced by diffusion down a favorable concentration gradient from the inner medullary collecting tubule into the interstitium (",
"    <a class=\"graphic graphic_figure graphicRef71317 \" href=\"UTD.htm?15/37/15967\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/13,19\">",
"     13,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ADH, acting in both the cortex and the medulla, plays a central role in this process by increasing the water permeability of the collecting tubules. As water is reabsorbed in the cortex and outer medulla, the urea concentration in the tubular fluid rises markedly, since these segments are essentially impermeable to urea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In contrast, permeability to urea in the innermost part of the medullary collecting tubule is relatively high in the basal state (mediated by specific luminal membrane urea carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]) and is increased further by ADH, apparently by insertion of new urea transporters into the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/13,22,23\">",
"     13,22,23",
"    </a>",
"    ]. These effects allow urea to passively diffuse into the interstitium at this site.",
"   </p>",
"   <p>",
"    The ADH-regulated urea transporter, UT-A1, that is primarily responsible for urea transport in the medullary collecting tubule has been identified and cloned [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/21\">",
"     21",
"    </a>",
"    ]. As expected, UT-A1 is principally expressed in the innermost part of the medullary collecting tubule. A splice variant of UT-A1, called UT-A3, also contributes to urea transport in this anatomic area [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to ADH, urea accumulation in the medulla is also indirectly dependent upon active NaCl transport in the ascending limb. The ensuing increase in interstitial osmolality affects urea transport in two ways. First, it directly increases the activity of the inner medullary urea transporter via an effect that is independent of ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/25\">",
"     25",
"    </a>",
"    ]. Second, loop NaCl reabsorption makes the tubular fluid dilute and the interstitium concentrated, thereby creating the osmotic gradients that allow water reabsorption to occur in the collecting tubules; the increase in water reabsorption raises the tubular fluid urea concentration, enhancing the gradient for urea entry into the interstitium.",
"   </p>",
"   <p>",
"    Some of the urea that accumulates in the interstitium reenters the tubule in the thin ascending limb and the descending limb [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/1,3,19\">",
"     1,3,19",
"    </a>",
"    ]. This recirculation of urea occurs via another urea transporter splice variant, UT-A2 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/21,26\">",
"     21,26",
"    </a>",
"    ]. The net effect of this urea recycling is that the quantity of urea in the early distal tubule is the same as or slightly exceeds the amount filtered, even though 60 to 65 percent of the filtered urea has been reabsorbed in the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, both urinary and interstitial urea concentrations are maintained at high levels in the presence of ADH&dagger;.",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;&dagger;The volume of the medullary interstitium is relatively small. The weight of both kidneys in humans is approximately 350 g, most of which is composed of nephron segments, tubular fluid, and blood vessels. Thus, the attainment of high concentrations of urea in the medullary interstitium requires only small amounts of urea. Since approximately 27 to 32 g (about 500 mmol) of urea is excreted per day, the interstitial accumulation of urea does not importantly affect total urea excretion.",
"   </p>",
"   <p>",
"    The rise in medullary interstitial osmolality produced by urea allows the concentrating process to be more efficient in several ways. The most evident is that the higher interstitial osmolality maximizes concentrating ability and allows the excretion of large quantities of urea without obligating concurrent water loss [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/22\">",
"     22",
"    </a>",
"    ]. The interstitial accumulation of urea also promotes osmotic water movement out the descending limb of the loop of Henle. This water flux leads to an elevation in the tubular fluid Na+ concentration entering the thin ascending limb and to a reduction (by dilution) in the interstitial Na+ concentration. Both of these changes promote passive Na+ reabsorption in the thin ascending limb (see below). Thus, urea indirectly plays an important role in primary step in the countercurrent mechanism: the transport of Na+ out of the ascending limb into the medullary interstitium.",
"   </p>",
"   <p>",
"    The overall importance of urea in the concentrating process can be appreciated from experimental studies in which ADH secretion is minimal because of a large water load or hereditary diabetes insipidus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In the absence of ADH, urea accumulation in the interstitium is virtually abolished, since the decline in water reabsorption in the cortical and outer medullary collecting tubules prevents the increase in the tubular fluid urea concentration that is necessary for urea diffusion (",
"    <a class=\"graphic graphic_figure graphicRef79201 \" href=\"UTD.htm?24/10/24749\">",
"     figure 8",
"    </a>",
"    ). NaCl accumulation is also reduced because, as just described, urea accumulation indirectly promotes NaCl reabsorption in the thin ascending limb.",
"   </p>",
"   <p>",
"    These findings demonstrate that papillary osmolality is not constant but varies with the availability of ADH. It is likely that a similar situation exists in humans. In patients with central diabetes insipidus or those who shut off ADH secretion by chronic water loading, the ability to concentrate the urine after the administration of ADH is impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/30\">",
"     30",
"    </a>",
"    ]. In one study, maintaining a high fluid intake in normal subjects for only three days was sufficient in one study to lower the maximum ADH-induced urine osmolality by over 400",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (from approximately 1180",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    to 760",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/31\">",
"     31",
"    </a>",
"    ]. Washout of medullary urea and NaCl was probably responsible for this effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NACL REABSORPTION IN THIN ASCENDING LIMB",
"    </span>",
"    &nbsp;&mdash;&nbsp;NaCl reabsorption in the thin ascending limb appears to be primarily passive, not active as in the thick ascending limb [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/3,32\">",
"     3,32",
"    </a>",
"    ]. How a favorable concentration gradient for NaCl diffusion might be created can be appreciated if we review the aspects of countercurrent multiplication that have been discussed thus far (",
"    <a class=\"graphic graphic_figure graphicRef68564 \" href=\"UTD.htm?32/57/33686\">",
"     figure 9",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Active NaCl reabsorption without water in the thick ascending limb makes the tubular fluid dilute and the interstitium concentrated (step 1). This dilute fluid, in the presence of ADH, equilibrates osmotically with the isosmotic interstitium in the cortical collecting tubule (step 2) and then with the hyperosmotic interstitium in the medullary collecting tubule (step 3). The removal of water (but not urea) from the tubular fluid in these segments results in a marked elevation in the urea concentration, which diffuses into the interstitium in the inner medullary collecting tubule (step 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At this point, let us suppose that the interstitial osmolality at the papillary tip is 1200",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    half of which is NaCl (300",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of both Na+ and Cl-) and half of which is urea. The fluid entering the descending limb from the proximal tubule has an osmolality of about 300",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    a Na+ concentration of 150",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and a urea concentration below 10",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    similar to that in the plasma. If we assume that equilibration with the hyperosmotic interstitium occurs entirely by water movement out of the tubule (step 4), then three-quarters of this fluid must be reabsorbed to raise the tubular fluid osmolality to 1200",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    the value at the hairpin turn in the interstitium (",
"    <a class=\"graphic graphic_figure graphicRef80628 \" href=\"UTD.htm?3/1/3102\">",
"     figure 5",
"    </a>",
"    ). If, however, osmotic equilibration is impaired because of the absence of aquaporin-1, then concentrating ability is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This elevation in osmolality will be accompanied by a four-fold increase in the tubular fluid Na+ concentration to about 600",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    well above that in the interstitium. This will promote passive NaCl diffusion out of the thin ascending limb, which is relatively permeable to these ions (step 5) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/3\">",
"     3",
"    </a>",
"    ]. Although there is a similar inward gradient for urea in this segment (since the interstitial concentration is so high), the degree of urea entry into the tubule is much less because of a lower urea permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, the net effect is NaCl reabsorption without water and a reduction in the tubular fluid osmolality, both of which are required for countercurrent multiplication.",
"   </p>",
"   <p>",
"    The major problem with this model is that it is dependent upon osmotic equilibration in the descending limb occurring almost entirely by water removal, thereby leading to a marked elevation in the transtubular NaCl concentration gradient. It is possible, however, that the high interstitial concentration of urea could lead to passive diffusion of this solute into the tubule. This is likely to occur, since parts of the descending limb have a relatively high urea permeability (",
"    <a class=\"graphic graphic_figure graphicRef54287 \" href=\"UTD.htm?17/40/18063\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. To the degree that osmotic equilibration occurs by urea entry, there will be a lesser rise in the tubular fluid NaCl concentration.",
"   </p>",
"   <p>",
"    The net effect is that there does not appear to be a sufficient transtubular NaCl gradient established to support the degree of passive transport required for countercurrent multiplication to proceed. Thus, the exact mechanism by which thin ascending limb reabsorption occurs is at present incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/2,3,32\">",
"     2,3,32",
"    </a>",
"    ]. It is possible that some component of active transport may be required in the later part of the thin ascending limb [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This model also does not explain the mechanisms of transcellular NaCl reabsorption in the thin ascending limb. Evidence suggests that Na+ reabsorption primarily occurs via the paracellular pathway between the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/34\">",
"     34",
"    </a>",
"    ], while Cl- reabsorption occurs via a kidney-specific Cl- channel called CLC-K1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How these processes are linked is not clear. A possible common thread is that high Cl- as well as Na+ and urea permeability prevents the dissipation of the inner medullary solutes by upward fluid flow in the thin ascending limb [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/36\">",
"     36",
"    </a>",
"    ]. The relative importance of the Cl- channel in urinary concentration has been demonstrated by the finding of polyuria due to ADH resistance in mice that lack this channel [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COUNTERCURRENT EXCHANGE: VASA RECTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The capillaries of the vasa recta are derived from the efferent arterioles of the juxtamedullary glomeruli and have a hairpin configuration, similar to the loops of Henle (",
"    <a class=\"graphic graphic_figure graphicRef72439 \" href=\"UTD.htm?18/11/18621\">",
"     figure 10",
"    </a>",
"    ). They play an important role in the maintenance of mass balance in the medulla by returning the NaCl and water reabsorbed in the loop of Henle and medullary collecting tubule to the systemic circulation. The ascending vasa recta are well adapted for such a role, since Starling's forces in these vessels are much in favor of fluid uptake: the oncotic pressure which promotes uptake is approximately 26 mmHg, whereas the hydraulic pressure which pushes fluid out of the capillary is only about 9 mmHg at the papillary tip [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The net effect is that the flow rate leaving the medulla in the ascending vasa recta is almost twice that entering the medulla in the descending vasa recta [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vasa recta also play an integral role in the maintenance of the medullary osmotic gradient [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/38\">",
"     38",
"    </a>",
"    ]. The vasa recta reach osmotic equilibrium with the interstitium, since they are permeable to solutes and water. Within the vasa recta, water permeability is dependent upon the water channel, aquaporin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the descending vasa recta, solute enters and water leaves as the plasma osmolality reaches a value similar to that in the interstitium at the papillary tip (",
"    <a class=\"graphic graphic_figure graphicRef72439 \" href=\"UTD.htm?18/11/18621\">",
"     figure 10",
"    </a>",
"    ). The very high interstitial sodium chloride and urea concentrations generate a sufficient osmotic pressure to promote free water loss, even though the direct effect of the intracapillary Starling's forces is to promote water and solute movement into the capillary [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the vasa recta left the kidney at the papilla, the combination of solute removal and water addition would reduce medullary osmolality. However, the medullary osmotic gradient is maintained because the vasa recta turn around at the papillary tip and return to the cortex. As a result, the solute removed from the interstitium in the descending limb is returned to the interstitium, i.e., exchanged, in the ascending limb down a favorable concentration gradient from the lumen to the interstitium. Similarly, water added to the interstitium in the descending limb reenters the capillary in the ascending limb. Allowing for a lag in equilibration, the blood returning to the cortex is only slightly hyperosmotic to plasma (325",
"    <span class=\"nowrap\">",
"     mosmol/kg).",
"    </span>",
"   </p>",
"   <p>",
"    Notice that this process of countercurrent exchange is driven by the preexisting transcapillary osmotic and concentration gradients. It is not dependent upon Starling's forces which, as described above, are more important in the net removal of the solutes and water that have entered the interstitium by tubular reabsorption.",
"   </p>",
"   <p>",
"    The low rate of medullary blood flow (6 percent of renal blood flow), which is partially under neurohumoral control [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/44\">",
"     44",
"    </a>",
"    ], also contributes to the maintenance of interstitial hyperosmolality. If medullary blood flow is increased, more blood at 325",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    will leave the medulla, and a significant washout of medullary solute can occur, with a reduction in interstitial osmolality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Washout of medullary solute can alter loop NaCl and water handling via the following sequence. It will diminish water reabsorption in the descending limb of the loop of Henle, since there is now a lesser osmotic gradient between the tubular fluid and the interstitium (step 4 in this figure (",
"    <a class=\"graphic graphic_figure graphicRef68564 \" href=\"UTD.htm?32/57/33686\">",
"     figure 9",
"    </a>",
"    )). This reduction in water removal will result in a lesser rise in the tubular fluid Na+ concentration, thereby decreasing passive NaCl reabsorption in the thin ascending limb (step 5 in this figure (",
"    <a class=\"graphic graphic_figure graphicRef68564 \" href=\"UTD.htm?32/57/33686\">",
"     figure 9",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    A clinical example in which each of these changes in loop function occurs is during an osmotic diuresis in which a large amount of nonreabsorbed solute is present in the urine. This may be seen with glucosuria in uncontrolled diabetes mellitus (see Chap. 25) or after an intravenous infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    . In these settings, medullary blood flow is enhanced by an unknown mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/45\">",
"     45",
"    </a>",
"    ], resulting sequentially in a decrease in papillary osmolality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/46\">",
"     46",
"    </a>",
"    ], and an elevation in both urine volume and Na+ excretion, primarily due to a fall in descending limb water reabsorption and ascending limb Na+ reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The countercurrent mechanism permits the kidney to excrete urine with an osmolality that varies in humans from a minimum of 50",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    to a maximum of 900 to 1400",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    The primary event in this process is active NaCl transport out of the thick ascending limb of the loop of Henle into the medullary interstitium, producing dilution of the tubular fluid and concentration of the interstitium. Because of the different permeability characteristics of the descending and ascending limbs, this first step results in countercurrent multiplication in which a medullary osmotic gradient is created that reaches its maximum at the papillary tip.",
"   </p>",
"   <p>",
"    The osmolal changes that may occur as the tubular fluid moves through the nephron are summarized in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef70181 \" href=\"UTD.htm?28/18/28974\">",
"     figure 11",
"    </a>",
"    ). The isosmotic urine delivered from the proximal tubule becomes hyperosmotic in the descending limb as it equilibrates with the medullary interstitium and then becomes hypoosmotic in the ascending limb as NaCl is reabsorbed without water. The final osmolality of the urine is determined in the collecting tubules in a manner dependent upon ADH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the presence of ADH, collecting tubule water permeability is increased, allowing osmotic equilibration of the tubular fluid with the isosmotic interstitium in the cortex and then the hyperosmotic interstitium in the medulla. The result is the excretion of a concentrated urine. ADH also contributes to the high medullary osmolality by permitting urea entry into the interstitium and, in some species, by promoting NaCl reabsorption in the medullary thick ascending limb.",
"     </li>",
"     <li>",
"      In the absence of ADH, the hypoosmotic urine leaving the loop of Henle does not equilibrate with the interstitium, and a dilute urine is excreted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These effects of ADH are dose-related. This is important because normal daily needs usually do not require maximal dilution or concentration of the urine. A normal subject, for example, may need to excrete 800 mosmol of solute and two liters of water per day to remain in the steady state. The excretion of urine with an average osmolality of 400",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    requires a submaximal ADH response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical example",
"    </span>",
"    &nbsp;&mdash;&nbsp;This chapter has emphasized the importance of ADH in the production of a concentrated urine. However, other factors also can contribute, including the effective circulating volume (i.e., the rate of effective tissue perfusion). As an example, the absence of ADH, as after a water load or with impaired production due to central diabetes insipidus, is generally associated with a urine osmolality below 100",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    and a urine output that can exceed 10",
"    <span class=\"nowrap\">",
"     L/day.",
"    </span>",
"   </p>",
"   <p>",
"    If,",
"    however, effective volume depletion is superimposed, the urine osmolality can rise to as high as 400",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    or more [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In this setting, the associated reduction in glomerular filtration rate and increment in proximal Na+ and water reabsorption can markedly diminish water delivery to the collecting tubules. The inner medullary collecting tubule is mildly permeable to water even in the absence of ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/13\">",
"     13",
"    </a>",
"    ]. As a result, the combination of a very low rate of delivery and a small amount of water reabsorption at this site can substantially raise the urine osmolality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29384/abstract/49\">",
"     49",
"    </a>",
"    ]. The net effect is that the presence of diabetes insipidus may be masked, since neither marked polyuria nor a very dilute urine is present. Volume repletion will reverse these changes and allow the correct diagnosis to be suspected.",
"   </p>",
"   <p>",
"    This discussion is continued elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13203?source=see_link\">",
"     \"Chapter 4C: Maintenance of cell volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/1\">",
"      Jamison RL, Maffly RH. The urinary concentrating mechanism. N Engl J Med 1976; 295:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/2\">",
"      Sands JM, Kokko JP. Current concepts of the countercurrent multiplication system. Kidney Int Suppl 1996; 57:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/3\">",
"      Wexler AS, Kalaba RE, Marsh DJ. Three-dimensional anatomy and renal concentrating mechanism. II. Sensitivity results. Am J Physiol 1991; 260:F384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/4\">",
"      Chou CL, Nielsen S, Knepper MA. Structural-functional correlation in chinchilla long loop of Henle thin limbs: a novel papillary subsegment. Am J Physiol 1993; 265:F863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/5\">",
"      Nielsen S, Pallone T, Smith BL, et al. Aquaporin-1 water channels in short and long loop descending thin limbs and in descending vasa recta in rat kidney. Am J Physiol 1995; 268:F1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/6\">",
"      Chou CL, Knepper MA, Hoek AN, et al. Reduced water permeability and altered ultrastructure in thin descending limb of Henle in aquaporin-1 null mice. J Clin Invest 1999; 103:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/7\">",
"      Nielsen S, Kwon TH, Christensen BM, et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/8\">",
"      Molony DA, Reeves WB, Andreoli TE. Na+:K+:2Cl- cotransport and the thick ascending limb. Kidney Int 1989; 36:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/9\">",
"      Molony DA, Reeves WB, Hebert SC, Andreoli TE. ADH increases apical Na+, K+, 2Cl- entry in mouse medullary thick ascending limbs of Henle. Am J Physiol 1987; 252:F177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/10\">",
"      Kim GH, Ecelbarger CA, Mitchell C, et al. Vasopressin increases Na-K-2Cl cotransporter expression in thick ascending limb of Henle's loop. Am J Physiol 1999; 276:F96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/11\">",
"      Morel F, Imbert-Teboul M, Chabard&egrave;s D. Receptors to vasopressin and other hormones in the mammalian kidney. Kidney Int 1987; 31:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/12\">",
"      Greger R, Vel&aacute;zquez H. The cortical thick ascending limb and early distal convoluted tubule in the urinary concentrating mechanism. Kidney Int 1987; 31:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/13\">",
"      Sands JM, Nonoguchi H, Knepper MA. Vasopressin effects on urea and H2O transport in inner medullary collecting duct subsegments. Am J Physiol 1987; 253:F823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/14\">",
"      Kokko JP. The role of the collecting duct in urinary concentration. Kidney Int 1987; 31:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/15\">",
"      Deen PM, Verdijk MA, Knoers NV, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994; 264:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/16\">",
"      GOTTSCHALK CW, MYLLE M. Micropuncture study of the mammalian urinary concentrating mechanism: evidence for the countercurrent hypothesis. Am J Physiol 1959; 196:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/17\">",
"      Woodhall PB, Tisher CC. Response of the distal tubule and cortical collecting duct to vasopressin in the rat. J Clin Invest 1973; 52:3095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/18\">",
"      Imai M. The connecting tubule: a functional subdivision of the rabbit distal nephron segments. Kidney Int 1979; 15:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/19\">",
"      Knepper MA, Roch-Ramel F. Pathways of urea transport in the mammalian kidney. Kidney Int 1987; 31:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/20\">",
"      You G, Smith CP, Kanai Y, et al. Cloning and characterization of the vasopressin-regulated urea transporter. Nature 1993; 365:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/21\">",
"      Shayakul C, Steel A, Hediger MA. Molecular cloning and characterization of the vasopressin-regulated urea transporter of rat kidney collecting ducts. J Clin Invest 1996; 98:2580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/22\">",
"      Knepper MA, Star RA. The vasopressin-regulated urea transporter in renal inner medullary collecting duct. Am J Physiol 1990; 259:F393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/23\">",
"      Nielsen S, Knepper MA. Vasopressin activates collecting duct urea transporters and water channels by distinct physical processes. Am J Physiol 1993; 265:F204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/24\">",
"      Terris JM, Knepper MA, Wade JB. UT-A3: localization and characterization of an additional urea transporter isoform in the IMCD. Am J Physiol Renal Physiol 2001; 280:F325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/25\">",
"      Sands JM, Schrader DC. An independent effect of osmolality on urea transport in rat terminal inner medullary collecting ducts. J Clin Invest 1991; 88:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/26\">",
"      Bagnasco SM. Gene structure of urea transporters. Am J Physiol Renal Physiol 2003; 284:F3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/27\">",
"      LASSITER WE, MYLLE M, GOTTSCHALK CW. NET TRANSTUBULAR MOVEMENT OF WATER AND UREA IN SALINE DIURESIS. Am J Physiol 1964; 206:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/28\">",
"      LEVITIN H, GOODMAN A, PIGEON G, EPSTEIN FH. Composition of the renal medulla during water diuresis. J Clin Invest 1962; 41:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/29\">",
"      Harrington AR, Valtin H. Impaired urinary concentration after vasopressin and its gradual correction in hypothalamic diabetes insipidus. J Clin Invest 1968; 47:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/30\">",
"      Miller M, Dalakos T, Moses AM, et al. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med 1970; 73:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/31\">",
"      EPSTEIN FH, KLEEMAN CR, HENDRIKX A. The influence of bodily hydration on the renal concentrating process. J Clin Invest 1957; 36:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/32\">",
"      Kondo Y, Abe K, Igarashi Y, et al. Direct evidence for the absence of active Na+ reabsorption in hamster ascending thin limb of Henle's loop. J Clin Invest 1993; 91:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/33\">",
"      Stephenson JL, Zhang Y, Tewarson R. Electrolyte, urea, and water transport in a two-nephron central core model of the renal medulla. Am J Physiol 1989; 257:F399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/34\">",
"      Koyama S, Yoshitomi K, Imai M. Effect of protamine on ion conductance of ascending thin limb of Henle's loop from hamsters. Am J Physiol 1991; 261:F593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/35\">",
"      Matsumura Y, Uchida S, Kondo Y, et al. Overt nephrogenic diabetes insipidus in mice lacking the CLC-K1 chloride channel. Nat Genet 1999; 21:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/36\">",
"      Knepper MA, Saidel GM, Hascall VC, Dwyer T. Concentration of solutes in the renal inner medulla: interstitial hyaluronan as a mechano-osmotic transducer. Am J Physiol Renal Physiol 2003; 284:F433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/37\">",
"      Devuyst O, Guggino WB. Chloride channels in the kidney: lessons learned from knockout animals. Am J Physiol Renal Physiol 2002; 283:F1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/38\">",
"      Zimmerhackl BL, Robertson CR, Jamison RL. The medullary microcirculation. Kidney Int 1987; 31:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/39\">",
"      Sanjana VM, Johnston PA, Deen WM, et al. Hydraulic and oncotic pressure measurements in inner medulla of mammalian kidney. Am J Physiol 1975; 228:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/40\">",
"      Pallone TL, Zhang Z, Rhinehart K. Physiology of the renal medullary microcirculation. Am J Physiol Renal Physiol 2003; 284:F253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/41\">",
"      Zimmerhackl B, Robertson CR, Jamison RL. Fluid uptake in the renal papilla by vasa recta estimated by two methods simultaneously. Am J Physiol 1985; 248:F347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/42\">",
"      Pallone TL, Edwards A, Ma T, et al. Requirement of aquaporin-1 for NaCl-driven water transport across descending vasa recta. J Clin Invest 2000; 105:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/43\">",
"      Pallone TL. Effect of sodium chloride gradients on water flux in rat descending vasa recta. J Clin Invest 1991; 87:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/44\">",
"      Chou SY, Porush JG, Faubert PF. Renal medullary circulation: hormonal control. Kidney Int 1990; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/45\">",
"      THURAU K. RENAL HEMODYNAMICS. Am J Med 1964; 36:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/46\">",
"      Goldberg M, Ramirez MA. Effects of saline and mannitol diuresis on the renal concentrating mechanism in dogs: alterations in renal tissue solutes and water. Clin Sci 1967; 32:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/47\">",
"      Seely JF, Dirks JH. Micropuncture study of hypertonic mannitol diuresis in the proximal and distal tubule of the dog kidney. J Clin Invest 1969; 48:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/48\">",
"      BERLINER RW, DAVIDSON DG. Production of hypertonic urine in the absence of pituitary antidiuretic hormone. J Clin Invest 1957; 36:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29384/abstract/49\">",
"      Valtin H, Edwards BR. GFR and the concentration of urine in the absence of vasopressin. Berliner-Davidson re-explored. Kidney Int 1987; 31:634.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7283 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-EB31556FB1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29384=[""].join("\n");
var outline_f28_44_29384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COUNTERCURRENT MULTIPLICATION: LOOPS OF HENLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Generation of medullary interstitial hyperosmolality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COLLECTING TUBULES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ROLE OF UREA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NACL REABSORPTION IN THIN ASCENDING LIMB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COUNTERCURRENT EXCHANGE: VASA RECTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical example",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7283\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7283|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/40/18063\" title=\"figure 1\">",
"      Loop permeability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/62/31725\" title=\"figure 2\">",
"      Loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/61/20446\" title=\"figure 3\">",
"      Countercurrent mechanism I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/43/18103\" title=\"figure 4\">",
"      Countercurrent mechanism II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/1/3102\" title=\"figure 5\">",
"      Countercurrent mechanism III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/5/33885\" title=\"figure 6\">",
"      Countercurrent mechanism CCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/37/15967\" title=\"figure 7\">",
"      Countercurrent mechanism urea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/10/24749\" title=\"figure 8\">",
"      Papillary composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/57/33686\" title=\"figure 9\">",
"      Countercurrent mechanism Review",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/11/18621\" title=\"figure 10\">",
"      Vasa recta flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/18/28974\" title=\"figure 11\">",
"      Concentration and dilution",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13203?source=related_link\">",
"      Chapter 4C: Maintenance of cell volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_44_29385="Pulmonary veno-occlusive disease";
var content_f28_44_29385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary veno-occlusive disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/44/29385/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29385/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29385/contributors\">",
"     Peter F Clardy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/44/29385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29385/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/44/29385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29385/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/44/29385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary veno-occlusive disease (PVOD) is a clinicopathologic syndrome that accounts for a small number of cases of pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The terms \"isolated pulmonary venous sclerosis,\" \"obstructive disease of the pulmonary veins,\" and \"venous form of primary pulmonary hypertension\" were previously used to describe the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. PVOD remains a poorly understood entity, with fundamental questions about its epidemiology, causes, natural history, and optimal treatment.",
"   </p>",
"   <p>",
"    PVOD is reviewed here. Issues related to the diagnosis and management of pulmonary hypertension are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true incidence of PVOD is unknown, primarily because many cases are probably misclassified as idiopathic pulmonary arterial hypertension (IPAH) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/8\">",
"     8",
"    </a>",
"    ]. The proportion of patients diagnosed with IPAH who fulfill criteria for PVOD was 10 percent in a pooled analysis of data from seven series (465 patients), with a range from 5 to 25 percent in separate reports [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/9-16\">",
"     9-16",
"    </a>",
"    ]. These data suggest that the annual incidence of PVOD is 0.1 to 0.2 cases per million persons in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of PVOD are detected in children and young adults, although the age at diagnosis has ranged from eight weeks to the seventh decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/18\">",
"     18",
"    </a>",
"    ]. The ratio of men to women with PVOD is approximately 1:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic hallmark of PVOD is extensive and diffuse occlusion of the pulmonary veins by fibrous tissue. The fibrous tissue may be loose and edematous, or dense and sclerotic. The former probably reflects an earlier stage of development (",
"    <a class=\"graphic graphic_figure graphicRef52802 \" href=\"UTD.htm?19/55/20342\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/9,21-23\">",
"     9,21-23",
"    </a>",
"    ]. The media of the pulmonary veins may become arterialized with an increase in elastic fibers. Recanalization of completely occluded vessels occurs over time, and calcium may encrust the elastic fibers in the walls of the veins or alveoli. Intimal thickening tends to be eccentric and usually involves the venules and small veins in the interlobular septa. Involvement of larger veins is rare.",
"   </p>",
"   <p>",
"    Pulmonary arterioles may also be involved, with moderate to severe medial hypertrophy in approximately one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/24\">",
"     24",
"    </a>",
"    ]. Arteritis and arterial plexiform lesions are usually absent.",
"   </p>",
"   <p>",
"    Alveolar capillaries may be engorged and tortuous, consistent with pulmonary capillary hemangiomatosis (PCH) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. In a retrospective cohort study, 73 percent of patients with PVOD had coexisting PCH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/28\">",
"     28",
"    </a>",
"    ]. This observation has led to the hypothesis that PCH may be caused by PVOD; specifically, PCH may be a proliferative response to pulmonary venous hypertension. Supporting this hypothesis, PCH can complicate other diseases characterized by pulmonary venous hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional findings include dilated pulmonary lymphatics, dilated pleural lymphatics, and interstitial edema that is most notable in lobular septa (",
"    <a class=\"graphic graphic_picture graphicRef72794 \" href=\"UTD.htm?2/8/2184\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/31\">",
"     31",
"    </a>",
"    ]. Concomitant type II pneumocyte hyperplasia and focal lymphocytic infiltrates occur in many patients and can be extensive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/23,32\">",
"     23,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-standing PVOD can result in the deposition of collagen fibers within lobular septa and, to a lesser degree, alveolar walls. These changes are similar to those noted in long-standing mitral stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/33\">",
"     33",
"    </a>",
"    ]. Fibrosis may be sufficiently extensive that the differential diagnosis includes idiopathic pulmonary fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef66071 \" href=\"UTD.htm?11/47/12024\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A slightly less common finding is hemosiderin in alveolar macrophages or the interstitium. Hemorrhage may also be present, but it is difficult to distinguish blood due to disease from blood due to the biopsy procedure. Occasionally, hemosiderin or blood is sufficiently prominent that the diagnosis of idiopathic pulmonary hemosiderosis or a healed vasculitis such as granulomatosis with polyangiitis (formerly called Wegener's granulomatosis) is entertained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=see_link\">",
"     \"Idiopathic pulmonary hemosiderosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that PVOD represents a common pattern of injury resulting from a multiplicity of possible insults. A variety of risk factors for PVOD have been described; however, most are based upon case reports and small case series. No case-control or cohort studies have been performed that specifically address the potential causes of this rare condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Families with multiple siblings affected by PVOD have been identified, suggesting a possible genetic basis for this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/7,15,34,35\">",
"     7,15,34,35",
"    </a>",
"    ]. The age at which the disease presented in such families has ranged from eight weeks to the mid-teens; in a case of two siblings, each became symptomatic within one year of the other. Further evidence for a genetic etiology comes from a report of an infant with PVOD born to a mother who had severe pulmonary arterial hypertension caused by PVOD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/36\">",
"     36",
"    </a>",
"    ]. Both the mother and child shared a mutation in bone morphogenetic protein receptor type II (BMPR2), the gene responsible for up to half of all cases of familial pulmonary arterial hypertension, and as many as 25 percent of cases of sporadic pulmonary arterial hypertension. The bone morphogenetic protein family of proteins is related to TGF-beta and consists of at least 10 peptides that are produced by many different cells and have multiple actions on growth and development.",
"   </p>",
"   <p>",
"    While the occurrence of a rare disease in two members of the same family may indicate an exclusively genetic component, common exposures to food, drugs, environmental agents, or infectious diseases could also play a role. None of the reports that described a potential genetic basis identified possible source exposures, but neither have these reports definitively excluded such exposures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is considered a possible cause of PVOD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Observations that support this hypothesis include the following: an influenza-like illness often precedes the development of PVOD, serological tests performed around the time of diagnosis have suggested recent infection with Toxoplasma gondii or measles [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/4,5,39\">",
"     4,5,39",
"    </a>",
"    ], features suggestive of Epstein-Barr or cytomegalovirus infection (eg, lymphadenopathy, fever, and erythrophagocytosis) have been reported around the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/40\">",
"     40",
"    </a>",
"    ], and two cases have been reported in association with human immunodeficiency virus (HIV) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Despite such reports, there are no convincing data linking PVOD to a specific infectious insult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Toxic exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of hepatic veno-occlusive disease (HVOD) as a complication of antineoplastic chemotherapy was followed by reports of a similar association between PVOD and a variety of chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/43\">",
"     43",
"    </a>",
"    ]. Culprit regimens have been difficult to identify because many patients are exposed to multiple chemotherapy regimens over several years; however,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    (BCNU) are thought to confer the greatest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. PVOD may be a consequence of the toxic metabolites of antineoplastic chemotherapy damaging the pulmonary venules. It appears to be more common after bone marrow or hematopoietic stem cell transplantation (allogeneic or autologous) than following routine cytoreductive chemotherapy, but this impression is anecdotal and has not been confirmed with empirical evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemical exposures may also contribute to the development of PVOD, although the evidence is scarce. In one case report, a 14 year-old boy who had a two-year history of ingesting and sniffing a powdered cleaning product developed PVOD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/47\">",
"     47",
"    </a>",
"    ]. The cleaning product contained silica, soda ash, dodecyl benzyl sulfonate, and trichloro-s-triazinetriome. In contrast, drugs that are risk factors for pulmonary arterial hypertension (eg, cocaine, anorectic agents such as fenfluramine) or HVOD (eg, bush teas containing pyrrolizidine alkaloids) have not been associated with PVOD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/35,48-50\">",
"     35,48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Thrombotic diathesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of researchers have theorized that a thrombotic diathesis (ie, a predisposition toward thrombosis or a defect in fibrinolysis) may play a role in the pathogenesis of PVOD, based upon the observation that thrombotic occlusion of pulmonary veins is a prominent feature of PVOD. The theory is supported by early reports of increased platelet adhesiveness in patients with PVOD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/4,51\">",
"     4,51",
"    </a>",
"    ], as well as cases in which PVOD occurred in conjunction with risk factors for hypercoagulability (eg, oral contraceptive use or pregnancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Arguing against the theory, documented venous or arterial thrombi are rare in the extrapulmonary circulation of patients with PVOD and many patients do not have evidence of pulmonary venous thrombi on histopathologic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective autoimmune destruction of pulmonary venules, either as a primary event or secondary to viral infection, could explain the anatomic specificity of PVOD. Most patients with PVOD lack features of systemic autoimmune disease, although case reports have described PVOD in association with rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, sarcoidosis, Langerhans cell histiocytosis, systemic sclerosis, mixed connective tissue disease, and CREST syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/54-62\">",
"     54-62",
"    </a>",
"    ]. PVOD with granulomatous venulitis has also been described as part of a focal or systemic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5527924\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with PVOD present with nonspecific complaints (eg, dyspnea on exertion, lethargy) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/20\">",
"     20",
"    </a>",
"    ]. Since these symptoms frequently follow an upper respiratory infection, patients are often empirically treated with an antibiotic, but fail to improve [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/5\">",
"     5",
"    </a>",
"    ]. Additional symptoms may include a chronic cough (productive or nonproductive), chest pain, right upper quadrant pain secondary to hepatic congestion, exertional syncope, orthopnea, or hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/32,66,67\">",
"     32,66,67",
"    </a>",
"    ]. The hemoptysis is rarely massive and life threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The signs of PVOD are generally related to progressive pulmonary hypertension, including cyanosis, digital clubbing, a loud pulmonic component of the second heart sound, a split second heart sound, right-sided cardiac murmurs (eg, tricuspid regurgitation), a third or fourth heart sound (ie, gallop), a left parasternal heave, a downward subxiphoid thrust, a pulmonary artery tap, elevated jugular venous pressure, an enlarged liver, and peripheral edema. Auscultatory crackles may occur in patients who have prominent chronic pulmonary infiltrates and decreased breath sounds with dullness to percussion may exist in patients with pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/7,32\">",
"     7,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diffuse alveolar hemorrhage and sudden death are uncommon presentations of PVOD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusions are frequently seen on the chest radiographs of patients with PVOD. The effusions are probably due to postcapillary obstruction elevating the pulmonary capillary and visceral pleural capillary hydrostatic pressures, leading to transudation of fluid into the pleural space. In contrast, pleural effusions are rare in idiopathic pulmonary arterial hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest radiographs may also demonstrate engorgement of the central pulmonary arteries and scattered patchy parenchymal opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/4\">",
"     4",
"    </a>",
"    ]. Kerley B lines may be present, likely due to chronic pulmonary capillary hypertension, transudation of fluid into the interstitium, and enlargement of pulmonary lymphatic channels (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53287 \" href=\"UTD.htm?12/20/12608\">",
"     image 1",
"    </a>",
"    ). The absence of Kerley B lines or other radiographic abnormalities does NOT exclude the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/20,27,71-73\">",
"     20,27,71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomographic (CT) scans may reveal smooth septal thickening, diffuse or mosaic ground glass opacities, multiple small nodules, pleural effusions, or areas of alveolar consolidation (may be gravitationally dependent) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71206 \" href=\"UTD.htm?1/54/1890\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/69,74-77\">",
"     69,74-77",
"    </a>",
"    ]. The pathologic correlate of the ground glass opacities is uncertain, but may result from alveolar septal thickening with associated hyperplasia of lining epithelium. In addition, the central pulmonary veins and the left atrium are usually not enlarged. Prominent mediastinal lymphadenopathy has been noted in some cases, which may be consequence of venolymphatic shunts and circulating angiogenic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/74,78-81\">",
"     74,78-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ventilation-perfusion",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    images are often normal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/82\">",
"     82",
"    </a>",
"    ] or reveal normal ventilation with focal areas of hypoperfusion, which may lead to a misdiagnosis of chronic thromboembolic pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/20,32,66,68,72,75,83\">",
"     20,32,66,68,72,75,83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary artery occlusion pressure (ie, a pulmonary capillary wedge pressure) tracing is often difficult to recognize in patients with PVOD. The reason is that flushing the distal port of the wedged catheter causes the infused saline to become trapped between the catheter tip and narrowed pulmonary veins; as a result, the pressure rises disproportionately and falls extremely slowly to baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/4,68,84\">",
"     4,68,84",
"    </a>",
"    ]. To document successful wedging of the catheter, an oxygen tension similar to arterial blood may need to be demonstrated using blood slowly aspirated from the distal port of the pulmonary artery catheter.",
"   </p>",
"   <p>",
"    Ideally, the pulmonary artery occlusion pressure should be measured in several different locations to insure that a given measurement is not spurious or the result of a local phenomenon. The pulmonary artery occlusion pressure is generally normal or decreased, despite the fact that pulmonary capillary pressures are elevated. This occurs because the catheter abuts a static column of blood when it is in the wedge position, and this column of blood extends beyond the pulmonary venules to the central pulmonary veins and left atrium. The measured pulmonary artery occlusion pressure is the pressure that is transmitted from these distal structures, which tend to be normal in PVOD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Extensive pulmonary venule stenosis may dampen this pressure tracing.",
"   </p>",
"   <p>",
"    Acute pulmonary edema, respiratory failure, and death can occur if a short-acting pulmonary arterial vasodilator (eg, inhaled nitric oxide, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    , or adenosine) is administered at the time of catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/87\">",
"     87",
"    </a>",
"    ]. The presumed mechanism is pulmonary arterial vasodilation without concomitant pulmonary venodilation, producing increased transcapillary hydrostatic pressures and transudation of fluid into the pulmonary interstitium and alveoli. The development of pulmonary edema in response to a pulmonary vasodilator is strongly suggestive of PVOD, but not pathognomonic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function testing may reveal a reduced single-breath diffusing capacity for carbon monoxide (DLCO) and a restrictive ventilatory defect in PVOD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/72,75\">",
"     72,75",
"    </a>",
"    ]. Laboratory tests are generally unremarkable, although microangiopathic hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/88\">",
"     88",
"    </a>",
"    ], heavy proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/5\">",
"     5",
"    </a>",
"    ], and elevations in serum IgG and IgM concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/89\">",
"     89",
"    </a>",
"    ] have been described in isolated cases.",
"   </p>",
"   <p>",
"    A bronchoscopic airway inspection may reveal intense hyperemia of the lobar and segmental bronchi, with vascular engorgement in the form of bright red longitudinal streaks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/90\">",
"     90",
"    </a>",
"    ]. This is a consequence of the lobar bronchi and more distal airways draining into the pulmonary veins and becoming hyperemic by virtue of decreased venous runoff. These findings are not present in the trachea and main bronchi, presumably because the venous drainage of central airways is into nonoccluded bronchial veins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features alone are often insufficient to separate patients with PVOD from those with idiopathic pulmonary arterial hypertension (IPAH) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/91\">",
"     91",
"    </a>",
"    ]. PVOD is suggested by the following triad [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe pulmonary arterial hypertension",
"     </li>",
"     <li>",
"      Radiographic evidence of pulmonary edema",
"     </li>",
"     <li>",
"      Normal pulmonary artery occlusion pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no universally accepted definition of &ldquo;severe&rdquo; pulmonary arterial hypertension. In our clinical practices, we generally consider pulmonary arterial hypertension to be severe when the mean pulmonary artery pressure is &ge;45 mmHg in a patient whose World Health Organization (WHO) functional class is 3 or 4 (",
"    <a class=\"graphic graphic_table graphicRef62080 \" href=\"UTD.htm?24/47/25339\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The triad of findings listed above is insensitive. Therefore, definitive diagnosis of PVOD requires a surgical lung biopsy. It cannot be made from transbronchial biopsy specimens. PVOD may be suggested if hemosiderosis and one or more sclerosed venules are identified in a transbronchial biopsy specimen, but this is imperfect because intimal sclerosis can be a normal consequence of aging. The presence of an occasional sclerosed pulmonary vein is not sufficient for diagnosis and must be interpreted in conjunction with clinical and radiographic features.",
"   </p>",
"   <p>",
"    The need to make a definitive diagnosis via lung biopsy has been questioned, since treatment of PVOD is minimally efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. We favor surgical lung biopsy for patients with clinical and radiographic features suggestive of PVOD, assuming that the surgical risk is acceptable, since a definitive diagnosis of PVOD provides prognostic information and may impact the timing of evaluation for lung transplantation.",
"   </p>",
"   <p>",
"    Delays in the diagnosis of PVOD are common. Many patients are initially presumed to have heart failure (due to the abnormalities on chest radiographs and CT scans), chronic thromboembolic pulmonary hypertension (due to abnormalities on ventilation-perfusion scans), or advanced parenchymal lung disease, such as sarcoidosis, cystic fibrosis, or pneumoconiosis (due to prominent chronic interstitial changes on chest radiographs) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary vasodilators (eg, calcium-channel antagonists, prostanoids, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors) have an established role in the treatment of idiopathic pulmonary arterial hypertension (IPAH) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .) However, the value of these therapies in patients with PVOD is unclear.",
"   </p>",
"   <p>",
"    There is a theoretical reason why pulmonary vasodilator therapy may not be efficacious or may harm patients with PVOD. If the pulmonary arterioles dilate and the pulmonary veins remain fixed, then transcapillary hydrostatic pressure may increase and cause pulmonary edema. In fact, death due to massive pulmonary edema following the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    in a patient with PVOD has been reported, supporting this concern [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, there is also low quality evidence that suggests that some patients with PVOD improve from pulmonary vasodilator therapy, at least temporarily:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"       Epoprostenol",
"      </a>",
"      therapy was associated with an improvement in hemodynamics, exercise capacity, and functional class in a case report and case series [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/95,96\">",
"       95,96",
"      </a>",
"      ]. The case series included 12 patients with PVOD who were treated with epoprostenol plus high dose diuretics (beginning at a low starting dose, the dose was increased in small increments) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/96\">",
"       96",
"      </a>",
"      ]. There was improvement in the functional class, cardiac index, and pulmonary vascular resistance. Mild pulmonary edema occurred in only one patient.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       Nifedipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      were associated with an improvement in hemodynamics and exercise capacity in a case report and a case series of three patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/97,98\">",
"       97,98",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our clinical practice, we cautiously administer pulmonary vasodilators because we recognize that patients with PVOD have limited therapeutic options and we believe that a subgroup of patients probably benefits from such therapy. We begin with a trial of a short-acting agent, such as nitric oxide, adenosine, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    , and we monitor the hemodynamic response with a pulmonary artery catheter. Such trials should only be undertaken in a well-staffed and fully equipped setting, such as a cardiac catheterization laboratory or an intensive care unit. Patients are continued on chronic epoprostenol if they have a favorable hemodynamic response. There is limited experience with the endothelin receptor antagonists and phosphodiesterase-5 inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/2\">",
"     2",
"    </a>",
"    ], so we generally do not use them in patients with PVOD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Immunosuppressive medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive medications (eg, corticosteroids, antimetabolites) have been employed in PVOD, particularly among patients with extensive interstitial lung disease or concomitant features of autoimmune diseases. Among the patients with features of autoimmune disease, immunosuppressive therapy was frequently initiated despite the fact that complement levels and the erythrocyte sedimentation rates were within normal limits [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunosuppressive protocols have not been well studied, so definitive conclusions regarding their efficacy cannot be drawn. However, our general impression is that these drugs rarely palliate the symptoms of PVOD or affect the terminal nature of the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/89,99,100\">",
"     89,99,100",
"    </a>",
"    ]. The best documented response occurred in a 46-year old woman with biopsy-proven PVOD who was treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (150",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and had progressive improvement in both subjective and objective exercise capacity during approximately two years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/89\">",
"     89",
"    </a>",
"    ]. Of note, this patient had a variety of features suggesting concomitant autoimmune phenomena, including Raynaud phenomenon with digital ulceration, alopecia, arthritis, elevated serum IgG and IgM concentrations, and a positive antinuclear antibody.",
"   </p>",
"   <p>",
"    The role of immunosuppressive medications in the treatment of PVOD remains undefined, but it is possible that these medications are modestly effective in a subset of patients. Despite the paucity of data, we favor a four-week trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at doses of 0.75 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in patients with PVOD and prominent autoimmune features, since some apparent responses have occurred and few other treatment options exist. We follow symptoms, radiographs, diffusing capacity, and the alveolar-arterial oxygen gradient. If a patient improves on this therapy, we slowly taper the dose to 20 to 40",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have suggested that patients with IPAH survive longer when anticoagulated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/94,101\">",
"     94,101",
"    </a>",
"    ]. Based upon this indirect evidence and the observation that thrombotic occlusion of pulmonary veins is a prominent feature of PVOD, we treat all patients who have PVOD with long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (titrated to achieve an international normalized ratio of 2 to 3), unless contraindications are present. Small-volume hemoptysis is common and usually does not require the discontinuation of anticoagulant therapy; however, we typically terminate anticoagulant therapy if more than 50 mL of blood are expectorated over a 24-hour period. We also discontinue anticoagulant therapy if significant extrapulmonary hemorrhage occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term supplemental oxygen is indicated for hypoxemic patients with PVOD. This is based upon indirect evidence extrapolated from trials of long-term supplemental oxygen for chronic obstructive pulmonary disease, as well as the observation that supplemental oxygen has few adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .) In an uncontrolled trial of 15 patients, those with systemic sclerosis-related pulmonary arterial hypertension had a significant decline in pulmonary vascular resistance following the initiation of supplemental oxygen, while those with IPAH had a decline in pulmonary vascular resistance that did not reach statistical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transtracheal oxygen therapy permits delivery of higher oxygen flow rates. However, local bleeding complications may be problematic in patients receiving chronic anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37015?source=see_link\">",
"     \"Transtracheal oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplantation is the only therapy that appears to significantly prolong the lives of patients with PVOD, although the cumulative experience is small [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/76,105,106\">",
"     76,105,106",
"    </a>",
"    ]. We refer all patients with PVOD to be evaluated for lung transplantation at the time of diagnosis. However, the utility of lung transplantation is diminished by the fact that the average wait time in many parts of the United States exceeds the life expectancy of patients with PVOD.",
"   </p>",
"   <p>",
"    Single-lung and double-lung transplantation procedures have both been performed, with recurrence of PVOD reported in only one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/107\">",
"     107",
"    </a>",
"    ]. Infection and the development of obliterative bronchiolitis remain major causes of morbidity and mortality in patients who undergo lung transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3480?source=see_link\">",
"     \"Lung transplantation: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Experimental therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of experimental therapies are undergoing evaluation in patients with HVOD, some of which have also been used in patients with PVOD. Most of these therapies involve antithrombotic treatment with agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , thrombolytic therapy with agents such as recombinant tissue plasminogen activator (tPA), or antithrombin III concentrate in patients with a documented antithrombin III deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another experimental therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/8/41091?source=see_link\">",
"     defibrotide",
"    </a>",
"    , is a polydeoxyribonucleotide derived from mammalian cells. It is associated with little bleeding risk but has multiple activities that may hasten the resolution of thrombi. These include its actions as an adenosine receptor agonist and its ability to increase concentrations of endogenous prostaglandins (PGI2 and E2), stimulate the expression of thrombomodulin in endothelial cells, modulate platelet activity, increase the function of endogenous tPA, and diminish the activity of plasminogen activator inhibitor-1 (PAI-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/109-111\">",
"     109-111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unlikely that these novel antithrombotic drugs will markedly improve PVOD, since the time course of PVOD development suggests that acute thrombosis probably plays a smaller pathogenic role in PVOD than HVOD. Therefore, we recommend against the routine treatment of patients who have PVOD with the agents described above, except in the context of well-defined clinical trials.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    are kinase inhibitors that have anti-angiogenesis effects and may promote vascular remodeling via nonantithrombotic mechanisms. Animal studies and case reports suggest a potentially beneficial role in PAH and PVOD, but no clinical trials have been performed to validate their use [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. In a case report, sorafenib (but not imatinib) appeared to improve exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1902968\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with PVOD die within two years of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29385/abstract/114\">",
"     114",
"    </a>",
"    ]. Randomized trials have not been conducted because PVOD is a rare condition; therefore, the degree to which current treatments favorably impact outcomes is unclear. The impression of most clinicians is that the impact of current treatments is not profound, with the possible exception of lung transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6670311\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary veno-occlusive disease (PVOD) is a clinicopathologic syndrome that accounts for a small number of cases of pulmonary hypertension, although its precise incidence is unknown. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathologic hallmark of PVOD is extensive and diffuse occlusion of the pulmonary veins by fibrous tissue, which likely represents a common pattern of injury resulting from a multiplicity of possible insults. A variety of risk factors for PVOD have been described, but a definitive cause has not been identified. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with PVOD present with nonspecific complaints (eg, dyspnea on exertion, lethargy), which frequently follow an upper respiratory infection. The signs of PVOD are the same as those seen in other types of pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PVOD is suggested by the triad of severe pulmonary arterial hypertension, radiographic evidence of pulmonary edema, and a normal pulmonary artery occlusion pressure. However, the triad is insensitive, since many patients with PVOD do not have the triad. Definitive diagnosis of PVOD requires a surgical lung biopsy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with PVOD who are hypoxemic, we recommend supplemental oxygen (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Oxygen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with PVOD, we recommend evaluation for lung transplantation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Lung transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with PVOD who are not at increased risk for bleeding, we suggest chronic anticoagulant therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and target an International Normalized Ratio (INR) between 2 and 3. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Anticoagulants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with PVOD and features of autoimmune disease, we suggest a trial of immunosuppressive therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We generally perform a four-week trial using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 0.75 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Immunosuppressive medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with PVOD whose hemodynamics improve during a trial of short-acting pulmonary vasodilators, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The trial of short-acting pulmonary vasodilators should only be undertaken in a well-staffed and fully equipped setting, with a pulmonary artery catheter in position. Moreover, both the trial and subsequent therapy must be undertaken with extreme caution because of the risk of precipitating severe pulmonary edema. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Vasodilators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with PVOD die within two years of diagnosis. The impact of current treatments is not profound, with the possible exception of lung transplantation. (See",
"      <a class=\"local\" href=\"#H1902968\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/1\">",
"      Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009; 33:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/2\">",
"      Montani D, Achouh L, Dorfm&uuml;ller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008; 87:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/3\">",
"      O'Callaghan DS, Dorfmuller P, Ja&iuml;s X, et al. Pulmonary veno-occlusive disease: the b&ecirc;te noire of pulmonary hypertension in connective tissue diseases? Presse Med 2011; 40:e65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/4\">",
"      Brown CH, Harrison CV. Pulmonary veno-occlusive disease. Lancet 1966; 2:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/5\">",
"      Heath D, Segel N, Bishop J. Pulmonary veno-occlusive disease. Circulation 1966; 34:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/6\">",
"      Weisser K, Wyler F, Gloor F. Pulmonary veno-occlusive disease. Arch Dis Child 1967; 42:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/7\">",
"      Rosenthal A, Vawter G, Wagenvoort CA. Intrapulmonary veno-occlusive disease. Am J Cardiol 1973; 31:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/8\">",
"      Palazzini M, Manes A. Pulmonary veno-occlusive disease misdiagnosed as idiopathic pulmonary arterial hypertension. Eur Respir Rev 2009; 18:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/9\">",
"      Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/10\">",
"      Palevsky HI, Schloo BL, Pietra GG, et al. Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 1989; 80:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/11\">",
"      Wagenvoort CA. Lung biopsy specimens in the evaluation of pulmonary vascular disease. Chest 1980; 77:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/12\">",
"      Kinare SG, Deshpande J. Primary pulmonary hypertension in India (autopsy study of 26 cases). Indian Heart J 1987; 39:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/13\">",
"      Burke AP, Farb A, Virmani R. The pathology of primary pulmonary hypertension. Mod Pathol 1991; 4:269.",
"     </a>",
"    </li>",
"    <li>",
"     Pietra GG. The pathology of primary pulmonary hypertension. In: Primary pulmonary hypertension: lung biology in health and disease, Rubin LJ, Rich S (Eds), Marcel Dekker, Inc, New York 1997. p.19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/15\">",
"      Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985; 60:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/16\">",
"      Wagenvoort, CA, Wagenvoort, N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/17\">",
"      Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/18\">",
"      Veeraraghavan S, Koss MN, Sharma OP. Pulmonary veno-occlusive disease. Curr Opin Pulm Med 1999; 5:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/19\">",
"      Wagenvoort CA. Pulmonary veno-occlusive disease. Entity or syndrome? Chest 1976; 69:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/20\">",
"      Thadani U, Burrow C, Whitaker W, Heath D. Pulmonary veno-occlusive disease. Q J Med 1975; 44:133.",
"     </a>",
"    </li>",
"    <li>",
"     World Symposium on Primary Pulmonary Hypertension 1998. Evian, France, 1998.",
"    </li>",
"    <li>",
"     Rubin E, Farber JL. The respiratory system. In: Pathology, 2nd ed, Rubin E, Farber JL (Eds), J.B. Lippincott, Philadelphia 1994. p.557.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/23\">",
"      Wagenvoort CA, Wagenvoort N. The pathology of pulmonary veno-occlusive disease. Virchows Arch A Pathol Anat Histol 1974; 364:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/24\">",
"      Wagenvoort CA, Wagenvoort N, Takahashi T. Pulmonary veno-occlusive disease: involvement of pulmonary arteries and review of the literature. Hum Pathol 1985; 16:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/25\">",
"      Almagro P, Juli&agrave; J, Sanjaume M, et al. Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literature. Medicine (Baltimore) 2002; 81:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/26\">",
"      Ito K, Ichiki T, Ohi K, et al. Pulmonary capillary hemangiomatosis with severe pulmonary hypertension. Circ J 2003; 67:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/27\">",
"      Frazier AA, Franks TJ, Mohammed TL, et al. From the Archives of the AFIP: pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Radiographics 2007; 27:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/28\">",
"      Lantu&eacute;joul S, Sheppard MN, Corrin B, et al. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006; 30:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/29\">",
"      Fishman AP. Clinical classification of pulmonary hypertension. Clin Chest Med 2001; 22:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/30\">",
"      Oviedo A, Abramson LP, Worthington R, et al. Congenital pulmonary capillary hemangiomatosis: Report of two cases and review of the literature. Pediatr Pulmonol 2003; 36:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/31\">",
"      Carrington CB, Liebow AA. Pulmonary veno-occlusive disease. Hum Pathol 1970; 1:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/32\">",
"      Glassroth J, Woodford DW, Carrington CB, Gaensler EA. Pulmonary veno-occlusive disease in the middle-aged. Respiration 1985; 47:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/33\">",
"      Cortese DA. Pulmonary function in mitral stenosis. Mayo Clin Proc 1978; 53:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/34\">",
"      Davies P, Reid L. Pulmonary veno-occlusive disease in siblings: case reports and morphometric study. Hum Pathol 1982; 13:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/35\">",
"      Voordes CG, Kuipers JR, Elema JD. Familial pulmonary veno-occlusive disease: a case report. Thorax 1977; 32:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/36\">",
"      Runo JR, Vnencak-Jones CL, Prince M, et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 2003; 167:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/37\">",
"      H&ouml;ra, J. Zur Histologie der klinischen \"primaren Pulmonalsklerose.\" Frankfurt Z Pathol 1934; 47:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/38\">",
"      Pulmonary veno-occlusive disease. Br Med J 1972; 3:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/39\">",
"      STOVIN PG, MITCHINSON MJ. PULMONARY HYPERTENSION DUE TO OBSTRUCTION OF THE INTRAPULMONARY VEINS. Thorax 1965; 20:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/40\">",
"      McDonnell PJ, Summer WR, Hutchins GM. Pulmonary veno-occlusive disease. Morphological changes suggesting a viral cause. JAMA 1981; 246:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/41\">",
"      Ruchelli ED, Nojadera G, Rutstein RM, Rudy B. Pulmonary veno-occlusive disease. Another vascular disorder associated with human immunodeficiency virus infection? Arch Pathol Lab Med 1994; 118:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/42\">",
"      Escamilla R, Hermant C, Berjaud J, et al. Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser. Eur Respir J 1995; 8:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/43\">",
"      Doll DC, Yarbro JW. Vascular toxicity associated with chemotherapy and hormonotherapy. Curr Opin Oncol 1994; 6:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/44\">",
"      Gagnadoux F, Capron F, Lebeau B. Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma. Lung Cancer 2002; 36:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/45\">",
"      Williams LM, Fussell S, Veith RW, et al. Pulmonary veno-occlusive disease in an adult following bone marrow transplantation. Case report and review of the literature. Chest 1996; 109:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/46\">",
"      Bunte MC, Patnaik MM, Pritzker MR, Burns LJ. Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction. Bone Marrow Transplant 2008; 41:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/47\">",
"      Liu, L, Sackler, JP. A case of pulmonary veno-occlusive disease: etiological and therapeutic appraisal. Angiology 1973; 23:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/48\">",
"      Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/49\">",
"      Kumana CR, Ng M, Lin HJ, et al. Herbal tea induced hepatic veno-occlusive disease: quantification of toxic alkaloid exposure in adults. Gut 1985; 26:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/50\">",
"      Tandon BN, Tandon HD, Tandon RK, et al. An epidemic of veno-occlusive disease of liver in central India. Lancet 1976; 2:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/51\">",
"      A case of veno-occlusive disease. Demonstrated at the Royal Postgraduate Medical School. Br Med J 1968; 1:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/52\">",
"      Townend JN, Roberts DH, Jones EL, Davies MK. Fatal pulmonary venoocclusive disease after use of oral contraceptives. Am Heart J 1992; 124:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/53\">",
"      Tsou E, Waldhorn RE, Kerwin DM, et al. Pulmonary venoocclusive disease in pregnancy. Obstet Gynecol 1984; 64:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/54\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-1983. A 67-year-old woman with pulmonary hypertension. N Engl J Med 1983; 308:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/55\">",
"      Hussein A, Trowitzsch E, Brockmann M. Pulmonary veno-occlusive disease, antiphospholipid antibody and pulmonary hypertension in an adolescent. Klin Padiatr 1999; 211:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/56\">",
"      Kishida Y, Kanai Y, Kuramochi S, Hosoda Y. Pulmonary venoocclusive disease in a patient with systemic lupus erythematosus. J Rheumatol 1993; 20:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/57\">",
"      Hoffstein V, Ranganathan N, Mullen JB. Sarcoidosis simulating pulmonary veno-occlusive disease. Am Rev Respir Dis 1986; 134:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/58\">",
"      Hamada K, Teramoto S, Narita N, et al. Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis. Eur Respir J 2000; 15:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/59\">",
"      Morassut PA, Walley VM, Smith CD. Pulmonary veno-occlusive disease and the CREST variant of scleroderma. Can J Cardiol 1992; 8:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/60\">",
"      Saito A, Takizawa H, Ito K, et al. A case of pulmonary veno-occlusive disease associated with systemic sclerosis. Respirology 2003; 8:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/61\">",
"      Zhang L, Visscher D, Rihal C, Aubry MC. Pulmonary veno-occlusive disease as a primary cause of pulmonary hypertension in a patient with mixed connective tissue disease. Rheumatol Int 2007; 27:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/62\">",
"      Johnson SR, Patsios D, Hwang DM, Granton JT. Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol 2006; 33:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/63\">",
"      Crissman JD, Koss M, Carson RP. Pulmonary veno-occlusive disease secondary to granulomatous venulitis. Am J Surg Pathol 1980; 4:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/64\">",
"      Liang MH, Stern S, Fortin PR, et al. Fatal pulmonary venoocclusive disease secondary to a generalized venulopathy: a new syndrome presenting with facial swelling and pericardial tamponade. Arthritis Rheum 1991; 34:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/65\">",
"      Dwyer N, Smith R, Challis D, et al. Granulomatous angiitis leading to a pulmonary veno-occlusive disease-like picture. Eur Respir J 2009; 33:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/66\">",
"      Calderon M, Burdine JA. Pulmonary veno-occlusive disease. J Nucl Med 1974; 15:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/67\">",
"      Holcomb BW Jr, Loyd JE, Ely EW, et al. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000; 118:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/68\">",
"      Chawla SK, Kittle CF, Faber LP, Jensik RJ. Pulmonary venoocclusive disease. Ann Thorac Surg 1976; 22:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/69\">",
"      Swensen SJ, Tashjian JH, Myers JL, et al. Pulmonary venoocclusive disease: CT findings in eight patients. AJR Am J Roentgenol 1996; 167:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/70\">",
"      Wiener-Kronish JP, Goldstein R, Matthay RA, et al. Lack of association of pleural effusion with chronic pulmonary arterial and right atrial hypertension. Chest 1987; 92:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/71\">",
"      Leinonen H, Pohjola-Sintonen S, Krogerus L. Pulmonary veno-occlusive disease. Acta Med Scand 1987; 221:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/72\">",
"      Elliott CG, Colby TV, Hill T, Crapo RO. Pulmonary veno-occlusive disease associated with severe reduction of single-breath carbon monoxide diffusing capacity. Respiration 1988; 53:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/73\">",
"      Scheibel RL, Dedeker KL, Gleason DF, et al. Radiographic and angiographic characteristics of pulmonary veno-occlusive disease. Radiology 1972; 103:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/74\">",
"      Resten A, Maitre S, Humbert M, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004; 183:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/75\">",
"      Maltby JD, Gouverne ML. CT findings in pulmonary venoocclusive disease. J Comput Assist Tomogr 1984; 8:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/76\">",
"      Cassart M, Gevenois PA, Kramer M, et al. Pulmonary venoocclusive disease: CT findings before and after single-lung transplantation. AJR Am J Roentgenol 1993; 160:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/77\">",
"      Worthy SA, M&uuml;ller NL, Hartman TE, et al. Mosaic attenuation pattern on thin-section CT scans of the lung: differentiation among infiltrative lung, airway, and vascular diseases as a cause. Radiology 1997; 205:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/78\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 48-1993. A 27-year-old woman with mediastinal lymphadenopathy and relentless cor pulmonale. N Engl J Med 1993; 329:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/79\">",
"      Dufour B, Ma&icirc;tre S, Humbert M, et al. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. AJR Am J Roentgenol 1998; 171:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/80\">",
"      Resten A, Ma&icirc;tre S, Humbert M, et al. Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure. Radiology 2002; 222:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/81\">",
"      Thomas de Montpr&eacute;ville V, Dulmet E, Fadel E, Dartevelle P. Lymph node pathology in pulmonary veno-occlusive disease and pulmonary capillary heamangiomatosis. Virchows Arch 2008; 453:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/82\">",
"      Seferian A, Helal B, Ja&iuml;s X, et al. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. Eur Respir J 2012; 40:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/83\">",
"      Rich S, Pietra GG, Kieras K, et al. Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. Ann Intern Med 1986; 105:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/84\">",
"      Rapidly progressive dyspnea in a teenage boy. Clinical pathological conference. JAMA 1973; 223:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/85\">",
"      Weed HG. Pulmonary \"capillary\" wedge pressure not the pressure in the pulmonary capillaries. Chest 1991; 100:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/86\">",
"      Rambihar VS, Fallen EL, Cairns JA. Pulmonary veno-occlusive disease: antemortem diagnosis from roentgenographic and hemodynamic findings. Can Med Assoc J 1979; 120:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/87\">",
"      Palmer SM, Robinson LJ, Wang A, et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998; 113:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/88\">",
"      Waldhorn RE, Tsou E, Smith FP, Kerwin DM. Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma. Med Pediatr Oncol 1984; 12:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/89\">",
"      Sanderson JE, Spiro SG, Hendry AT, Turner-Warwick M. A case of pulmonary veno-occlusive disease respondong to treatment with azathioprine. Thorax 1977; 32:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/90\">",
"      Matthews AW, Buchanan R. A case of pulmonary veno-occlusive disease and a new bronchoscopic sign. Respir Med 1990; 84:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/91\">",
"      Montani D, Kemp K, Dorfmuller P, et al. Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. Semin Respir Crit Care Med 2009; 30:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/92\">",
"      Montani D, O'Callaghan DS, Savale L, et al. Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med 2010; 104 Suppl 1:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/93\">",
"      De Vries TW, Weening JJ, Roorda RJ. Pulmonary veno-occlusive disease: a case report and a review of therapeutic possibilities. Eur Respir J 1991; 4:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/94\">",
"      Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/95\">",
"      Okumura H, Nagaya N, Kyotani S, et al. Effects of continuous IV prostacyclin in a patient with pulmonary veno-occlusive disease. Chest 2002; 122:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/96\">",
"      Montani D, Ja&iuml;s X, Price LC, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009; 34:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/97\">",
"      Salzman GA, Rosa UW. Prolonged survival in pulmonary veno-occlusive disease treated with nifedipine. Chest 1989; 95:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/98\">",
"      Palevsky HI, Pietra GG, Fishman AP. Pulmonary veno-occlusive disease and its response to vasodilator agents. Am Rev Respir Dis 1990; 142:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/99\">",
"      Hackman RC, Madtes DK, Petersen FB, Clark JG. Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation 1989; 47:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/100\">",
"      Gilroy RJ Jr, Teague MW, Loyd JE. Pulmonary veno-occlusive disease. Fatal progression of pulmonary hypertension despite steroid-induced remission of interstitial pneumonitis. Am Rev Respir Dis 1991; 143:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/101\">",
"      Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/102\">",
"      Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/103\">",
"      Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/104\">",
"      Morgan JM, Griffiths M, du Bois RM, Evans TW. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest 1991; 99:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/105\">",
"      Kramer MR, Estenne M, Berkman N, et al. Radiation-induced pulmonary veno-occlusive disease. Chest 1993; 104:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/106\">",
"      Stewart S, McNeil K, Nashef SA, et al. Audit of referral and explant diagnoses in lung transplantation: a pathologic study of lungs removed for parenchymal disease. J Heart Lung Transplant 1995; 14:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/107\">",
"      Izbicki G, Shitrit D, Schechtman I, et al. Recurrence of pulmonary veno-occlusive disease after heart-lung transplantation. J Heart Lung Transplant 2005; 24:635.",
"     </a>",
"    </li>",
"    <li>",
"     Negrin RS. Treatment and prevention of hepatic veno-occlusive disease following bone marrow transplantation. In: S Chopra, JT LaMont, editors. UpToDate in gastroenterology and hepatology. Wellesley, MA: Up To Date in Medicine; 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/109\">",
"      Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/110\">",
"      Abecasis MM, Concei&ccedil;&atilde;o Silva JP, Ferreira I, et al. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/111\">",
"      Willems E, Canivet JL, Ghaye B, et al. Pulmonary veno-occlusive disease in myeloproliferative disorder. Eur Respir J 2009; 33:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/112\">",
"      Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, et al. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J 2008; 32:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/113\">",
"      Kataoka M, Yanagisawa R, Fukuda K, et al. Sorafenib is effective in the treatment of pulmonary veno-occlusive disease. Cardiology 2012; 123:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29385/abstract/114\">",
"      Shackelford GD, Sacks EJ, Mullins JD, McAlister WH. Pulmonary venoocclusive disease: case report and review of the literature. AJR Am J Roentgenol 1977; 128:643.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8269 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29385=[""].join("\n");
var outline_f28_44_29385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6670311\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Toxic exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Thrombotic diathesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5527924\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vasodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Immunosuppressive medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Experimental therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1902968\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6670311\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8269\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8269|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/20/12608\" title=\"diagnostic image 1\">",
"      PVOD CXR PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/54/1890\" title=\"diagnostic image 2\">",
"      PVOD CT image",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8269|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/55/20342\" title=\"figure 1\">",
"      PVOD venous obliteration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8269|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/8/2184\" title=\"picture 1\">",
"      PVOD septal thickening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/47/12024\" title=\"picture 2\">",
"      PVOD interstitial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8269|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/47/25339\" title=\"table 1\">",
"      Classification PH function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=related_link\">",
"      Idiopathic pulmonary hemosiderosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3480?source=related_link\">",
"      Lung transplantation: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37015?source=related_link\">",
"      Transtracheal oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_44_29386="Genetics of hypertrophic cardiomyopathy";
var content_f28_44_29386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics of hypertrophic cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/44/29386/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29386/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/44/29386/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29386/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29386/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/44/29386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/44/29386/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/44/29386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease most often (60 to 70 percent) caused by mutations in one of several sarcomere genes that encode components of the contractile apparatus.",
"   </p>",
"   <p>",
"    HCM is characterized by left ventricular hypertrophy of various morphologies, with a wide array of clinical manifestations and hemodynamic abnormalities (",
"    <a class=\"graphic graphic_figure graphicRef58156 \" href=\"UTD.htm?11/9/11411\">",
"     figure 1",
"    </a>",
"    ). Depending in part upon the site and extent of cardiac hypertrophy, patients with HCM can develop one or more of the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LV outflow obstruction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"       \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diastolic dysfunction",
"     </li>",
"     <li>",
"      Myocardial ischemia",
"     </li>",
"     <li>",
"      Mitral regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These structural and functional abnormalities can produce a variety of symptoms, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Presyncope or syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In broad terms, the symptoms related to HCM can be categorized as those related to heart failure (HF), chest pain, or arrhythmias. Patients with HCM have an increased incidence of both supraventricular and ventricular arrhythmias and are at an increased risk for sudden cardiac death (SCD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the majority of patients with HCM, LVH is not progressive, and the clinical course is relatively benign. A small subset of patients, however, will progress to an end-stage form of the disease that is characterized by LV dilation and wall thinning and systolic dysfunction. Such patients are managed according to the standard approach to patients with HF due to systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical diagnosis of HCM is based upon the finding of unexplained LVH, documented by electrocardiography and echocardiography, which can be subtle or massive, concentric (symmetrical) or asymmetric, and diffuse or focal (",
"    <a class=\"graphic graphic_table graphicRef61384 \" href=\"UTD.htm?35/41/36507\">",
"     table 1",
"    </a>",
"    ). Data suggest that hypertrophy and other clinical and pathological phenotypes are compensatory secondary to defects due to metabolic consequences of sarcomere dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, preclinical diagnosis of HCM (so-called genotype positive, phenotype negative HCM) often occurs when screening first-degree relatives of patients with HCM.",
"   </p>",
"   <p>",
"    The genetics of HCM will be reviewed here, including a discussion of the role of genetic testing and screening. Other issues such as the clinical manifestations, natural history, clinical diagnosis and evaluation, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link\">",
"     \"Natural history of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic linkage studies in familial HCM have demonstrated autosomal dominant disease loci at a variety of sites including chromosomes 1q32, 2q31, 3p21.2-p21.3, 7q3, 11p11.2, 12q23-q24.3, 14q12, 15q11-q14, 15q22.1, and 19q13.4 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. Patients with HCM and apparent X-linked recessive inheritance may have Fabry disease that can be limited to the heart, or which exhibit cardiac and other abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17111?source=see_link\">",
"     \"Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion will emphasize the major mutations that have been described. A more complete listing can be obtained at",
"    <a class=\"external\" href=\"file://genetics.med.harvard.edu/~seidman/cg3/index.html\">",
"     file://genetics.med.harvard.edu/~seidman/cg3/index.html",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Most of the genetic loci in familial HCM encode one of the myocardial contractile proteins, and mutations have subsequently been identified in the genes themselves. The involved contractile proteins include: cardiac troponin T, cardiac troponin I, myosin regulatory light chain, myosin essential light chain, cardiac myosin binding protein-C, cardiac alpha and beta-myosin heavy chain, cardiac alpha actin, alpha tropomyosin, and titin.",
"   </p>",
"   <p>",
"    A few genes that do not encode contractile proteins have also been implicated in HCM. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The GLA gene for Fabry disease which encodes for the enzyme alpha-galactosidase [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genes involved in the RAS MAP kinase pathway cause Noonan syndrome associated with HCM [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The gene for muscle LIM protein (MLP), which is a regulator of myogenic differentiation and contributes to the linking of the contractile apparatus with the sarcolemma [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The genes encoding the gamma-2 regulatory subunit of adenosine monophosphate-activated protein kinase (PRKAG2), an enzyme that modulates glucose uptake and glycolysis, and the gene encoding lysosome-associated membrane protein 2 (LAMP2), which may be involved in lysosomal enzyme targeting, autophagy, and lysosomal biogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'PRKAG2 and LAMP2 genes and WPW syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The gene for the protein titin-cap",
"      <span class=\"nowrap\">",
"       (T-cap/telethonin),",
"      </span>",
"      which is a component of the Z-disc thought to play a role in sarcomere assembly [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/16\">",
"       16",
"      </a>",
"      ]. Two T-cap mutations were found in patients with HCM and another in a patient with dilated cardiomyopathy (DCM). A qualitative assay revealed that HCM associated mutations augmented, while DCM mutations impaired, the ability of T-cap to interact with titin and calsarcin-1. The authors suggested that the different clinical phenotype (HCM versus DCM) may relate to altered binding of Z-disc components. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"       \"Genetics of dilated cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with sporadic disease, in which the parents are clinically well, have similar genetic abnormalities as those with familial disease. De novo mutations in cardiac myosin binding protein-C, cardiac beta-myosin heavy chain, cardiac troponin T and alpha-tropomyosin genes have been found in isolated case reports of individuals with sporadic HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MUTATIONS IN SARCOMERIC PROTEIN GENES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequences of HCM mutations in contractile protein genes appear to be directly related to effects on sarcomere function, leading to the characterization of HCM as a \"disease of the sarcomere.\" [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/21-27\">",
"     21-27",
"    </a>",
"    ]. However, a unifying explanation of the effect of these mutations on contraction and thereby on hemodynamic function has not been established. Some mutations appear to enhance contractility, while others have the opposite effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=see_link\">",
"     \"Excitation-contraction coupling in myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of myosin mutations on the calcium sensitivity of myofilaments was studied in slow twitch skeletal muscle (soleus) from patients with HCM and selected myosin mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/28\">",
"     28",
"    </a>",
"    ]. Fibers from some of the mutations showed a decrease in mean calcium sensitivity, whereas others showed an increase, with higher active forces at low calcium concentrations and residual active force even under relaxing conditions. In addition, there was marked variability in calcium sensitivity between individual fibers carrying the same mutation; such effects were not observed in controls. The authors speculated that the variability in calcium sensitivity from fiber to fiber was likely to cause imbalances in force generation and be the final common pathway causing contractile dysfunction and development of disarray in the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others have suggested that the common abnormality is an increase in the energy cost of force production [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/29\">",
"     29",
"    </a>",
"    ]. In support of this hypothesis, the ratio of phosphocreatine to ATP (a measure of myocardial energy reserve) is reduced by 30 percent in patients with HCM, regardless of genotype and even in the absence of overt hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many genes are upregulated in the hearts of patients with HCM, including those producing secondary hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/31\">",
"     31",
"    </a>",
"    ]. This suggests that the pathogenesis of the diverse cardiac phenotypes in part results from upregulation of the expression of various genes in response to the primary impetus provided by the mutant contractile protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Frequency of identified mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of identified mutations has varied in different studies, ranging from 30 percent in a Swedish study to 36 to 38 percent in the United States to 61 percent in a French study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17,32,33\">",
"     17,32,33",
"    </a>",
"    ]. In all study populations, mutations in the cardiac myosin binding protein C gene are most common, being present in 14 to 26 percent of patients and, in the largest studies, accounting for 40 to 48 percent of mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17,32,34\">",
"     17,32,34",
"    </a>",
"    ]. Mutations in the cardiac beta-myosin heavy chain gene are second in frequency, being present in 13 to 25 percent of patients and, in the largest studies, accounting for 36 to 42 percent of mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17,32,33\">",
"     17,32,33",
"    </a>",
"    ]. Mutations in the troponin I, troponin T, and alpha-tropomyosin genes account for only 5 to 10 percent of cases, but may present with distinctive phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17,35\">",
"     17,35",
"    </a>",
"    ]. Up to 5 percent of patients have multiple mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17,32\">",
"     17,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report of 84 children diagnosed with isolated unexplained left ventricular hypertrophy before 15 years of age found mutations in genes associated with HCM in adults in about half (25 of 51) of presumed sporadic cases and in nearly two-thirds (21 of 33) of familial cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/36\">",
"     36",
"    </a>",
"    ]. Among 11 of 25 children with presumed sporadic disease, four carried new mutations and seven inherited the mutations. In &gt;75 percent of the children, mutations occurred in the cardiac beta-myosin heavy chain gene or the cardiac myosin binding protein-C gene.",
"   </p>",
"   <p>",
"    In a study of 79 consecutive patients age 13 or younger who were diagnosed with HCM, 47 mutations were identified in 42 patients, with mutations involving the sarcomere protein genes MYBPC3 and MYH7 being the most common (49 and 36 percent of patients, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Cardiac myosin binding protein-C gene'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Cardiac beta-myosin heavy chain gene'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Issues related to the clinical utility of genetic testing are discussed below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Genetic testing and screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Frequency of benign mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that genetic diagnosis may help to stratify individuals at high or low risk for mortality, including sudden death. As the number of defined genetic defects that cause HCM grows, increasing numbers of individuals have been identified who bear these mutations but lack clinical manifestations of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/38\">",
"     38",
"    </a>",
"    ]. These subjects are often children who may develop signs and symptoms of the disorder at a later age, as well as adults with nonpenetrant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/35,39\">",
"     35,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have identified particular mutations that appear to be associated with near-normal survival in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/40-45\">",
"     40-45",
"    </a>",
"    ]. However, other reports have not confirmed the benign nature of these mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/39,46,47\">",
"     39,46,47",
"    </a>",
"    ]. Furthermore, even when a patient's mutation is known, his or her clinical course cannot be predicted with any degree of certainty [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue was directly addressed in a review from the Mayo Clinic of 293 unrelated patients with HCM who were genotyped for specific \"benign\" mutations in the genes for the cardiac beta- myosin heavy chain, troponin T, and alpha tropomyosin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/47\">",
"     47",
"    </a>",
"    ]. Only five patients (1.7 percent) possessed one of these benign mutations; all had severe manifestations of HCM and three had a family history of sudden death. Similarly, only three patients (1 percent) had \"malignant\" mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/49\">",
"     49",
"    </a>",
"    ]. It was concluded that genetic screening of patients with HCM to identify benign mutations will detect very few cases. In addition, such a targeted strategy is unlikely to be effective given that most families have their own private mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renin-angiotensin system polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an interaction between several HCM gene mutations and genetic polymorphisms of the renin-angiotensin-aldosterone system (RAAS), which may account for variability in the presence and extent of hypertrophy among individuals, even those within the same family [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/50-55\">",
"     50-55",
"    </a>",
"    ]. As an example, patients with the DD genotype of the angiotensin converting enzyme (ACE) gene generally have the greatest amount of septal hypertrophy compared to those with the ID or II genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Variations in the angiotensinogen gene may also contribute to different phenotypic expressions of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/50,54\">",
"     50,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link\">",
"     \"Actions of angiotensin II on the heart\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The influence of the RAAS is particularly evident with genetic mutations involving the myosin binding protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In a study of 26 patients from one family who had cardiac myosin binding protein-C gene mutations, those with mutations resulting in genotypes associated with higher activation of the RAAS (pro-LVH genotype) had a significant increase in left ventricular muscle mass, increased interventricular septal thickness, and pathologic ECG abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/55\">",
"     55",
"    </a>",
"    ]. Those without these genotypes did not have LVH or ECG abnormalities. On multivariate analysis, there was an independent association between the presence of pro-LVH polymorphisms and left ventricular mass. In contrast, the ACE genotype appears to have no effect in mutations involving the cardiac beta-myosin heavy chain gene [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/50\">",
"     50",
"    </a>",
"    ]. This suggests that RAAS genotypes may modify the clinical phenotype of HCM in a disease gene specific fashion. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Cardiac myosin binding protein-C gene'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiac myosin binding protein-C gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of cardiac myosin binding protein-C in patients with HCM have demonstrated mutations that map to chromosome 11p11.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/7,43,56-59\">",
"     7,43,56-59",
"    </a>",
"    ]. Mutations in the cardiac myosin binding protein C gene (MYBPC3 gene) are the most common cause of HCM, being present in 14 to 26 percent of patients and, in the largest studies, accounting for 40 to 48 percent of mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17,32,34\">",
"     17,32,34",
"    </a>",
"    ]. However, this may represent an underestimate since these gene defects may be associated with late onset disease expression, though this appears to be uncommon (eg, age-related penetrance). Mutations in cardiac myosin binding protein-C gene have also been identified in patients with dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac myosin binding protein-C is a 137 kD polypeptide that has structural and regulatory functions in the sarcomere. During cardiac embryogenesis it participates in the alignment and assembly of thick filaments [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/61\">",
"     61",
"    </a>",
"    ]. In the adult myocardium, phosphorylation of cardiac myosin binding protein-C by a catecholamine-sensitive pathway may provide dynamic regulation of cardiac contraction in response to adrenergic stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/62\">",
"     62",
"    </a>",
"    ]. Whether these or other unknown functions are perturbed by mutations that cause HCM remains unknown.",
"   </p>",
"   <p>",
"    Although patients with familial HCM are generally heterozygous for a mutation of this gene, bearing one mutant and one normal allele, the effect of two mutant alleles on cardiac phenotype was evaluated in an animal study; animals homozygous for a genetic mutation of the cardiac myosin binding protein-C gene had the neonatal onset of a progressive dilated cardiomyopathy with prominent myocyte hypertrophy, myofibrillar disarray, fibrosis, and dystrophic calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/63\">",
"     63",
"    </a>",
"    ]. These observations suggest that cardiac myosin binding protein-C not only plays a role in myofibrillogenesis during cardiac development but also has importance for long-term sarcomere function and normal cardiac morphology.",
"   </p>",
"   <p>",
"    A broad range of gene defects in cardiac myosin binding protein-C can cause HCM and numerous novel mutations, including missense, nonsense, splicing, and deletion and insertion mutations, have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/43,57-59,64-66\">",
"     43,57-59,64-66",
"    </a>",
"    ]. Protein truncated mutations cause a more severe disease phenotype than missense or deletion mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In one report, the expected abnormal protein did not seem to be incorporated into the myocardium in significant amounts even though the mRNA was expressed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/59\">",
"     59",
"    </a>",
"    ]. It was suggested that the truncated protein was rapidly degraded and the defect in myocardial function in this family may have resulted from a disturbance in the dynamic process of myofibrillar assembly; this could result in a pattern of sarcomere disorganization and dysgenesis since the truncated protein displays an abnormal striation pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Late-onset disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenotypic expression of disease is heterogeneous, even in families with the same cardiac myosin binding protein-C mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/60\">",
"     60",
"    </a>",
"    ]. Patients with cardiac myosin binding protein-C mutations may not present until adult life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/43,44,60,68-70\">",
"     43,44,60,68-70",
"    </a>",
"    ]. In a prospective echocardiographic study, approximately 15 percent (7 of 48) of genetically affected adults had a normal ECG and echo; 3 of these developed LVH at ages 33, 34, and 42 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A cardiac myosin binding protein-C variant involving a 25 bp deletion appears to be common (approximately 4 percent prevalence) in South Asia and present in Southeast Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/70\">",
"     70",
"    </a>",
"    ]. This variant was associated with late-onset heritable cardiomyopathy and risk of heart failure.",
"   </p>",
"   <p>",
"    One possible explanation for late onset disease is an interaction with genetic polymorphisms of the renin-angiotensin-aldosterone system (RAAS) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/55\">",
"     55",
"    </a>",
"    ]. However, some studies have not noted a later age at diagnosis with cardiac myosin binding protein-C mutations compared to other HCM mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'HCM in the elderly'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Renin-angiotensin system polymorphisms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Prognosis appears to be better for patients with cardiac myosin binding protein-C mutations than for patients with HCM associated with mutations in cardiac troponin T or the cardiac beta-myosin heavy chain (",
"    <a class=\"graphic graphic_table graphicRef51823 \" href=\"UTD.htm?13/50/14124\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69871 \" href=\"UTD.htm?29/49/30493\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/44\">",
"     44",
"    </a>",
"    ]. Approximately 40 percent of adults under the age of 50 do not have cardiac hypertrophy, and disease penetrance may remain incomplete through the age of 60 (",
"    <a class=\"graphic graphic_figure graphicRef81726 \" href=\"UTD.htm?19/47/20221\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/43\">",
"     43",
"    </a>",
"    ]. However, the risk of sudden death is increased in at least one cardiac myosin binding protein-C mutation. In addition, one study found that death from cardiac causes occurs in nearly 13 percent of individuals (of whom 94 percent have sudden cardiac death) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/43\">",
"     43",
"    </a>",
"    ]. The better survival in C protein disease is a function of late onset expression, but once disease develops, patients are at risk of the recognized disease complications, particularly stroke and sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cardiac beta-myosin heavy chain gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies suggested that up to 50 percent of cases of HCM were caused by a cardiac beta-myosin heavy chain gene (MYH7 gene) mutation (chromosome 14q12) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/40\">",
"     40",
"    </a>",
"    ]. However, in more recent analyses of large cohorts of unrelated patients, such mutations were found in only 13 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17,32,33\">",
"     17,32,33",
"    </a>",
"    ]. The earlier overestimate may be a consequence of differences in the clinical expression of different genetic forms of HCM. Compared to HCM due to mutations at other loci, HCM due to cardiac beta-myosin mutations is associated with younger age at diagnosis and more severe hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within this group, there is substantial clinical heterogeneity in the phenotypic expression of HCM due to one or more of the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The substantial diversity of gene defects that cause the condition. There have been more than 50 different missense mutations reported that alter an amino acid residue in the globular head or head-rod junction of the cardiac beta-myosin heavy chain. These mutations are expressed with a high degree of penetrance and most affected individuals exhibit significant LVH on 2-dimensional echocardiography. In one report, a mean maximal left ventricular wall thickness of 24 mm was found in affected individuals from families with different myosin mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An interaction between the gene mutation and angiotensin converting enzyme (ACE) and angiotensinogen genetic polymorphism. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Renin-angiotensin system polymorphisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The coexistence of other genetic abnormalities, such as mitochondrial DNA mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several observations suggest that familial restrictive cardiomyopathy may be part of the spectrum of familial hypertrophic cardiomyopathy in which there is different phenotypic expression of mutations in the cardiac beta-myosin heavy chain gene [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/73\">",
"     73",
"    </a>",
"    ]. The supportive data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H4#H4\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'Relation to restrictive cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to variation in the phenotypic expression of the disease, survival in those with HCM due to a cardiac beta-myosin heavy chain mutation varies considerably despite nearly complete disease penetrance and significant hypertrophy. This is in part mutation-specific (",
"    <a class=\"graphic graphic_table graphicRef51823 \" href=\"UTD.htm?13/50/14124\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69871 \" href=\"UTD.htm?29/49/30493\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In one series, for example, individuals with the Arg403Gln mutation had markedly shortened life expectancies with death occurring at an average age of 33 years; in contrast, survival was near normal in individuals carrying the Val606Met mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/40\">",
"     40",
"    </a>",
"    ]. Families have been reported in which the latter mutation was associated with multiple premature sudden deaths. Such exceptions and the childhood onset of a very severe phenotype should raise clinical suspicion of more than one potential disease causing mutation in the family [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17,32,39,46\">",
"     17,32,39,46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Frequency of benign mutations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In general, conservative mutations and those associated with no change in charge are associated with a better prognosis than nonconservative mutations or those associated with a change in charge [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Troponin T gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of cardiac troponin T gene defects (missense mutations, small deletions and mutations in splice signals; chromosome 1q32) are responsible for 4 to 15 percent of cases of HCM, depending upon the series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17,74,75\">",
"     17,74,75",
"    </a>",
"    ]. The cardiac phenotype produced by these gene defects is characterized by less hypertrophy than that observed with myosin gene mutations. In one study, for example, the mean maximal left ventricular wall thickness resulting from six different cardiac troponin T mutations was 16.7 mm compared with 23.7 mm in patients with cardiac beta-myosin heavy chain mutations (p&lt;0.001) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/75\">",
"     75",
"    </a>",
"    ]. Some adults with cardiac troponin gene mutations have normal cardiac wall thickness but have marked myocyte disarray and frequent episodes of sudden death at an early age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. Other patients have the early onset of left ventricular dilation and heart failure resulting in premature death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the apparently less severe phenotype, most reported cardiac troponin T mutations are associated with markedly reduced survival [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/75\">",
"     75",
"    </a>",
"    ]. Homozygous troponin T disease (Ser179Phe) has been reported to cause a severe form of HCM with significant morphologic abnormalities and early sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/41\">",
"     41",
"    </a>",
"    ]. Another mutation, the Phe110Ile missense mutation, has been reported, although detailed pedigree evaluation was not performed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Troponin I gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the cardiac troponin I (cTnI) gene (chromosome 19q13.4) have been identified in 2 to 7 percent of cases of HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17,35,74\">",
"     17,35,74",
"    </a>",
"    ]. Thirteen mutations of the cTnI gene, located on chromosome 1, have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/35,80\">",
"     35,80",
"    </a>",
"    ]. In one study of 130 unrelated probands with HCM, seven had a Lys183 deletion mutation in exon 7 of the cTnI gene; this mutation was associated with a high disease penetrance, sudden death at any age, and dilated cardiomyopathy-like features in 44 percent in those over the age of 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/81\">",
"     81",
"    </a>",
"    ]. In another report of 748 HCM families, 23 were found with 13 different mutations in cTnI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/35\">",
"     35",
"    </a>",
"    ]. In these families, the clinical expression of HCM was very heterogeneous and varied within families with no apparent mutation- or gene-specific disease pattern. Overall disease penetrance in the adults was approximately 50%.",
"   </p>",
"   <p>",
"    Several observations suggest that familial restrictive cardiomyopathy may be part of the spectrum of familial hypertrophic cardiomyopathy in which there is variable phenotypic expression of mutations in the troponin I gene, including typical HCM with asymmetric septal hypertrophy, as well as isolated RCM within the same family [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/82\">",
"     82",
"    </a>",
"    ]. The supportive data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H4#H4\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'Relation to restrictive cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A troponin I mutation has also been identified in one family with autosomal recessive familial dilated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link&amp;anchor=H5900723#H5900723\">",
"     \"Genetics of dilated cardiomyopathy\", section on 'Autosomal recessive transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Alpha tropomyosin gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha tropomyosin gene mutations that affect the thin filament of the sarcomere account for less than 5 percent of cases of HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17,74\">",
"     17,74",
"    </a>",
"    ]. Five disease-causing missense mutations have been identified and linked to chromosome 15q22.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/75,83\">",
"     75,83",
"    </a>",
"    ]. Some may alter the binding of alpha tropomyosin to actin, while others may alter calcium-dependent troponin T binding and thin filament activation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/83\">",
"     83",
"    </a>",
"    ]. The Asp175Asn defect may reflect a mutational hot spot within the gene, since it has arisen independently in multiple families [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypertrophic response to the alpha tropomyosin mutation Asp175Asn varies considerably among different families, suggesting that modifying genes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    environment influence this cardiac phenotype. Survival is near normal in most of these patients, although this does not apply to all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/45,47\">",
"     45,47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Frequency of benign mutations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Another of these mutations, V95A, is associated with several abnormalities of tropomyosin function, a low disease penetrance (53 percent), and a mild and unusual distribution of left ventricular hypertrophy, which is localized to the posterior basal wall, anterolateral free wall,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    apex without left ventricular outflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/83\">",
"     83",
"    </a>",
"    ]. Despite the mild phenotype, the prognosis is poor in affected individuals, with a cumulative survival rate of 73 percent at the age 40.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Myosin regulatory or essential light chain gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in myosin regulatory or essential light chain gene, which is located on chromosome 3p21.2-p21.3 are a rare cause of hypertrophic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/5,84\">",
"     5,84",
"    </a>",
"    ]. The limited number of families with these gene defects has hindered correlation of genotype and phenotype but there appears to be varied penetrance of at least some mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above mutated sarcomeric genes do not account for all cases of HCM. Other sarcomeric mutations involve the genes for alpha-cardiac myosin heavy chain (chromosome 14q12), alpha-cardiac actin (chromosome 15q11-q14), titin (chromosome 2q31), titin-cap",
"    <span class=\"nowrap\">",
"     (T-cap/telethonin),",
"    </span>",
"    muscle LIM protein (MLP) and ventricular essential myosin light chain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/14,84-87\">",
"     14,84-87",
"    </a>",
"    ]. In addition, non sarcomeric gene mutations may cause HCM. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Non sarcomeric gene mutations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     NON SARCOMERIC GENE MUTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8480231\">",
"    <span class=\"h2\">",
"     RAS MAPK pathways genes and Noonan syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of patients with Noonan syndrome, an autosomal dominant disorder characterized by facial dysmorphism, short stature, and congenital heart disease (pulmonary stenosis, septal defects), will also develop HCM. Several different gene mutations have been described in Noonan syndrome, but mutations in the genes coding for components of the RAS MAPK pathway have been associated with the development of HCM in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Genetic studies'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link&amp;anchor=H19#H19\">",
"     \"Causes of short stature\", section on 'Noonan syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     PRKAG2 and LAMP2 genes and WPW syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the genes encoding the gamma-2 regulatory subunit of adenosine monophosphate (AMP)-activated protein kinase (PRKAG2) and lysosome-associated membrane protein 2 (LAMP2) have been associated with hypertrophic cardiomyopathy in association with Wolff-Parkinson-White (WPW) syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/3,6,15,88-91\">",
"     3,6,15,88-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These disorders are uncommon, but represent exceptions to the principle that HCM is due to genetic abnormalities in the contractile apparatus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/3\">",
"     3",
"    </a>",
"    ]. In one study, only one of 200 consecutive patients with HCM had a PRKAG2 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/90\">",
"     90",
"    </a>",
"    ]. In another study of 24 selected patients with HCM and ventricular preexcitation, seven had PRKAG2 mutations and four had LAMP2 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast, there were no mutations in either gene in 20 patients with massive hypertrophy but no electrophysiologic abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     PRKAG2 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;PRKAG2 is an enzyme that modulates glucose uptake and glycolysis. The defect in the mutated gene, which is inherited in an autosomal dominant pattern, may cause inappropriate activation of AMP-activated protein kinase, leading to glycogen accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/91\">",
"     91",
"    </a>",
"    ]. The associated cardiomyopathy results from vacuoles within the myocytes that are filled with glycogen-associated granules; the myocyte and myofibrillar disarray and cardiac fibrosis characteristic of mutations in genes encoding sarcomeric proteins are not seen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The myocardium of patients with HCM due to a PRKAG2 mutation has distinctive changes on histologic examination. In HCM due to sarcomere gene mutations, the pathologic hallmark is myocyte hypertrophy and disarray, with increased interstitial fibrosis. In contrast, PRKAG2 mutations produce myocyte enlargement with pronounced vacuole formation within the cells; histochemical studies have demonstrated that these vacuoles are filled with glycogen-associated granules [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/3,89\">",
"     3,89",
"    </a>",
"    ]. Similar findings are seen with LAMP2 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, it appears that PRKAG2 and LAMP2 mutations cause a form of metabolic storage disease of the myocardium rather than true hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of HCM due to PRKAG2 mutations were evaluated in a review of 45 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/90\">",
"     90",
"    </a>",
"    ]. Symptoms typical of HCM (palpitations, dyspnea, chest pain, and syncope) were present in 31 (69 percent). In addition, seven patients (15 percent) complained of myalgia and had a proximal myopathy. Typical ECG abnormalities were seen in all patients by age 18, while left ventricular hypertrophy was present on echocardiography in 78 percent of adults and was progressive during follow-up. Progressive conduction system disease requiring pacemaker implantation occurred in 17 patients (38 percent) at a mean age of 38 years.",
"   </p>",
"   <p>",
"    Other mutations in PRKAG2 cause WPW syndrome without HCM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Familial WPW'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     LAMP2 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAMP2 may be involved in lysosomal enzyme targeting, autophagy, and lysosomal biogenesis. Mutations in LAMP2 cause glycogen storage disease IIb (also called Danon disease), a semidominant X-linked disorder which is characterized by cardiomyopathy, skeletal myopathy, and variable mental retardation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43315?source=see_link\">",
"     \"Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In those with LAMP2 mutations, the age of onset appears to be younger than in those with PRKAG2 mutations (mean of 15 versus 31 years), cardiomyopathy occurs earlier and more often in males, and most patients have elevations in serum alanine aminotransferase and creatine kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/15\">",
"     15",
"    </a>",
"    ]. Cardiomyopathy usually develops before age 20 in males and in adulthood in females [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/15,92\">",
"     15,92",
"    </a>",
"    ]. The cardiomyopathy is typically hypertrophic in males, may be more often dilated in females, and is usually associated with preexcitation syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/15,92\">",
"     15,92",
"    </a>",
"    ]. Some patients with LAMP2 mutations have predominantly cardiac manifestations without other features of Danon disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LAMP2 mutations are associated with massive hypertrophy with the average maximal left ventricular wall thickness being significantly greater than in HCM due to sarcomere gene mutations or PRKAG2 mutations (35 versus 24 and 17 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/15\">",
"     15",
"    </a>",
"    ]. Most patients with LAMP2 mutations and hypertrophic cardiomyopathy show rapid progression to end-stage heart failure by early adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/15,93\">",
"     15,93",
"    </a>",
"    ]. In one series of seven children (six male) with LAMP2 mutations and cardiac abnormalities (all with severe hypertrophic cardiomyopathy and six with preexcitation ECG patterns) the age at diagnosis was 7 to 17 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/93\">",
"     93",
"    </a>",
"    ]. None had overt skeletal myopathy or mental retardation. During a mean follow-up of 8.6 years, adverse clinical outcomes included progressive refractory heart failure and death in four, sudden death in one, aborted cardiac arrest in one, and heart transplant in one.",
"   </p>",
"   <p>",
"    Danon disease may be an under-recognized cause of hypertrophic cardiomyopathy in childhood. This was illustrated by a review of an unselected population of 50 children with HCM (mean age at diagnosis seven years) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/94\">",
"     94",
"    </a>",
"    ]. Two (4 percent) had LAMP2 mutations; both had Wolff-Parkinson-White syndrome and skeletal myopathy.",
"   </p>",
"   <p>",
"    A milder cardiac phenotype has been described in a family with a missense mutation in LAMP2B [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Alpha-galactosidase A and Fabry disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the gene encoding alpha-galactosidase A cause Fabry disease, an X-linked recessive disorder that can be limited to the heart. Fabry disease may be responsible for as many as 12 percent of late-onset LVH and no hypertension or aortic valve disease in women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/96\">",
"     96",
"    </a>",
"    ], though other series of unexplained LVH identify Fabry disease in 6.3 percent of men &ge;40 and 1.4 percent &lt;40 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17111?source=see_link\">",
"     \"Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     HCM IN THE ELDERLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although familial HCM is most often a disease of young adults, many of the pathophysiologic features can be observed in much older individuals, although the age of symptom onset and the absence of known affected relatives are notable clinical differences. The incidence of otherwise unexplained hypertrophy was illustrated in a series of 1862 unrelated individuals from the Framingham Heart Study who did not have hypertension or aortic valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/98\">",
"     98",
"    </a>",
"    ]. Fifty (3 percent), mean age 60 years, had unexplained increase in left ventricular wall thickness. Sarcomeric contractile protein gene mutations were found in 7 of the 50 (18 percent).",
"   </p>",
"   <p>",
"    This issue was also addressed in a study of 31 individuals with late-onset HCM, who first developed symptoms at an average age of 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/68\">",
"     68",
"    </a>",
"    ]. In contrast to familial early-onset HCM, which results from defects in cardiac beta-myosin heavy chain, cardiac troponin T, and alpha tropomyosin genes in more than 45 percent of cases, mutations in cardiac myosin binding protein-C, troponin I, and alpha cardiac myosin heavy chain genes caused elderly-onset HCM. In addition, the likelihood of identifying a mutation may be lower in late-onset HCM than in earlier onset HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H3#H3\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'Late onset disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A sigmoid septal morphology is common particularly among older adults diagnosed with HCM (as well as in older adults without HCM) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/100\">",
"     100",
"    </a>",
"    ]. Among patients with HCM, this morphologic subtype appears to be less commonly associated with a mutation than other morphologic variants. Among 382 unrelated patients with HCM, a sigmoid septum was observed in 67 percent of the 126 patients diagnosed at or after 50 years of age as compared to 38 percent of younger patients. Only 23 percent of older patients had an identifiable mutation as compared to 44 percent of younger patients. Among 181 patients with a sigmoid septum, only 8 percent were genotype positive as compared to 79 percent of 131 patients with reverse curvature HCM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SKELETAL MUSCLE INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some mutations that cause hypertrophic cardiomyopathy are also expressed in skeletal muscle:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac beta-myosin heavy chains are abundant in the myocardium and are found in lower levels in slow twitch skeletal muscles. Muscle fibers expressing cardiac beta-myosin heavy chain mutations have abnormal contractile properties and histologic evidence of central core disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/101,102\">",
"       101,102",
"      </a>",
"      ]. However, the relevance of these in vitro findings to the human pathology is unclear; skeletal myopathy does not appear to be a significant component of this form of HCM, although abnormalities in skeletal muscle metabolism have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/103-107\">",
"       103-107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although alpha tropomyosin is widely expressed in skeletal and cardiac muscle, mutations in this peptide produce a cardiac-specific phenotype without clinical features of skeletal muscle involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/75\">",
"       75",
"      </a>",
"      ]. Interactions with cardiac troponin T but not skeletal muscle troponin T may be perturbed, thereby restricting dysfunction to the myocardium. Essential and regulatory light chain mutations may also produce a cardiac phenotype by predominantly impairing function of cardiac myosin heavy chains [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Myalgias and a proximal myopathy are present in approximately 15 percent of patients with PRKAG2 mutations, which is not associated with genetic abnormalities in the contractile apparatus [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/90\">",
"       90",
"      </a>",
"      ]. Histologic examination of skeletal muscle reveals excess mitochondria and ragged red fibers with minimal glycogen accumulation.",
"     </li>",
"     <li>",
"      Skeletal myopathy is a component of glycogen storage disease IIb (Danon disease) in patients with LAMP2 gene mutations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43315?source=see_link\">",
"       \"Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ANIMAL MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;How the varied defects in human HCM impair the biophysical properties of the sarcomere is not completely understood. In an attempt to address this issue, animal models of hypertrophic cardiomyopathy have been produced, by overexpression of a mutant contractile protein transgene in the heart or by homologous recombination in which physiologic expression of a contractile protein mutation, or deletion of a contractile protein gene, occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/108-115\">",
"     108-115",
"    </a>",
"    ]. Affected animals develop, to varying degrees depending upon the mutation, histologic changes in the heart similar to that observed in human hypertrophic cardiomyopathy including myocyte disarray, hypertrophy and injury with replacement fibrosis. In at least one model, hemodynamic dysfunction precedes the histopathologic changes, suggesting that the hypertrophic phenotype may be a compensatory response to sarcomere mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/103,113,114,116\">",
"     103,113,114,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Provocative tests used to evaluate patients with HCM have also been performed in mutant mice. Vigorous exercise in mice with the Arg403Gln mutation in the cardiac alpha-myosin heavy chain results in sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/117\">",
"     117",
"    </a>",
"    ]. These mice also have increased arrhythmogenicity, compared to wild type controls, when exposed to provocative electrophysiologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacologic intervention in animal models suggests that these animals might be useful for conducting preclinical therapeutic trials. The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    induced regression of hypertrophy and fibrosis in a cardiac beta-myosin heavy chain rabbit model [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/118\">",
"     118",
"    </a>",
"    ]. Angiotensin II receptor blockade reduced interstitial fibrosis in cardiac troponin T transgenic mice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/119\">",
"     119",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    reduced myocyte disarray, hypertrophy and fibrosis in a cardiac beta-myosin heavy chain mouse model [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/120\">",
"     120",
"    </a>",
"    ]. The clinical relevance of these observations remains to be established in man.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     GENETIC TESTING AND SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of gene mutations for HCM has led to interest in the development of DNA-based testing of patients with HCM to aid diagnosis and management of patients, and to permit cascade screening of families. However, genetic testing for HCM is not as straightforward as it might at first appear [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. First-degree relatives of an affected individual should be clinically evaluated (by history, physical examination, electrocardiography, and echocardiography) for possible inheritance of the disease. Mutation specific genetic testing should be considered for first-degree relatives following the index case diagnosis of HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Screening of first-degree relatives'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several issues complicate the use of genetic testing as a screening tool:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some of the genes responsible for HCM have not yet been identified; the recognized disease causing genes are thought to account for up to 80 percent of cases of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/113,123\">",
"       113,123",
"      </a>",
"      ]. However, in different series, the frequency of identifying a mutation has been lower, ranging from 30 to 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/121\">",
"       121",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Frequency of identified mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A large number of genes have been implicated in HCM. Among the genes that have been identified, the spectrum of possible disease-causing mutations is still incomplete. As a result, a thorough evaluation of known genes would require extensive DNA sequencing (at least 15 kb for just four of the most common genes), which is onerous for routine clinical testing. Less rigorous methods (such as selective sequencing) would reduce the likelihood of identifying the responsible mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Population studies have demonstrated that up to 5 percent of patients are compound heterozygotes (inheriting two different mutations within a single HCM gene), double heterozygotes (inheriting mutations in two HCM genes), or homozygotes (inheriting the same mutation from both parents). To be certain of detecting such genotypes, sequencing of candidate genes would need to continue in a given patient even after a single mutation was identified [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is sufficient heterogeneity in the clinical manifestations of a given gene mutation that, even when a patient's mutation is known, his or her clinical course cannot be predicted with any degree of certainty [",
"      <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/48\">",
"       48",
"      </a>",
"      ]. In addition, the prognostic impact of a given mutation may relate to a particular family and not to the population at large. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Frequency of benign mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many families, particularly with the two commonest gene abnormalities beta-myosin heavy chain and myosin binding protein C, have their own 'private' mutations and thus most of the time, knowledge of the gene abnormalities cannot be linked to experience from other families.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study to assess the feasibility of genetic testing for HCM, 197 unrelated patients with either familial or sporadic HCM were screened by performing single-strand conformation polymorphism analysis of the coding sequence of nine genes, followed by DNA sequencing of abnormal patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/17\">",
"     17",
"    </a>",
"    ]. Disease-causing mutations were identified in 124 patients (63 percent). A total of 97 different mutations, including 60 novel ones, were identified. Mutations in the cardiac beta-myosin heavy chain and cardiac myosin binding protein C genes accounted for more than 80 percent of the detected mutations.",
"   </p>",
"   <p>",
"    A review of 389 unrelated patients seen at the Mayo Clinic attempted to identify predictive factors in the 38 percent of patients who had a mutation in one of the eight most common sarcomere mutations associated with HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/99\">",
"     99",
"    </a>",
"    ]. The likelihood of a mutation was greater in patients with a family history of HCM (54 percent), increased left ventricular wall thickness (49 percent if &ge;25 mm), younger age at diagnosis (49 percent under age 45), and need for an implantable cardioverter-defibrillator (ICD).",
"   </p>",
"   <p>",
"    However, none of these findings was very useful since patients without a family history of HCM or increased left ventricular wall thickness or those &ge;45 years of age had an appreciable likelihood of having a mutation (22 to 30 percent). The absence of a family history could reflect a new mutation, incomplete penetrance, or undiagnosed disease in first-degree relatives. If the risk markers sufficient to implant an ICD were used as a criterion for genetic testing, more than one-half of patients with a mutation would be excluded.",
"   </p>",
"   <p>",
"    As noted above, among 84 children diagnosed with isolated unexplained left ventricular hypertrophy before 15 years of age, mutations in genes associated with HCM in adults in about half (25 of 51) of presumed sporadic cases and in nearly two-thirds (21 of 33) of familial cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of identifying a mutation is lowest in patients &ge;65 years of age. This finding is consistent with clinical studies showing cardiac differences in HCM in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?28/44/29386/abstract/124,125\">",
"     124,125",
"    </a>",
"    ] and suggests that elderly patients may have a different disease from younger patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H3#H3\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'Late onset disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1381757\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic linkage studies in familial hypertrophic cardiomyopathy (HCM) have demonstrated autosomal dominant disease loci at a variety of chromosomal sites. Most of the genetic loci in familial HCM encode one of the myocardial contractile proteins, and mutations have subsequently been identified in the genes themselves. Some patients with sporadic disease, in which the parents are clinically well, have similar genetic abnormalities as those with familial disease. On rare occasions, genes which do not encode contractile proteins (GLA in Fabry disease, RAS MAPK in Noonan syndrome) have also been associated with HCM. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The consequences of HCM mutations in contractile protein genes appear to be directly related to effects on sarcomere function, leading to the characterization of HCM as a \"disease of the sarcomere\". However, a unifying explanation of the effect of these mutations on systolic and diastolic function has not been established. Some mutations appear to enhance contractility, while others have the opposite effect. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mutations in the cardiac myosin binding protein C gene are most common, being present in up to 48 percent of cases, with mutations in the cardiac beta-myosin heavy chain gene being second most common (up to 42 percent of cases). Mutations in the troponin I, troponin T, and alpha-tropomyosin genes account for only 5 to 10 percent of cases, with up to 5 percent of patients have multiple mutations. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Frequency of identified mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A broad range of gene defects in cardiac myosin binding protein-C can cause HCM, and numerous novel mutations, including missense, nonsense, splicing, and deletion and insertion mutations, have been identified. Protein-truncated mutations cause a more severe disease phenotype than missense or deletion mutations. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cardiac myosin binding protein-C gene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prognosis appears to be better for patients with cardiac myosin binding protein-C mutations than for patients with HCM associated with mutations in cardiac troponin T or the cardiac beta-myosin heavy chain. The better survival in C protein disease is a function of late onset expression, but once disease develops, patients are at risk of the recognized disease complications, particularly stroke and sudden death. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Late-onset disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with HCM due to mutations at other loci, HCM due to cardiac beta-myosin mutations is associated with younger age at diagnosis and more severe hypertrophy. There have been more than 50 different missense mutations reported that alter an amino acid residue in the globular head or head-rod junction of the cardiac beta-myosin heavy chain. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cardiac beta-myosin heavy chain gene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of cardiac troponin T gene defects (missense mutations, small deletions and mutations in splice signals; chromosome 1q32) are responsible for 4 to 15 percent of cases of HCM, depending upon the series. The cardiac phenotype produced by these gene defects is characterized by less hypertrophy than that observed with myosin gene mutations. Despite the apparently less severe phenotype, most reported cardiac troponin T mutations are associated with markedly reduced survival. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Troponin T gene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mutations in the genes encoding the gamma-2 regulatory subunit of adenosine monophosphate (AMP)-activated protein kinase (PRKAG2) and lysosome-associated membrane protein 2 (LAMP2) have been associated with hypertrophic cardiomyopathy in association with Wolff-Parkinson-White (WPW) syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      PRKAG2 is an enzyme that modulates glucose uptake and glycolysis. The defect in the mutated gene, which is inherited in an autosomal dominant pattern, may cause inappropriate activation of AMP-activated protein kinase, leading to glycogen accumulation, and an associated cardiomyopathy results from glycogen-associated granules that fill vacuoles within the myocytes. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'PRKAG2 gene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LAMP2 may be involved in lysosomal enzyme targeting, autophagy, and lysosomal biogenesis. Mutations in LAMP2 cause glycogen storage disease IIb (also called Danon disease), a semidominant X-linked disorder which is characterized by cardiomyopathy, skeletal myopathy, and variable mental retardation. LAMP2 mutations are associated with massive hypertrophy, with the average maximal left ventricular wall thickness being significantly greater than in HCM due to sarcomere gene mutations or PRKAG2 mutations (35 versus 24 and 17 mm). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'LAMP2 gene'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although familial HCM is most often a disease of young adults, many of the pathophysiologic features can be observed in much older individuals, although the age of symptom onset and the absence of known affected relatives are notable clinical differences. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'HCM in the elderly'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The identification of gene mutations for HCM has led to interest in the development of DNA-based testing of patients with HCM to aid the diagnosis and management of patients and to permit cascade screening of families. However, genetic testing for HCM is not as straightforward as it might at first appear due to the large number of gene mutations that can cause HCM as well as some as yet undetermined genes. First-degree relatives of an affected individual should be clinically evaluated by history, physical examination, electrocardiography, and echocardiography for possible inheritance of the disease. Mutation specific genetic testing should then be considered for first-degree relatives following the index case diagnosis of HCM. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Genetic testing and screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/1\">",
"      Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001; 33:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/2\">",
"      Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. Trends Genet 2003; 19:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/3\">",
"      Seidman C. Genetic causes of inherited cardiac hypertrophy: Robert L. Frye Lecture. Mayo Clin Proc 2002; 77:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/4\">",
"      Watkins H, MacRae C, Thierfelder L, et al. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet 1993; 3:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/5\">",
"      Poetter K, Jiang H, Hassanzadeh S, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 1996; 13:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/6\">",
"      MacRae CA, Ghaisas N, Kass S, et al. Familial Hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest 1995; 96:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/7\">",
"      Carrier L, Hengstenberg C, Beckmann JS, et al. Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11. Nat Genet 1993; 4:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/8\">",
"      Jarcho JA, McKenna W, Pare JA, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 1989; 321:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/9\">",
"      Thierfelder L, MacRae C, Watkins H, et al. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci U S A 1993; 90:6270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/10\">",
"      Monserrat L, Gimeno-Blanes JR, Mar&iacute;n F, et al. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007; 50:2399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/11\">",
"      Elliott P, Baker R, Pasquale F, et al. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart 2011; 97:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/12\">",
"      Wu X, Simpson J, Hong JH, et al. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest 2011; 121:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/13\">",
"      Marin TM, Keith K, Davies B, et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest 2011; 121:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/14\">",
"      Geier C, Perrot A, Ozcelik C, et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation 2003; 107:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/15\">",
"      Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/16\">",
"      Hayashi T, Arimura T, Itoh-Satoh M, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol 2004; 44:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/17\">",
"      Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003; 107:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/18\">",
"      Watkins H, Thierfelder L, Anan R, et al. Independent origin of identical beta cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy. Am J Hum Genet 1993; 53:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/19\">",
"      Watkins H, Anan R, Coviello DA, et al. A de novo mutation in alpha-tropomyosin that causes hypertrophic cardiomyopathy. Circulation 1995; 91:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/20\">",
"      Anan R, Niimura H, Takenaka T, et al. Mutations in the genes for sarcomeric proteins in Japanese patients with onset sporadic hypertrophic cardiomyopathy after age 40 years. Am J Cardiol 2007; 99:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/21\">",
"      Rayment I, Holden HM, Sellers JR, et al. Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A 1995; 92:3864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/22\">",
"      Watkins H, Seidman JG, Seidman CE. Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Hum Mol Genet 1995; 4 Spec No:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/23\">",
"      Sweeney HL, Straceski AJ, Leinwand LA, et al. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J Biol Chem 1994; 269:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/24\">",
"      Straceski AJ, Geisterfer-Lowrance A, Seidman CE, et al. Functional analysis of myosin missense mutations in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A 1994; 91:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/25\">",
"      Sata M, Ikebe M. Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome. J Clin Invest 1996; 98:2866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/26\">",
"      Lin D, Bobkova A, Homsher E, Tobacman LS. Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. J Clin Invest 1996; 97:2842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/27\">",
"      Watkins H, Seidman CE, Seidman JG, et al. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. J Clin Invest 1996; 98:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/28\">",
"      Kirschner SE, Becker E, Antognozzi M, et al. Hypertrophic cardiomyopathy-related beta-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells. Am J Physiol Heart Circ Physiol 2005; 288:H1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/29\">",
"      Watkins H. Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies. Circulation 2003; 107:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/30\">",
"      Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003; 41:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/31\">",
"      Lim DS, Roberts R, Marian AJ. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. J Am Coll Cardiol 2001; 38:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/32\">",
"      Van Driest SL, Ommen SR, Tajik AJ, et al. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc 2005; 80:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/33\">",
"      Van Driest SL, Jaeger MA, Ommen SR, et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/34\">",
"      Van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/35\">",
"      Mogensen J, Murphy RT, Kubo T, et al. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/36\">",
"      Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2008; 358:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/37\">",
"      Kaski JP, Syrris P, Esteban MT, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2009; 2:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/38\">",
"      Rosenzweig A, Watkins H, Hwang DS, et al. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med 1991; 325:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/39\">",
"      Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation 1994; 89:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/40\">",
"      Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992; 326:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/41\">",
"      Ho CY, Lever HM, DeSanctis R, et al. Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy. Circulation 2000; 102:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/42\">",
"      Anan R, Shono H, Kisanuki A, et al. Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis. Circulation 1998; 98:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/43\">",
"      Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998; 338:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/44\">",
"      Charron P, Dubourg O, Desnos M, et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 1998; 97:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/45\">",
"      Coviello DA, Maron BJ, Spirito P, et al. Clinical features of hypertrophic cardiomyopathy caused by mutation of a \"hot spot\" in the alpha-tropomyosin gene. J Am Coll Cardiol 1997; 29:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/46\">",
"      Havndrup O, Bundgaard H, Andersen PS, et al. The Val606Met mutation in the cardiac beta-myosin heavy chain gene in patients with familial hypertrophic cardiomyopathy is associated with a high risk of sudden death at young age. Am J Cardiol 2001; 87:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/47\">",
"      Van Driest SL, Ackerman MJ, Ommen SR, et al. Prevalence and severity of \"benign\" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation 2002; 106:3085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/48\">",
"      Marian AJ. On genetic and phenotypic variability of hypertrophic cardiomyopathy: nature versus nurture. J Am Coll Cardiol 2001; 38:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/49\">",
"      Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol 2002; 39:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/50\">",
"      Perkins MJ, Van Driest SL, Ellsworth EG, et al. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J 2005; 26:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/51\">",
"      Tesson F, Dufour C, Moolman JC, et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol 1997; 29:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/52\">",
"      Lechin M, Qui&ntilde;ones MA, Omran A, et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 1995; 92:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/53\">",
"      Yoneya K, Okamoto H, Machida M, et al. Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J 1995; 130:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/54\">",
"      Ishanov A, Okamoto H, Yoneya K, et al. Angiotensinogen gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J 1997; 133:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/55\">",
"      Ortlepp JR, Vosberg HP, Reith S, et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart 2002; 87:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/56\">",
"      Watkins H, Conner D, Thierfelder L, et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995; 11:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/57\">",
"      Bonne G, Carrier L, Bercovici J, et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 1995; 11:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/58\">",
"      Carrier L, Bonne G, B&auml;hrend E, et al. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ Res 1997; 80:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/59\">",
"      Rottbauer W, Gautel M, Zehelein J, et al. Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein. J Clin Invest 1997; 100:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/60\">",
"      Ehlermann P, Weichenhan D, Zehelein J, et al. Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene. BMC Med Genet 2008; 9:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/61\">",
"      Gilbert R, Kelly MG, Mikawa T, Fischman DA. The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle. J Cell Sci 1996; 109 ( Pt 1):101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/62\">",
"      Gautel M, Zuffardi O, Freiburg A, Labeit S. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? EMBO J 1995; 14:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/63\">",
"      McConnell BK, Jones KA, Fatkin D, et al. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest 1999; 104:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/64\">",
"      Moolman JA, Reith S, Uhl K, et al. A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation 2000; 101:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/65\">",
"      Erdmann J, Raible J, Maki-Abadi J, et al. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol 2001; 38:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/66\">",
"      Konno T, Shimizu M, Ino H, et al. A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients. J Am Coll Cardiol 2003; 41:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/67\">",
"      Yang Q, Sanbe A, Osinska H, et al. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J Clin Invest 1998; 102:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/68\">",
"      Niimura H, Patton KK, McKenna WJ, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 2002; 105:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/69\">",
"      Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001; 38:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/70\">",
"      Dhandapany PS, Sadayappan S, Xue Y, et al. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. Nat Genet 2009; 41:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/71\">",
"      Solomon SD, Wolff S, Watkins H, et al. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol 1993; 22:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/72\">",
"      Arbustini E, Fasani R, Morbini P, et al. Coexistence of mitochondrial DNA and beta myosin heavy chain mutations in hypertrophic cardiomyopathy with late congestive heart failure. Heart 1998; 80:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/73\">",
"      Kubo T, Gimeno JR, Bahl A, et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 2007; 49:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/74\">",
"      Van Driest SL, Ellsworth EG, Ommen SR, et al. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation 2003; 108:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/75\">",
"      Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995; 332:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/76\">",
"      Varnava A, Baboonian C, Davison F, et al. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. Heart 1999; 82:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/77\">",
"      Varnava AM, Elliott PM, Baboonian C, et al. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation 2001; 104:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/78\">",
"      Fujino N, Shimizu M, Ino H, et al. A novel mutation Lys273Glu in the cardiac troponin T gene shows high degree of penetrance and transition from hypertrophic to dilated cardiomyopathy. Am J Cardiol 2002; 89:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/79\">",
"      Li D, Czernuszewicz GZ, Gonzalez O, et al. Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy. Circulation 2001; 104:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/80\">",
"      Kimura A, Harada H, Park JE, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997; 16:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/81\">",
"      Kokado H, Shimizu M, Yoshio H, et al. Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. Circulation 2000; 102:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/82\">",
"      Mogensen J, Kubo T, Duque M, et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 2003; 111:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/83\">",
"      Karibe A, Tobacman LS, Strand J, et al. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis. Circulation 2001; 103:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/84\">",
"      Lee W, Hwang TH, Kimura A, et al. Different expressivity of a ventricular essential myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy. Am Heart J 2001; 141:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/85\">",
"      Carniel E, Taylor MR, Sinagra G, et al. Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation 2005; 112:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/86\">",
"      Satoh M, Takahashi M, Sakamoto T, et al. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem Biophys Res Commun 1999; 262:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/87\">",
"      Mogensen J, Klausen IC, Pedersen AK, et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999; 103:R39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/88\">",
"      Blair E, Redwood C, Ashrafian H, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001; 10:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/89\">",
"      Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002; 109:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/90\">",
"      Murphy RT, Mogensen J, McGarry K, et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 2005; 45:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/91\">",
"      Ahmad F, Arad M, Musi N, et al. Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy. Circulation 2005; 112:3140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/92\">",
"      Sugie K, Yamamoto A, Murayama K, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002; 58:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/93\">",
"      Maron BJ, Roberts WC, Arad M, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 2009; 301:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/94\">",
"      Yang Z, McMahon CJ, Smith LR, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation 2005; 112:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/95\">",
"      van der Kooi AJ, van Langen IM, Aronica E, et al. Extension of the clinical spectrum of Danon disease. Neurology 2008; 70:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/96\">",
"      Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004; 110:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/97\">",
"      Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/98\">",
"      Morita H, Larson MG, Barr SC, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 2006; 113:2697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/99\">",
"      Van Driest SL, Ommen SR, Tajik AJ, et al. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin Proc 2005; 80:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/100\">",
"      Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc 2006; 81:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/101\">",
"      Lankford EB, Epstein ND, Fananapazir L, Sweeney HL. Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest 1995; 95:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/102\">",
"      Fananapazir L, Dalakas MC, Cyran F, et al. Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A 1993; 90:3993.",
"     </a>",
"    </li>",
"    <li>",
"     Wynne, J, Braunwald, E. The cardiomyopathies and myocarditides: toxic, chemical, and physical damage to the heart. In: Heart Disease: A Textbook of Cardiovascular Medicine, 4th ed, Braunwald, E (Eds), WB Saunders, Philadelphia 1991. p.139.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/104\">",
"      Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/105\">",
"      Thompson CH, Kemp GJ, Taylor DJ, et al. Abnormal skeletal muscle bioenergetics in familial hypertrophic cardiomyopathy. Heart 1997; 78:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/106\">",
"      Caforio AL, Rossi B, Risaliti R, et al. Type 1 fiber abnormalities in skeletal muscle of patients with hypertrophic and dilated cardiomyopathy: evidence of subclinical myogenic myopathy. J Am Coll Cardiol 1989; 14:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/107\">",
"      Smith ER, Heffernan LP, Sangalang VE, et al. Voluntary muscle involvement in hypertrophic cardiomyopathy. A study of eleven patients. Ann Intern Med 1976; 85:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/108\">",
"      Vikstrom KL, Factor SM, Leinwand LA. A murine model for hypertrophic cardiomyopathy. Z Kardiol 1995; 84 Suppl 4:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/109\">",
"      James J, Zhang Y, Osinska H, et al. Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. Circ Res 2000; 87:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/110\">",
"      Marian AJ, Wu Y, Lim DS, et al. A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest 1999; 104:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/111\">",
"      Tardiff JC, Factor SM, Tompkins BD, et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest 1998; 101:2800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/112\">",
"      Dalloz F, Osinska H, Robbins J. Manipulating the contractile apparatus: genetically defined animal models of cardiovascular disease. J Mol Cell Cardiol 2001; 33:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/113\">",
"      Arad M, Seidman JG, Seidman CE. Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet 2002; 11:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/114\">",
"      Geisterfer-Lowrance AA, Christe M, Conner DA, et al. A mouse model of familial hypertrophic cardiomyopathy. Science 1996; 272:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/115\">",
"      Blanchard EM, Iizuka K, Christe M, et al. Targeted ablation of the murine alpha-tropomyosin gene. Circ Res 1997; 81:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/116\">",
"      Georgakopoulos D, Christe ME, Giewat M, et al. The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation. Nat Med 1999; 5:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/117\">",
"      Berul CI, Christe ME, Aronovitz MJ, et al. Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice. J Clin Invest 1997; 99:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/118\">",
"      Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/119\">",
"      Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001; 103:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/120\">",
"      Semsarian C, Ahmad I, Giewat M, et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 2002; 109:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/121\">",
"      Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/122\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/123\">",
"      Marian AJ, Roberts R. To screen or not is not the question--it is when and how to screen. Circulation 2003; 107:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/124\">",
"      Lever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. Circulation 1989; 79:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/44/29386/abstract/125\">",
"      Lewis JF, Maron BJ. Elderly patients with hypertrophic cardiomyopathy: a subset with distinctive left ventricular morphology and progressive clinical course late in life. J Am Coll Cardiol 1989; 13:36.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4956 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-1745D172DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29386=[""].join("\n");
var outline_f28_44_29386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1381757\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MUTATIONS IN SARCOMERIC PROTEIN GENES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Frequency of identified mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Frequency of benign mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renin-angiotensin system polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiac myosin binding protein-C gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Late-onset disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cardiac beta-myosin heavy chain gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Troponin T gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Troponin I gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Alpha tropomyosin gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Myosin regulatory or essential light chain gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other genes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NON SARCOMERIC GENE MUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8480231\">",
"      RAS MAPK pathways genes and Noonan syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PRKAG2 and LAMP2 genes and WPW syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - PRKAG2 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - LAMP2 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Alpha-galactosidase A and Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HCM IN THE ELDERLY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SKELETAL MUSCLE INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ANIMAL MODELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      GENETIC TESTING AND SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1381757\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4956\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4956|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/9/11411\" title=\"figure 1\">",
"      Morphologic variants HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/49/30493\" title=\"figure 2\">",
"      Genetic mutations survival I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/47/20221\" title=\"figure 3\">",
"      Genetic mutations survival II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4956|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/41/36507\" title=\"table 1\">",
"      Risks benefits genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/50/14124\" title=\"table 2\">",
"      Diagnostic criteria HCM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17111?source=related_link\">",
"      Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=related_link\">",
"      Excitation-contraction coupling in myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43315?source=related_link\">",
"      Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_44_29387="Mgmt fecal incontinence ACG II";
var content_f28_44_29387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American College of Gastroenterology recommendations for management of fecal incontinence (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supportive measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Such as avoiding offending foods, ritualizing bowel habit, improving skin hygiene and instituting lifestyle changes may be useful adjuncts.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pharmacologic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loperamide or diphenoxylate/atropine can produce modest improvement in symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Biofeedback therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is a safe and effective treatment. It improves symptoms of fecal incontinence, restores quality of life, and improves objective parameters of anorectal function. It is useful in patients with weak sphincters and/or impaired rectal sensation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Plugs, bulkers, electrical stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anal plug devices, sphincter bulking therapies or electrical stimulation should be considered as experimental and merit controlled clinical trials.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should be considered in selected patients who have failed conservative measures or biofeedback therapy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Rao, SS. Diagnosis and management of fecal incontinence. Am J Gastroenterol 2004; 99:1585.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29387=[""].join("\n");
var outline_f28_44_29387=null;
var title_f28_44_29388="Causes of tachycardia in children";
var content_f28_44_29388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of tachycardia in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Life threatening cardiac conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Supraventricular tachycardia (SVT)",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Ventricular tachycardia (VT)",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Other arrhythmias (eg, torsades de pointes, atrial flutter)",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Hypertrophic cardiomyopathy (HCM)",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Myocarditis, cardiomyopathy",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Pericardial effusion",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Life threatening non-cardiac conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Substrate deficiency (hypoxemia, hypoglycemia)",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Hypovolemic shock",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Anaphylaxis",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Toxic exposure",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Sepsis",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Electrolyte imbalance (hyperkalemia, hypocalcemia, hypomagnesiumia)",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Pheochromocytoma",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Common conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Fever",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Exercise",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Crying",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Pain",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Anxiety, hyperventilation syndrome",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Anemia",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Drug-induced (caffeine, herbal medications, dietary supplements, illicit drugs)",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kawasaki disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute rheumatic fever",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyperthyroidism",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Red = life threatening condition; Green = common condition",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29388=[""].join("\n");
var outline_f28_44_29388=null;
var title_f28_44_29389="IP ABX continuous dosing2";
var content_f28_44_29389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intraperitoneal antibiotic dosing recommendations for continuous administration in peritoneal dialysis patients (adult)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial IP loading dose (per liter of dialysate)",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Maintenance IP dose* (per liter of dialysate)",
"        </p>",
"        <p>",
"         For patients with residual renal function (defined as greater than 100 mL per day urine output) empirically increase dose shown by twenty-five percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Aminoglycosides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Continuous IP administration of aminoglycosides is not recommended. See text and accompanying table on intermittent IP antibiotic administration and dosing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Cephalosporins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefazolin",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefepime",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cephalothin&bull;",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cephradine&bull;",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ceftazidime",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ceftizoxime",
"       </td>",
"       <td>",
"        250 mg",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Penicillins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amoxicillin&bull;",
"       </td>",
"       <td>",
"        250 to 500 mg",
"       </td>",
"       <td>",
"        50 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ampicillin",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azlocillin&bull;",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        250 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oxacillin",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nafcillin",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penicillin G",
"       </td>",
"       <td>",
"        50,000 units",
"       </td>",
"       <td>",
"        25,000 units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vancomycin",
"       </td>",
"       <td>",
"        1 gram",
"       </td>",
"       <td>",
"        25 mg (modify dose based on serum drug concentrations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aztreonam",
"       </td>",
"       <td>",
"        1 gram",
"       </td>",
"       <td>",
"        250 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        50 mg",
"       </td>",
"       <td>",
"        25 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Daptomycin",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Linezolid",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        ORAL: 200 to 300 mg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Teicoplanin&bull;",
"       </td>",
"       <td>",
"        400 mg",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Combinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ampicillin-sulbactam&Delta;",
"       </td>",
"       <td>",
"        1 gram",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Imipenem-cilastatin&loz;",
"       </td>",
"       <td>",
"        250 mg",
"       </td>",
"       <td>",
"        50 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trimethoprim-sulfamethoxazole (co-trimoxazole)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        ORAL: one 960 mg double strength tablet (trimethoprim 160 mg and sulfamethoxazole 800 mg) two times per day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Table shows suggested dose of antibiotics for IP administration (except as noted otherwise) in all exchanges of peritoneal dialysate for treatment of continuous ambulatory PD associated peritonitis. For dosing of antibiotics administered intermittently with PD, see text and accompanying table.",
"    <div class=\"footnotes\">",
"     IP: intraperitoneal; PD: peritoneal dialysis.",
"     <br>",
"      * Dose, in mg per liter of dialysate, administered with each exchange following loading dose.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Parenteral preparation not available in United States.",
"       <br>",
"        &Delta; Based on ampicillin component.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Based on imipenem component.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Li, PK, Szeto, CC, Piraino, B, et al. Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. Perit Dial Int 2010; 30:393. Published in Peritoneal Dialysis International. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29389=[""].join("\n");
var outline_f28_44_29389=null;
var title_f28_44_29390="Mortality rates for esophageal perforation";
var content_f28_44_29390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Imapct of delay in diagnosis on mortality rates for patients with an esophageal perforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 398px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure represents the effect of delay in diagnosis on mortality rates for patients with an esophageal perforation. The overall mortality rate of an early diagnosis made within 24 hours is lower compared with a delay in diagnosis greater than 24 hours (14 versus 27 percent). Patients treated with a primary closure within 24 hours had a lower mortality rate compared with those repaired after 24 hours (4 versus 14 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Brinster CJ, Singhal S, Lee L, et al. Evolving options in the management of esophageal perforation. Ann Thorac Surg 2004; 77:1475.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29390=[""].join("\n");
var outline_f28_44_29390=null;
var title_f28_44_29391="Incidence rates of primary brain tumors";
var content_f28_44_29391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Incidence rates of primary brain tumors by major neuroepithelial tissue and meningeal histologic types and age group, CBTRUS, 1992-1997",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 362px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The category All Brain Tumors includes some specific types not individually shown (tumors of cranial and spinal nerves, hemangioblastomas, primary lymphomas, germ cell tumors, and tumors of the sellar region). The Astrocytoma category includes diffuse astrocytomas, anaplastic astrocytomas, unique astrocytoma variants, and astrocytomas not otherwise specified.",
"    <div class=\"footnotes\">",
"     PNET: primitive neuroectodermal tumor.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wrensch, M, Minn, Y, Chew, T, et al. Epidemiology of primary brain tumors: Current concepts and review of the literature. Neuro-Oncology 2002; 4:278. Copyright &copy; 2002 Margaret Wrensch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_44_29391=[""].join("\n");
var outline_f28_44_29391=null;
